Anti-smagp antibodies

Abstract

The present disclosure provides antibodies and polypeptides that specifically bind to Small Cell Adhesion Glycoprotein (SMAGP). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Description

Attorney Docket No. DEMB-010 / 02WOANTI-SMAGP ANTIBODIESCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit to U. S. Provisional Application No. 63 / 817,861. filed on June 4, 2025, and U. S. Provisional Application No. 63 / 724,799, filed on November 25, 2024, the contents of which are each herein incorporated by reference in their entireties.FIELD

[0002] The present disclosure relates to antibodies that are specific for Small Cell Adhesion Glycoprotein, also known as small cell adhesion glycoprotein (SMAGP), and methods of use thereof.BACKGROUND

[0003] Small cell adhesion glycoprotein (SMAGP) is a 97 amino acid single-pass membrane protein that is expressed in various tissues and exhibits a variety of cellular functions. Dysregulated expression of SMAGP is associated with tumorigenesis and metastasis, and elevated expression of SMAGP and its mRNA expression compared to healthy counterpart tissue can be used as tumor markers and as potential therapeutic targets. As SMAGP is a cell surface protein that is highly expressed or is upregulated in a myriad of cancers, including but not limited to colon, rectal, gastric, esophageal, bladder, pancreatic, cervical, lung, liver, breast, thyroid and kidney cancer; there is a need for therapies targeting SMAGP.SUMMARY

[0004] The present disclosure provides antibodies and polypeptides that specifically bind to SMAGP. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies, Tire antibodies provided herein are particularly advantageous because they specifically bind SMAGP -expressing cells, allowing targeted delivery of therapeutic and diagnostic agents, and therefore have utility in the treatment of cancer (e.g., SMAGP -expressing cancer).

[0005] 'The present disclosure provides compositions and methods of use for those compositions, e.g., for reducing binding between SMAGP and its receptors. In some embodiments, the reduced binding between SMAGP and its receptors promotes phagocytosis of SMAGP-expressing cancer cells by macrophages and / or dendritic cells. In someAttorney Docket No. DEMB-010 / 02WOembodiments, die reduced binding between SMAGP and its receptors triggers neutrophil-mediated cancer cell killing. In some embodiments, the reduced binding between SMAGP and its receptors inhibits Tregs to stimulate (e.g., indirectly stimulate) adaptive antitumor immunity.

[0006] The disclosure provides an antibody that specifically binds Small Cell Adhesion Glycoprotein (SMAGP), wherein the antibody comprises: a heavy chain variable region (VH) comprising the CDRII1, CDRII2, and CDRII3 amino acid sequences of the VH amino acid sequence set forth in any one of SEQ ID NOs: 2-123; and a light chain variable region (VL) comprising die CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in any one of SEQ ID NOs: 124-252.

[0007] In certain embodiments, die VH amino acid sequence and VL amino acid sequence are as set forth in: SEQ ID NOs: 44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, 70 and 197, 2 and 124, 3 and 125, 4 and 126, 5 and 127, 6 and 128, 7 and 129, 8 and 130, 9 and 131, 10 and 132, II and 133, 12 and 134, 13 and 135, 14 and 136, 15 and 137, 16 and 138, 17 and 139, 18 and 140, 19 and 141, 20 and 142, 21 and 143, 22 and 144, 24 and 146, 25 and 147, 26 and 148, 27 and 149, 28 and 150, 29 and 151, 30 and 152, 31 and 153, 32 and 154, 33 and 155, 34 and 156, 35 and 157, 36 and 158, 37 and 159, 38 and 160, 39 and 161, 40 and 162, 41 and 163, 42 and 164, 43 and 165, 45 and 168, 46 and 169, 47 and 170, 48 and 171, 49 and 172, 50 and 173, 51 and 174, 52 and 175, 53 and 176, 54 and 177, 55 and 178, 56 and 179, 57 and 180, 58 and 181, 59 and 182, 60 and 183, 61 and 184, 62 and 185, 63 and 186, 64 and 187, 65 and 188, 71 and 189, 72 and 190, 73 and 191, 74 and 192, 75 and 204, 76 and 205, 77 and 206, 78 and 207, 79 and 208, 80 and 209, 81 and 210, 82 and 211, 83 and 212, 84 and 213, 85 and 214, 86 and 215, 87 and 216, 88 and 217, 89 and 218, 90 and 219, 91 and 220, 92 and 221, 93 and 222, 94 and 223, 95 and 224, 96 and 225, 97 and 226, 98 and 227, 99 and 228, 100 and 229, 101 and 230, 102 and 231, 103 and 232, 104 and 233, 105 and 234, 106 and 235, 107 and 236, 108 and 237, 109 and 238, 110 and 239, Ill and 240, 112 and 241, 113 and 242, 114 and 243, 115 and 244, 116 and 245, 117 and 246, 118 and 247, 119 and 248, 120 and 249, 121 and 250, 122 and 251, or 123 and 252, respectively, in certain embodiments, the VH amino acid sequence and VL amino acid sequence are as set forth in: SEQ ID NOs: 44 and 166, 44 andAttorney Docket No. DEMB-010 / 02WO44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, or 70 and 197, respectively.

[0008] In certain embodiments, the CDRH1, CDRII2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, and 697; 489, 605, and 703; 487, 603, and 677; 487, 603, and 701; 487, 603, and 705; 487, 603, and 706; 487, 603, and 707; 487, 603, and 708; 487, 603, and 709; 487, 603, and 710; 462, 561, and 677; 441, 540, and 656; 442, 541, and 657; 443, 542, and 658; 444, 543, and 659; 445, 544, and 660; 446, 545, and 661; 447, 546, and 662; 448, 547, and 663; 449, 548, and 664; 450, 549, and 665; 451, 550, and 666; 452, 551, and 667; 453, 552, and 668; 454, 553, and 669; 455, 554, and 670; 456, 555, and 671; 457, 556, and 672; 458, 557, and 673; 459, 558, and 674; 460, 559, and 675; 461, 560, and 676; 463, 562, and 678; 464, 563, and 679; 465, 564, and 680; 466, 565, and 681; 467, 566, and 682; 468, 567, and 683; 469, 568, and 684; 470, 569, and 685; 471, 570, and 686; 472, 571, and 687; 473, 572, and 688; 474, 573, and 689: 475, 574, and 690; 476, 575, and 691; 477, 576, and 692; 478, 577, and 693; 479, 578, and 694; 480, 579, and 695; 481, 580, and 696; 483, 582, and 698; 484, 583, and 699; 485, 584, and 700; 452, 585, and 667; 452, 586, and 667; 452, 587, and 667; 452, 588, and 667; 452, 589, and 667; 452, 590, and 667; 452, 591, and 667; 452, 592, and 667; 452, 593, and 667; 452, 594, and 667; 452, 595, and 667; 452, 596, and 667; 452, 1198, and 667; 452, 1199, and 667; 452, 1200, and 667; 452, 1201, and 667; 452, 1202, and 667; 452, 1203, and 667; 452, 1204, and 667; 452, 1205, and 667; 452, 1206, and 667; 486, 597, and 668; 486, 598, and 668; 486, 599, and 668; 486, 600, and 668; 486, 601, and 668; 486, 602, and 668; 488, 604, and 702; 488, 604, and 678; 490, 606, and 704; 491, 607, and 711; 492, 608, and 712; 493, 609, and 713; 494, 610, and 714; 495, 611, and 715; 496, 612, and 716; 497, 613, and 717; 498, 614, and 718; 499, 615, and 719; 500, 616, and 720; 501, 617, and 721; 502, 618, and 722; 503, 619, and 723; 504, 620, and 724; 505, 621, and 725; 506, 622, and 726; 507, 623, and 727; 508, 624, and 728; 509, 625, and 729; 510, 626, and 730; 511, 627, and 731; 512, 628, and 732; 513, 629, and 733; 514, 630, and 734; 515, 631, and 735; 516, 632, and 736; 517, 633, and 737; 518, 634, and 738; 519, 635, and 739; 520, 636, and 740; 521, 637, and 741; 522, 638, and 742; 523, 639, and 743; 524, 640, and 744; 525, 641, and 745; 526, 642, and 746; 527, 643, and 747; 528, 644, and 748; 529, 645, and 749; 530, 646, and 750; 531, 647, and 751; 532, 648, and 752; 533,Attorney Docket No. DEMB-010 / 02WO649, and 753; 534, 650, and 754; 535, 651, and 755; 536, 652, and 756; 537, 653, and 757; 538, 654, and 758; or 539, 655, and 759, respectively. In certain embodiments, the CDRH1, CDRII2, and CDRII3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, and 697, respectively. In certain embodiments, the CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 462, 561, and 677, respectively.

[0009] In certain embodiments, the CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 801, 919, and 1013; 823, 919, and 1013; 824, 919, and 1013; 825, 919, and 1013; 826, 919, and 1013; 827, 919, and 1013; 828, 919, and 1013; 781, 899, and 993; 814, 899, and 993; 818, 899, and 993; 819, 899, and 993; 820, 899, and 993; 821, 899, and 993; 822, 899, and 993; 760, 878, and 972; 761, 879, and 973; 762, 880, and 974; 763, 881, and 975; 764, 882, and 976; 765, 883, and 977; 766, 884, and 978; 767, 885, and 979; 768, 886, and 980; 769, 887, and 981; 770, 888, and 982; 771, 889, and 983; 772, 890, and 984; 773, 891, and 985; 774, 892, and 986; 775, 893, and 987; 776, 894, and 988; 777, 895, and 989; 778, 896, and 990; 779, 897, and 991; 780, 898, and 992; 782, 900, and 994; 783, 901, and 995; 784, 902, and 996; 785, 903, and 997; 786, 904, and 998; 787, 905, and 999; 788, 906, and 1000; 789, 907, and 1001; 790, 908, and 1002; 791, 909, and 1003; 792, 910, and 1004; 793, 911, and 1005; 794, 912, and 1006; 795, 913, and 1007; 796, 914, and 1008; 797, 915, and 1009; 798, 916, and 1010; 799, 917, and 1011; 800, 918, and 1012; 802, 920, and 1014; 803, 921, and 1015; 804, 922, and 1016; 805, 889, and 983; 806, 889, and 983; 807, 889, and 983; 808, 890, and 984; 809, 890, and 984; 810, 890, and 984; 811, 890, and 984; 812, 890, and 984; 813, 890, and 984; 815, 900, and 994; 816, 919, and 1013; 817, 920, and 1014; 829, 923, and 1017; 830, 924, and 1018; 831, 925, and 1019; 832, 926, and 1020; 833, 927, and 1021; 834, 928, and 1022; 835, 929, and 1023; 836, 930, and 1024; 837, 931, and 1025; 838, 932, and 1026; 839, 933, and 1027; 840, 934, and 1028; 841, 935, and 1029; 842, 936, and 1030; 843, 937, and 1031; 844, 938, and 1032; 845, 939, and 1033; 846, 940, and 1034; 847, 941, and 1035; 848, 942, and 1036; 849, 943, and 1037; 850, 944, and 1038; 851, 945, and 1039; 852, 946, and 1040; 853, 947, and 1041; 854, 948, and 1042; 855, 949, and 1043; 856, 950, and 1044; 857, 951, and 1045; 858, 952, and 1046; 859, 953, and 1047; 860, 954, and 1048; 861, 955, and 1049; 862, 956, and 1050; 863, 957, and 1051; 864, 958, and 1052; 865, 959, and 1053; 866, 960, and 1054; 867, 961, and 1055; 868, 962, and 1056; 869, 963, and 1057; 870, 964, and 1058; 871, 965, and 1059; 872, 966, and 1060; 873, 967, and 1061; 874, 968, and 1062; 875, 969, and 1063; 876, 970, and 1064; or 877, 971, and 1065, respectively. In certain embodiments, the CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 801, 919, and 1013, respectively. In certain embodiments, theAttorney Docket No. DEMB-010 / 02WOCDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 781. 899, and 993, respectively.

[0010] In certain embodiments, the CDRII1, CDRH2, CDRII3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, 697, 801, 919, and 1013; 489, 605, 703, 823, 919, and 1013; 489, 605, 703, 824, 919, and 1013; 489, 605, 703, 825, 919, and 1013; 489, 605, 703, 826, 919, and 1013; 489, 605, 703, 827, 919, and 1013; or 489, 605, 703, 828, 919, and 1013; 462, 561, 677, 781, 899, and 993; 462, 561, 677, 818, 899, and 993; 462, 561, 677, 819, 899, and 993; 462, 561, 677, 820, 899, and 993; 462, 561, 677, 821, 899, and 993; 462, 561, 677, 822, 899, and 993; 487, 603, 705, 781, 899, and 993; 487, 603, 705, 818, 899, and 993; 487, 603, 705, 819, 899, and 993; 487, 603, 705, 820, 899, and 993; 487, 603, 705, 821, 899, and 993; 487, 603, 705, 822, 899, and 993; 487, 603, 706, 781, 899, and 993; 487, 603, 706, 818, 899, and 993; 487, 603, 706, 819, 899, and 993; 487, 603, 706, 820, 899, and 993; 487, 603, 706, 821, 899, and 993; 487, 603, 706, 822, 899, and 993; 487, 603, 707, 781, 899, and 993; 487, 603, 707, 818, 899, and 993; 487, 603, 707, 819, 899, and 993; 487, 603, 707, 820, 899, and 993; 487, 603, 707, 821, 899, and 993; 487, 603, 707, 822, 899, and 993; 487, 603, 708, 781, 899, and 993; 487, 603, 708, 818, 899, and 993; 487, 603, 708, 819, 899, and 993; 487, 603, 708, 820, 899, and 993; 487, 603, 708, 821, 899, and 993; 487, 603, 708, 822, 899, and 993; 487, 603, 709, 781, 899, and 993; 487, 603, 709, 818, 899, and 993; 487, 603, 709, 819, 899, and 993; 487, 603, 709, 820, 899, and 993; 487, 603, 709, 821, 899, and 993: 487, 603, 709, 822, 899, and 993: 487, 603, 710, 781, 899, and 993: 487, 603, 710, 818, 899, and 993; 487, 603, 710, 819, 899, and 993; 487, 603, 710, 820, 899, and 993; 487, 603, 710, 821, 899, and 993; 487, 603, 710, 822, 899, and 993; 441, 540, 656, 760, 878, and 972; 442, 541, 657, 761, 879, and 973; 443, 542, 658, 762, 880, and 974; 444, 543, 659, 763, 881, and 975; 445, 544, 660, 764, 882, and 976; 446, 545, 661, 765, 883, and 977; 447, 546, 662, 766, 884, and 978; 448, 547, 663, 767, 885, and 979; 449, 548, 664, 768, 886, and 980; 450, 549, 665, 769, 887, and 981; 451, 550, 666, 770, 888, and 982; 452, 551, 667, 771, 889, and 983: 453, 552, 668, 772, 890, and 984: 454, 553, 669, 773, 891, and 985: 455, 554, 670, 774, 892, and 986; 456, 555, 671, 775, 893, and 987; 457, 556, 672, 776, 894, and 988; 458, 557, 673, 777, 895, and 989; 459, 558, 674, 778, 896, and 990; 460, 559, 675, 779, 897, and 991; 461, 560, 676, 780, 898, and 992; 463, 562, 678, 782, 900, and 994; 464, 563, 679, 783, 901, and 995; 465, 564, 680, 784, 902, and 996; 466, 565, 681, 785, 903, and 997; 467, 566, 682, 786, 904, and 998; 468, 567, 683, 787, 905, and 999; 469, 568, 684, 788, 906, and 1000; 470, 569, 685, 789, 907, and 1001; 471, 570, 686, 790, 908, and 1002; 472, 571, 687, 791, 909, and 1003; 473, 572, 688, 792, 910, and 1004; 474, 573, 689, 793, 911, andAttorney Docket No. DEMB-010 / 02WO1005; 475, 574, 690, 794, 912, and 1006; 476, 575, 691, 795, 913, and 1007; 477, 576, 692, 796, 914, and 1008; 478, 577, 693, 797, 915, and 1009; 479, 578, 694, 798, 916, and 1010; 480, 579, 695, 799, 917, and 1011; 481, 580, 696, 800, 918, and 1012; 483, 582, 698, 802, 920, and 1014; 484, 583, 699, 803, 921, and 1015; 485, 584, 700, 804, 922, and 1016; 452, 585, 667, 805, 889, and 983; 452, 586, 667, 805, 889, and 983; 452, 587, 667, 805, 889, and 983; 452, 588, 667, 805, 889, and 983; 452, 589, 667, 805, 889, and 983; 452, 590, 667, 805, 889, and 983; 452, 591, 667, 805, 889, and 983; 452, 592, 667, 805, 889, and 983; 452, 593, 667, 805, 889, and 983; 452, 594, 667, 805, 889, and 983; 452, 595, 667, 806, 889, and 983; 452, 596, 667, 807, 889, and 983; 452, 1198, 667, 805, 889, and 983; 452, 1199, 667, 805, 889, and 983; 452, 1200, 667, 805, 889, and 983; 452, 1201, 667, 805, 889, and 983; 452, 1202, 667, 805, 889, and 983; 452, 1203, 667, 805, 889, and 983; 452, 1204, 667, 805, 889, and 983; 452, 1205, 667, 805, 889, and 983; 452, 1206, 667, 805, 889, and 983; 452, 551, 667, 806, 889, and 983; 452, 551, 667, 807, 889, and 983; 486, 597, 668, 808, 890, and 984; 486, 598, 668, 809, 890, and 984; 486, 599, 668, 810, 890, and 984; 486, 600, 668, 811, 890, and 984; 486, 601, 668, 812, 890, and 984; 486, 602, 668, 813, 890, and 984; 488, 604, 702, 782, 900, and 994; 483, 582, 698, 817, 920, and 1014; 490, 606, 704, 817, 920, and 1014; 491, 607, 711, 829, 923, and 1017; 492, 608, 712, 830, 924, and 1018; 493, 609, 713, 831, 925, and 1019; 494, 610, 714, 832, 926, and 1020; 495, 611, 715, 833, 927, and 1021; 496, 612, 716, 834, 928, and 1022; 497, 613, 717, 835, 929, and 1023; 498, 614, 718, 836, 930, and 1024; 499, 615, 719, 837, 931, and 1025; 500, 616, 720, 838, 932, and 1026; 501, 617, 721, 839, 933, and 1027; 502, 618, 722, 840, 934, and 1028; 503, 619, 723, 841, 935, and 1029; 504, 620, 724, 842, 936, and 1030; 505, 621, 725, 843, 937, and 1031; 506, 622, 726, 844, 938, and 1032; 507, 623, 727, 845, 939, and 1033; 508, 624, 728, 846, 940, and 1034; 509, 625, 729, 847, 941, and 1035; 510, 626, 730, 848, 942, and 1036; 511, 627, 731, 849, 943, and 1037; 512, 628, 732, 850, 944, and 1038; 513, 629, 733, 851, 945, and 1039; 514, 630, 734, 852, 946, and 1040; 515, 631, 735, 853, 947, and 1041; 516, 632, 736, 854, 948, and 1042; 517, 633, 737, 855, 949, and 1043; 518, 634, 738, 856, 950, and 1044; 519, 635, 739, 857, 951, and 1045; 520, 636, 740, 858, 952, and 1046; 521, 637, 741, 859, 953, and 1047; 522, 638, 742, 860, 954, and 1048; 523, 639, 743, 861, 955, and 1049; 524, 640, 744, 862, 956, and 1050; 525, 641, 745, 863, 957, and 1051; 526, 642, 746, 864, 958, and 1052; 527, 643, 747, 865, 959, and 1053; 528, 644, 748, 866, 960, and 1054; 529, 645, 749, 867, 961, and 1055; 530, 646, 750, 868, 962, and 1056; 531, 647, 751, 869, 963, and 1057; 532, 648, 752, 870, 964, and 1058; 533, 649, 753, 871, 965, and 1059; 534, 650, 754, 872, 966, and 1060; 535, 651, 755, 873, 967, and 1061; 536, 652, 756, 874, 968, and 1062;Attorney Docket No. DEMB-010 / 02WO537, 653, 757, 875, 969, and 1063; 538, 654, 758, 876, 970, and 1064; or 539, 655, 759, 877, 971, and 1065, respectively.

[0011] In certain embodiments, the CDRH1, CDRH2, CDRII3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, 697, 801, 919, and 1013; 489, 605, 703, 823, 919, and 1013; 489, 605, 703, 824, 919, and 1013; 489, 605, 703, 825, 919, and 1013; 489, 605, 703, 826, 919, and 1013; 489, 605, 703, 827, 919, and 1013; or 489, 605, 703, 828, 919, and 1013; 462, 561, 677, 781, 899, and 993; 462, 561, 677, 818, 899, and 993; 462, 561, 677, 819, 899, and 993; 462, 561, 677, 820, 899, and 993; 462, 561, 677, 821, 899, and 993; 462, 561, 677, 822, 899, and 993; 487, 603, 705, 781, 899, and 993; 487, 603, 705, 818, 899, and 993; 487, 603, 705, 819, 899, and 993; 487, 603, 705, 820, 899, and 993; 487, 603, 705, 821, 899, and 993; 487, 603, 705, 822, 899, and 993; 487, 603, 706, 781, 899, and 993; 487, 603, 706, 818, 899, and 993; 487, 603, 706, 819, 899, and 993; 487, 603, 706, 820, 899, and 993; 487, 603, 706, 821, 899, and 993; 487, 603, 706, 822, 899, and 993; 487, 603, 707, 781, 899, and 993; 487, 603, 707, 818, 899, and 993; 487, 603, 707, 819, 899, and 993; 487, 603, 707, 820, 899, and 993; 487, 603, 707, 821, 899, and 993; 487, 603, 707, 822, 899, and 993; 487, 603, 708, 781, 899, and 993; 487, 603, 708, 818, 899, and 993; 487, 603, 708, 819, 899, and 993; 487, 603, 708, 820, 899, and 993; 487, 603, 708, 821, 899, and 993; 487, 603, 708, 822, 899, and 993; 487, 603, 709, 781, 899, and 993; 487, 603, 709, 818, 899, and 993; 487, 603, 709, 819, 899, and 993; 487, 603, 709, 820, 899, and 993; 487, 603, 709, 821, 899, and 993: 487, 603, 709, 822, 899, and 993: 487, 603, 710, 781, 899, and 993: 487, 603, 710, 818, 899, and 993; 487, 603, 710, 819, 899, and 993; 487, 603, 710, 820, 899, and 993; 487, 603, 710, 821, 899, and 993; or 487, 603, 710, 822, 899, and 993, respectively. In certain embodiments, the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, 697, 801, 919, and 1013, respectively. In certain embodiments, the CDRH1, CDRH2, CDRII3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 462, 561, 677, 781, 899, and 993, respectively.

[0012] In certain embodiments, the VII comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 2-123. In certain embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 44. In certain embodiments, the VH comprises the amino acid sequence of SEQ ID NOs: 23, 66, 67, 68, 69, or 70. In certain embodiments, the VH comprises tire amino acid sequence of SEQ ID NO: 23.Attorney Docket No. DEMB-010 / 02WO

[0013] In certain embodiments, the VL comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 124-252. In certain embodiments, the VL comprises the amino acid sequence of SEQ ID NOs: 166, 198, 199, 200, 201, 202, or 203. In certain embodiments, the VL comprises the ammo acid sequence of SEQ ID NO: 166. In certain embodiments, the VL comprises the amino acid sequence of SEQ ID NOs: 145, 193, 194, 195, 196, or 197. In certain embodiments, the VL comprises the amino acid sequence of SEQ ID NO: 145.

[0014] In certain embodiments, the VH amino acid sequence and the VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs: 44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, 70 and 197, 2 and 124, 3 and 125, 4 and 126, 5 and 127, 6 and 128, 7 and 129, 8 and 130, 9 and 131, 10 and 132, 11 and 133, 12 and 134, 13 and 135, 14 and 136, 15 and 137, 16 and 138, 17 and 139, 18 and 140, 19 and 141, 20 and 142, 21 and 143, 22 and 144, 24 and 146, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 25 and 147, 26 and 148, 27 and 149, 28 and 150, 29 and 151, 30 and 152, 31 and 53, 32 and 154, 33 and 155, 34 and 156, 35 and 157, 36 and 158, 37 and 159, 38 and 160, 39 and 161, 40 and 162, 41 and 163, 42 and 164, 43 and 165, 45 and 168, 46 and 169, 47 and 170, 48 and 171, 49 and 172, 50 and 173, 51 and 174, 52 and 175, 53 and 176, 54 and 177, 55 and 178, 56 and 179, 57 and 180, 58 and 181, 59 and 182, 60 and 183, 61 and 184, 62 and 185, 63 and 186, 64 and 187, 65 and 188, 71 and 189, 72 and 190, 73 and 191, 74 and 192, 75 and 204, 76 and 205, 77 and 206, 78 and 207, 79 and 208, 80 and 209, 81 and 210, 82 and 211, 83 and 212, 84 and 213, 85 and 214, 86 and 215, 87 and 216, 88 and 217, 89 and 218, 90 and 219, 91 and 220, 92 and 221, 93 and 222, 94 and 223, 95 and 224, 96 and 225, 97 and 226, 98 and 227, 99 and 228, 100 and 229, 101 and 230, 102 and 231, 103 and 232, 104 and 233, 105 and 234, 106 and 235, 107 and 236, 108 and 237, 109 and 238, 110 and 239, 111 and 240, 112 and 241, 113 and 242, 114 and 243, 115 and 244, 116 and 245, 117 and 246, 118 and 247, 119 and 248, 120 and 249, 121 and 250, 122 and 251, or 123 and 252, respectively. In certain embodiments, the VH amino acid sequence and the VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs:Attorney Docket No. DEMB-010 / 02WO44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, or 70 and 197, respectively. In certain embodiments, the VH amino acid sequence and the VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs: 44 and 166, respectively. In certain embodiments, the VH amino acid sequence and the VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs: 23 and 145, respectively.

[0015] In certain embodiments, the antibody comprises a heavy chain constant region. In certain embodiments, the heavy chain constant region is selected from the group consisting of human IgGi, IgGi, IgGs, IgG*, IgAi, and IgA2.

[0016] In certain embodiments, the heavy chain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity' to any of SEQ ID NOs: 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, or 1074. In certain embodiments, the antibody comprises an IgGi heavy¬ chain constant region. In certain embodiments, the IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1066 or 1070. In certain embodiments, the antibody comprises an IgGi heavy chain constant region comprising amino acids Asp239 and Glu332, wherein the amino acid position is indicated according to the EU numbering system. In certain embodiments, the IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1067 or 1071, In certain embodiments, the antibody comprises an IgGi heavy- chain constant region comprising amino acids Ala236, Asp239, and Glu332, wherein the amino acid position is indicated according to the EU numbering system. In certain embodiments, the IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1068 or 1072. In certain embodiments, the antibody comprises an IgGi heavy chain constant region comprising amino acids Ala234, Ala235, and Gly329, wherein the amino acid position is indicated according to the EU numbering system. In certain embodiments, the IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1069 or 1073. In certain embodiments, tire antibody comprises an afucosylated IgGi heavy chain constant region. In certain embodiments, the afucosylated IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1074 or 1174.Attorney Docket No. DEMB-010 / 02WO

[0017] In certain embodiments, the light chain constant region comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 1075, 1076, or 1077. In certain embodiments, the antibody comprises a light chain constant region comprising the amino acid sequences of SEQ ID NOs: 1075, 1076, or 1077. In certain embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92 %, at least 93%, at least 94 %, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 253-346, 1080-1173, or 1175-1184. In certain embodiments, the heavy chain lacks its C-terminal lysine. In certain embodiments, the antibody comprises a heavy chain comprising tire amino acid sequence of SEQ ID NO: 294, In certain embodiments, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 1121. In certain embodiments, the antibody comprises a heavy chain comprising tire amino acid sequence of SEQ ID NO: 274. In certain embodiments, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 1101.

[0018] In certain embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 347- 440 or 1185-1195. In certain embodiments, the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 388. In certain embodiments, the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 368.

[0019] In certain embodiments, the antibody comprises a heavy' chain comprising the amino acid sequence of any one of SEQ ID NOs: 253-346, 1080-1173, or 1175-1184; and a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 347-440 or 1185-1195. In certain embodiments, the heavy chain and light chain comprise the amino acid sequences of SEQ ID NOs: 294 and 388, 294 and 1190, 294 and 1191, 294 and 1192, 294 and 1193, 294 and 1194, 294 and 1195, 1121 and 388, 1121 and 1190, 1121 and 1191, 1121 and 1192, 1121 and 1193, 1121 and 1194, 1121 and 1195, 274 and 368, 1101 and 368, 274 and 1185, 274 and 1186, 274 and 1187, 274 and 1188, 274 and 1189, 1175 and 368, 1175 and 1185, 1175 and 1186, 1175 and 1187, 1175 and 1188, 1175 and 1189, 1176 and 368, 1176 and 1185, 1176 and 1186, 1176 and 1187, 1176 and 1188, 1176 and 1189, 1177 and 368, 1177 and 1185,Attorney Docket No. DEMB-010 / 02WO1177 and 1186, 1177 and 1187, 1177 and 1188, 1177 and 1189, 1178 and 368, 1178 and 1185, 1178 and 1186, 1178 and 1187, 1178 and 1188, 1178 and 1189, 1179 and 368, 1179 and 1185, 1179 and 1186, 1179 and 1187, 1179 and 1188, 1179 and 1189, 1101 and 1185, 1101 and 1186, 1101 and 1187, 1101 and 1188, 1101 and 1189, 1180 and 368, 1180 and 1185, 1180 and 1186, 1180 and 1187, 1180 and 1188, 1180 and 1189, 1181 and 368, 1181 and 1185, 1181 and 1186, 1181 and 1187, 1181 and 1188, 1181 and 1189, 1182 and 368, 1182 and 1185, 1182 and 1186, 1182 and 1187, 1182 and 1188, 1182 and 1189, 1183 and 368, 1183 and 1185, 1183 and 1186, 1183 and 1187, 1183 and 1188, 1183 and 1189, 1184 and 368, 1184 and 1185, 1184 and 1186, 1184 and 1187, 1184 and 1188, 1184 and 1189, 253 and 347, 254 and 348, 255 and 349, 256 and 350, 257 and 351, 258 and 352, 259 and 353, 260 and 354, 261 and 355, 262 and 356, 263 and 357, 264 and 358, 265 and 359, 266 and 360, 267 and 361, 268 and 362, 269 and 363, 270 and 364, 271 and 365, 272 and 366, 273 and 367, 275 and 369, 276 and 370, 277 and 371, 278 and 372, 279 and 373, 280 and 374, 281 and 375, 282 and 376, 283 and 377, 284 and 378, 285 and 379, 286 and 380, 287 and 381, 288 and 382, 289 and 383, 290 and 384, 291 and 385, 292 and 386, 293 and 387, 295 and 389, 296 and 390, 297 and 391, 298 and 392, 299 and 393, 300 and 394, 301 and 395, 302 and 396, 303 and 397, 304 and 398, 305 and 399, 306 and 400, 307 and 401, 308 and 402, 309 and 403, 310 and 404, 311 and 405, 312 and 406, 313 and 407, 314 and 408, 315 and 409, 316 and 410, 317 and 411, 318 and 412, 319 and 413, 320 and 414, 321 and 415, 322 and 416, 323 and 417, 324 and 418, 325 and 419, 326 and 420, 327 and 421, 328 and 422, 329 and 423, 330 and 424, 331 and 425, 332 and 426, 333 and 427, 334 and 428, 335 and 429, 336 and 430, 337 and 431, 338 and 432, 339 and 433, 340 and 434, 341 and 435, 342 and 436, 343 and 437, 344 and 438, 345 and 439, or 346 and 440, 1080 and 347,1081 and 348, 1082 and 349,1083 and 350,1084 and 351, 1085 and 352, 1086 and 353, 1087 and 354, 1088 and 355,1089 and 356, 1090 and 357, 1091 and 358, 1092 and 359, 1093 and 360, 1094 and 361, 1095 and 362, 1096 and 363, 1097 and 364, 1098 and 365, 1099 and 366, 1100 and 367,1102 and 369, 1103 and 370, 1104 and 371, 1105 and 372, 1106 and 373, 1107 and 374, 1108 and 375, 1109 and 376, 1110 and 377, 1111 and 378, 1112 and 379, 1113 and 380, 1114 and 381, 1115 and 382, 1116 and 383, 1117 and 384, 1118 and 385, 1119 and 386, 1120 and 387, 1122 and 389, 1123 and 390, 1124 and 391, 1125 and 392, 1126 and 393, 1127 and 394, 1128 and 395, 1129 and 396, 1130 and 397, 1131 and 398, 1132 and 399, 1133 and 400, 1134 and 401, 1135 and 402, 1136 and 403, 1137 and 404, 1138 and 405, 1139 and 406, 1140 and 407, 1141 and 408, 1142 and 409, 1143 and 410, 1144 and 411, 1145 and 412, 1146 and 413, 1147 and 414, 1148 and 415, 1149 and 416, 1150 and 417, 1151 and 418, 1152 and 419, 1153 and 420, 1154 and 421, 1155 and 422, 1156 and 423, 1157 and 424, 1158 and 425, 1159 andAttorney Docket No. DEMB-010 / 02WO426, 1160 and 427, 1161 and 428, 1162 and 429,1163 and 430, 1164 and 431, 1165 and 432, 1166 and 433, 1167 and 434, 1168 and 435, 1169 and 436, 1170 and 437, 1171 and 438, 1172 and 439, or 1173 and 440, respectively. In certain embodiments, the heavy chain and the light chain comprise the amino acid sequences of SEQ ID NOs: 294 and 388, respectively. In certain embodiments, the heavy chain and the light chain comprise the amino acid sequences of SEQ ID NOs: 1121 and 388, respectively. In certain embodiments, the heavy chain and the light chain comprise the amino acid sequences of SEQ ID NOs: 274 and 368, respectively. In certain embodiments, tire heavy chain and the light chain comprise the amino acid sequences of SEQ ID NOs: 1101 and 368, respectively.

[0020] The disclosure also provides an antibody that cross-competes for binding with the antibody described herein.

[0021] The disclosure also provides an antibody that specifically binds to the same epitope of human Small Cell Adhesion Glycoprotein (SMAGP) extracellular domain (ECD) as the antibody described herein.

[0022] Tire disclosure also provides an antibody that specifically binds to an epitope of human SMAGP ECD.

[0023] In certain embodiments, the human SMAGP ECD described herein comprises amino acids 1-36 of SEQ ID NO: 1. In certain embodiments, the epitope of human SMAGP ECD comprises amino acids selected from the group consisting of: Leu5; Thr7; Argl I; Glut 2; Glul3; Leul4; Metl5; ThrI6; Prol8; Ilel9; Leu20; Gln21; Pro22; Thr23: Glu24; Leu26; Leul4 and Metl5; IIel9 and Glu24; and GIn21 and Pro22. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consisting of: Gln21, Pro22, and Glu24; Gln21, Pro22, and Thr23; Glul3, Leu 14, and MetL5; and GluI2, Leul4, and Metl5, In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consisting of: Glul2, Glul3, Leul4, and Metl5; and Prol8, lie 19, Leu20, and Gln21. In certain embodiments, the antibody specifically binds to an epitope of human SM AGP ECD comprising amino acids selected from the group consisting of: Thr7; Glul2; GIul3; Leul4; Metl5; Prol8; Ilel9; Leu20; Gln21; Pro22; Thr23; Glu24; Leu20, Gln21, Pro22, Thr23, and Glu24; lie 19, Gln21, and Glu24; and Thr7 and Leul4. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consisting of: Glul2; Glul3; Leul4; Metl5; Prol8; Ilel9; Leu20; Gln21; Pro22; Thr23; Glu24; He 19, Gln21, Pro22, Glu24, and Leu26; He 19, Gln21, Glu24, and Leu26; Glul2, Leu 14, and Met 15; and He 19, Gln21, and Pro22. In certain embodiments, tire antibodyAttorney Docket No. DEMB-010 / 02WOspecifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consisting of: Leu5, Glul2, Glul3, Leul4, and MetI5; Glul2, GluI3, Leul4, Metl5, and Thrl6; and Thrl6, He 19, Leu20, Gln21, Pro22, Thr23, and Glu24. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Argil, Glul2, Glul3, Leul4, Metl5, and Thrl6. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Pro 18, He 19, Leu20, GIn21, Pro22, Thr23, Glu24, and Leu26. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Gln21, Pro22, or Ilir23. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Gln21 and Pro22. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids He 19, Leu20, Gln2I, Pro22, and Thr23. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Gln21, Pro22, and Thr23, In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Leu20, Gln21, Pro22, and Thr23. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Leu20, Gln21, Pro22, Thr23, and Glu24, In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids lie 19, Leu20, GIn21, Pro22, Thr23, and Glu24.

[0024] In certain embodiments, the antibody reduces binding of Paired Immunoglobulin-like Type 2 Receptor-a (PILRa) to SMAGP. In certain embodiments, the antibody reduces binding of CD 177 to SMAGP.

[0025] The disclosure also provides a polypeptide comprising a VH which comprises the CDRHI, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in any one of SEQ ID NOs: 2-123. In certain embodiments, the CDRHI, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, and 697; 489, 605, and 703; 487, 603, and 677; 487, 603, and 701; 487, 603, and 705; 487, 603, and 706; 487, 603, and 707; 487, 603, and 708; 487, 603, and 709; 487, 603, and 710; 462, 561, and 677; 441, 540, and 656; 442, 541, and 657; 443, 542, and 658; 444, 543, and 659; 445, 544, and 660; 446, 545, and 661; 447, 546, and 662; 448, 547, and 663; 449, 548, and 664; 450, 549, and 665; 451, 550, and 666; 452, 551, and 667; 453, 552, and 668; 454, 553, and 669; 455, 554, and 670; 456, 555, and 671; 457, 556, and 672; 458, 557, and 673; 459, 558, and 674; 460, 559, and 675; 461, 560, and 676; 463, 562, and 678; 464, 563, and 679; 465, 564, and 680; 466, 565, and 681; 467, 566, and 682; 468, 567, and 683; 469, 568, and 684; 470, 569, and 685;Attorney Docket No. DEMB-010 / 02WO471, 570, and 686; 472, 571, and 687; 473, 572, and 688; 474, 573, and 689; 475, 574, and 690; 476, 575, and 691; 477, 576, and 692; 478, 577, and 693; 479, 578, and 694; 480, 579, and 695; 481, 580, and 696; 483, 582, and 698; 484, 583, and 699; 485, 584, and 700; 452, 585, and 667; 452, 586, and 667; 452, 587, and 667; 452, 588, and 667; 452, 589, and 667; 452, 590, and 667; 452, 591, and 667; 452, 592, and 667; 452, 593, and 667; 452, 594, and 667; 452, 595, and 667; 452, 596, and 667; 452, 1198, and 667; 452, 1199, and 667; 452, 1200, and 667; 452, 1201, and 667; 452, 1202, and 667; 452, 1203, and 667; 452, 1204, and 667; 452, 1205, and 667; 452, 1206, and 667; 486, 597, and 668; 486, 598, and 668; 486, 599, and 668; 486, 600, and 668; 486, 601, and 668; 486, 602, and 668; 488, 604, and 702; 488, 604, and 678; 490, 606, and 704; 491, 607, and 711; 492, 608, and 712; 493, 609, and 713; 494, 610, and 714; 495, 611, and 715; 496, 612, and 716; 497, 613, and 717; 498, 614, and 718; 499, 615, and 719; 500, 616, and 720; 501, 617, and 721; 502, 618, and 722; 503, 619, and 723; 504, 620, and 724; 505, 621, and 725; 506, 622, and 726; 507, 623, and 727; 508, 624, and 728; 509, 625, and 729; 510, 626, and 730; 511, 627, and 731; 512, 628, and 732; 513, 629, and 733; 514, 630, and 734; 515, 631, and 735; 516, 632, and 736; 517, 633, and 737; 518, 634, and 738; 519, 635, and 739; 520, 636, and 740; 521, 637, and 741; 522, 638, and 742; 523, 639, and 743; 524, 640, and 744; 525, 641, and 745; 526, 642, and 746; 527, 643, and 747; 528, 644, and 748; 529, 645, and 749; 530, 646, and 750; 531, 647, and 751; 532, 648, and 752; 533, 649, and 753; 534, 650, and 754; 535, 651, and 755; 536, 652, and 756; 537, 653, and 757; 538, 654, and 758; or 539, 655, and 759, respectively.

[0026] Tire disclosure also provides a polypeptide comprising a VL which comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in any one of SEQ ID NOs: 124-252. In certain embodiments, the CDRLL CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 801, 919, and 1013; 823, 919, and 1013; 824, 919, and 1013; 825, 919, and 1013; 826, 919, and 1013; 827, 919, and 1013; 828, 919, and 1013; 781, 899, and 993; 814, 899, and 993; 818, 899, and 993; 819, 899, and 993; 820, 899, and 993; 821, 899, and 993; 822, 899, and 993; 760, 878, and 972; 761, 879, and 973; 762, 880, and 974; 763, 881, and 975; 764, 882, and 976; 765, 883, and 977; 766, 884, and 978; 767, 885, and 979; 768, 886, and 980; 769, 887, and 981; 770, 888, and 982; 771, 889, and 983; 772, 890, and 984; 773, 891, and 985; 774, 892, and 986; 775, 893, and 987; 776, 894, and 988; 777, 895, and 989; 778, 896, and 990; 779, 897, and 991; 780, 898, and 992; 782, 900, and 994; 783, 901, and 995; 784, 902, and 996; 785, 903, and 997; 786, 904, and 998; 787, 905, and 999; 788, 906, and 1000; 789, 907, and 1001; 790, 908, and 1002; 791, 909, and 1003; 792, 910, and 1004; 793, 911, and 1005; 794, 912, and 1006; 795, 913,Attorney Docket No. DEMB-010 / 02WOand 1007; 796, 914, and 1008; 797, 915, and 1009; 798, 916, and 1010; 799, 917, and 1011; 800, 918, and 1012; 802, 920, and 1014; 803, 921, and 1015; 804, 922, and 1016; 805, 889, and 983; 806, 889, and 983; 807, 889, and 983; 808, 890, and 984; 809, 890, and 984; 810, 890, and 984; 811, 890, and 984; 812, 890, and 984; 813, 890, and 984; 815, 900, and 994; 816, 919, and 1013; 817, 920, and 1014; 829, 923, and 1017; 830, 924, and 1018; 831, 925, and 1019; 832, 926, and 1020; 833, 927, and 1021; 834, 928, and 1022; 835, 929, and 1023; 836, 930, and 1024; 837, 931, and 1025; 838, 932, and 1026; 839, 933, and 1027; 840, 934, and 1028; 841, 935, and 1029; 842, 936, and 1030; 843, 937, and 1031; 844, 938, and 1032; 845, 939, and 1033; 846, 940, and 1034; 847, 941, and 1035; 848, 942, and 1036; 849, 943, and 1037; 850, 944, and 1038; 851, 945, and 1039; 852, 946, and 1040; 853, 947, and 1041; 854, 948, and 1042; 855, 949, and 1043; 856, 950, and 1044; 857, 951, and 1045; 858, 952, and 1046; 859, 953, and 1047; 860, 954, and 1048; 861, 955, and 1049; 862, 956, and 1050; 863, 957, and 1051; 864, 958, and 1052; 865, 959, and 1053; 866, 960, and 1054; 867, 961, and 1055; 868, 962, and 1056; 869, 963, and 1057; 870, 964, and 1058; 871, 965, and 1059; 872, 966, and 1060; 873, 967, and 1061; 874, 968, and 1062; 875, 969, and 1063; 876, 970, and 1064; or 877, 971, and 1065, respectively.

[0027] The disclosure also provides a polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs: 2-252.

[0028] In certain embodiments, the VH comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 2-123. In certain embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93?% at least 94%, at least 95%, at least 96%, at least 97%, at least 98?% at least 99%, or 100% sequence identity to any of SEQ ID NOs: 253-346, 1080-1173, or 1175-1184.

[0029] In certain embodiments, the VI, comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97?% at least 98?% at least 99?% or 100% sequence identity to any of SEQ ID NOs: 124-252. In certain embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 85%, at least 86?% at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93?% at least 94%, at least 95%, at least 96%, at least 97?% at least 98?% at least 99?% or 100% sequence identity to any of SEQ ID NOs: 347-440 or 1185-1195.Attorney Docket No. DEMB-010 / 02WO

[0030] The disclosure also provides a polynucleotide encoding: the VH, the VL, the heavy chain, and / or the light chain of the antibody described herein or tire polypeptide described herein. The disclosure also provides a vector comprising the polynucleotide described herein. The disclosure also provides a recombinant host cell comprising: the polynucleotide described herein; a vector described herein; a first polynucleotide encoding the VH or the heavy chain of an antibody described herein and a second polynucleotide encoding the VL or the light chain of an antibody described herein; and / or a first vector comprising a first polynucleotide encoding the VH or the heavy chain of an antibody described herein and a second vector comprising a second polynucleotide encoding tire VL or the light chain of the antibody of an antibody described herein.

[0031] The disclosure also provides a composition comprising an antibody described herein, a polypeptide described herein, a polynucleotide described herein, a vector described herein, or a host cell described herein, and a pharmaceutically acceptable carrier or excipient.

[0032] Tire disclosure also provides a method of producing an antibody, the method comprising culturing a cell described herein under suitable conditions such that a polynucleotide is expressed, and the antibody is produced.

[0033] The disclosure also provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject an effective amount of an antibody- described herein; a polypeptide described herein; a polynucleotide described herein; a vector described herein; a host cell described herein; or a composition described herein. In certain embodiments tire method comprises, further administering an additional therapeutic agent to the subject. In certain embodiments, the disease or disorder is a cancer. In certain embodiments, the cancer is selected from the group consisting of colon cancer, rectal cancer, colorectal cancer, gastric cancer, esophageal cancer, gastric-esophageal junction cancer, bladder cancer, pancreatic adenocarcinoma, cervical squamous and adenocarcinoma, lung squamous and adenocarcinoma, liver cancer (hepatocellular carcinoma), breast cancer, triple negative breast cancer, thyroid cancer, endometrial carcinoma, kidney renal papillary- cell carcinoma, glioblastoma, thymoma, and testicular germ cell tumor. In certain embodiments, the additional therapeutic agent is a chemotherapeutic, a radiotherapeutic, or a targeting agent.

[0034] In certain embodiments, the additional therapeutic agent is selected from the group consisting of an antagonist anti-PD-1 antibody, an antagonist anti-PD-Ll antibody, an antagonist anti-PD-L2 antibody, an antagonist anti-PD-l / VEGF antibody, an antagonist anti-CTLA-4 antibody, an anti-HERl antibody, an anti-HERl-LGR5 antibody, an anti-HERl-MET antibody, an anti-HER2 antibody, an anti-EGFR antibody, an anti-CMET antibody, an antiAttorney Docket No. DEMB-010 / 02WOVEGF antibody, an anti-VEGFR antibody, an anti-VEGFR-2 antibody, a TROP-2 directed antibody, an anti-Nectin-4 antibody, an antagonist anti-TIM-3 antibody, an antagonist anti-LAG-3 antibody, an antagonist anti-VISTA antibody, an antagonist tyrosine kinase inhibitor antibody, an antagonist anti-TIGIT antibody, an antagonist anti-SIRPa antibody, an antagonist BRAF inhibitor antibody, a BRAF inhibitor, an anti-Claudin 18.2 antibody, an MEK inhibitor, an antagonist anti-CD96 antibody, an antagonist anti-CEACAMl antibody, an agonist anti-CD137 antibody, an mTOR inhibitor, a tropomyosin kinase receptor inhibitor, a CDK4 / 6 inhibitor, a PIK3CA inhibitor, an AKT inhibitor, a KRAS inhibitor, a pan-RAS inhibitor, an agonist anti-GITR antibody, and an agonist anti-OX40 antibody.

[0035] The disclosure also provides tire use of an antibody described herein; a polypeptide described herein; a polynucleotide described herein; a vector described herein; a host cell described herein; or a composition described herein, for the manufacture of a medicament for treating cancer.

[0036] Tire disclosure also provides an antibody described herein; a polypeptide described herein; a polynucleotide described herein; a vector described herein; a host cell described herein; or a composition described herein for use in medicine.

[0037] The disclosure also provides an antibody described herein; a polypeptide described herein; a polynucleotide described herein; a vector described herein; a host cell described herein; or a composition described herein, for use in treating cancer in a subject.

[0038] The disclosure also provides a kit comprising an antibody described herein; a polypeptide described herein; a polynucleotide described herein; a vector described herein; a host cell described herein; or a composition described herein.BRIEF DESCRIPTION OF THE DRAWINGS

[0039] FIG. 1A is a set of flow cytometry traces showing the binding of isotype control hlgGl, AbOOl-Gl, or Ab012-Gl to Ramos control tumor cells (“Ramos control”) or Ramos tumor cells overexpressing hSMAGP (“Ramos hSMAGPOE”). FIG. IB is a set of flow cytometry traces showing the binding of isotype control hlgGl, Ab002-Gl, or Ab013-Gl to Ramos control or Ramos hSMAGPOF.

[0040] FIGs. 2A-FIG. 2E are sets of flow cytometry' traces showing binding of Ab042-Gl to patient tumor cells. Each plot represents an individual patient from the following cancer types: colorectal (FIG. 2A), gastric (FIG. 2B), bladder (FIG. 2C), cervical (FIG. 2D), and lung (FIG. 2E). Isotype staining is denoted by the open histograms, while Ab042-Gl staining is denoted by the shaded histograms.Attorney Docket No. DEMB-010 / 02WO

[0041] FIG. 3A is a schematic showing the overview of the allelic architecture of the Smagp"ECDmouse transgene, which expresses the human SMAGP extracellular domain from its endogenous locus and under endogenous regulatory control. The first coding exon of the mouse (Mus musculus) Smagp gene (exon 2) is replaced with a construct containing a recombinant gene sequence that encodes the human SMAGP extracellular domain (ECD, amino acids 1-36) fused to the mouse SMAGP transmembrane (amino acids 37-57) and intracellular domains (amino acids 58-97), followed by a transcriptional stop sequence to prevent further endogenous locus transcription and translation.

[0042] FIG. 3B is a graph showing relative mRNA expression of the mouse Smagp"ECDgene as measured by RT-PCR and expressed as relative expression to average across all tissues, N = 5 homozygous animals per tissue type.

[0043] FIG. 3C is a graph showing relative mRN A expression of the human Smagp gene as measured by RNA sequencing and expressed as relative expression to average across all tissues. Data retrieved from the Human Protein Atlas in November 2024.

[0044] FIG. 4A is a set of flow cytometry histograms showing chimeric SMAGP expression in immune cells (left), epithelial cells (center), and non-immune / non-epithelial cells (right) from colon tissue (top panel) and lung tissue (botom panel) of SmagphECDtransgenic mice. Histograms for each population for both tire isotype control and Ab042-Gl are shown. Each histogram represents an individual mouse.

[0045] FIG. 4B is a set of images showing staining of SmagphECDmouse colon (left), wildtype mouse colon (center), and human colon (right) tissues by RbG (rabbit IgG region isotype control) and AbOlO-RbG.

[0046] FIGs. 5A-FIG. 5H are a set of images showing immunohistochemistry (IHC) staining in formalin-fixed, paraffin-embedded (FFPE) colon adenocarcinoma samples. FIGs.5A-5D show staining of Grade 1, Stage I colon adenocarcinoma tumor core on TMA CO20811a (Tissue Array). FIGs. 5E-5H show' staining of Grade 2, Stage 11A colon adenocarcinoma tumor core on TMA CO20 11a (Tissue Array). FIGs. 5 A and 5E show staining with RbG isotype control, 3.3x magnification. FIGs. 5B and 5F show' staining w'ith AbOlO-RbG, 3.3x magnification. FIGs. 5C and 5G show staining with RbG isotype control, lOx magnification. FIGs. 5D and 5H show' staining with AbOlO-RbG, lOx magnification. Lighter counterstain 'as used to mark nuclei, whereas darker DAB was used to stain SMAGP.

[0047] FIGs. 6A-FIG. 6B are heat maps showing the extent of loss of binding of each indicated anti-SMAGP antibody to each indicated hSMAGP alanine mutant, as determined by ELISA (FIG. 6A) and SPR (FIG. 6B). In FIG. 6A, the loss of binding is grouped into fourAttorney Docket No. DEMB-010 / 02WOcategories, with the corresponding degree of shading indicated at right: <30% loss of binding, 30-60% loss of binding, 60-90% loss of binding, and greater than 90% loss of binding. In FIG.6B, the loss of binding is grouped into four categories, with the corresponding degree of shading indicated at right: <5 fold loss of binding, 5-20 fold loss of binding, 20-100 fold loss of binding, and >100 fold loss of binding.

[0048] FIGs. 7A-FIG. 7C are plots showing the extent of binding of Ab022-Gl (FIG.7A), Ab038-Gl (FIG. 7B), and Ab042-Gl (FIG. 7C) to approximately 6,000 distinct human membrane proteins, including hSMAGP.

[0049] FIG. 8A is a set of flow cytometry plots showing the extent of binding of magrolimab biosimilar-hIgG4, Ab022-Gl, Ab042-Gl, Ab043-Gl or isotype control hlgGl to platelets (identified by CD42b detection) from whole blood from a single representative donor from n=3 donors. FIG. 8B is a set of flow cytometry plots showing the extent of binding of magrolimab biosimilar-hIgG4, Ab022-Gl, Ab042-Gl, Ab043-Gl or isotype control hlgG l to red blood cells (identified by CD235a detection) from whole blood from a single representative donor of n ==3 donors.

[0050] FIG. 9 is a set of flow cytometry plots showing the extent of binding of IgGl isotype control (dashed light gray lines), Ab022-Gl (solid black lines), Ab042-Gl (solid medium gray lines), and Ab043-Gl (dashed black line) to neutrophils, monocytes, B cells, T cells, NK cells, and dendritic cells (DCs) from whole blood from a single representative donor of n=3 donors.

[0051] FIG. 10 is a bar graph showing the percentage of RKO tumor cell killing, normalized to tumor cells alone, after an ADCC assay of tumor cells by human NK cells in the presence of the indicated of anti-SMAGP antibodies as shown. ****: p<0.0001, ‘‘NS”; non¬ significant p-value, each compared to isotype control, ordinary one-way ANOVA with Dunnett’s multiple comparisons test to isotype control. Data shown correspond to one representative donor out of n===3.

[0052] FIG. 11 is a bar graph showing the percentage of mSMAGP overexpressing Ramos tumor cells remaining, normalized to tumor cells alone, after an ADCP assay of tumor cells by human macrophages in the presence of Ab001-m2a and mSMAGP affinity-matured anti-SMAGP antibodies. ****: pO. OOOl compared to isotype control, ordinary one-way ANOVA with Tukey’s multiple comparisons.

[0053] FIG. 12A is a bar graph showing the percentage of RKO tumor cells remaining normalized to tumor cells alone, after an ADCP assay of tumor cells by human macrophages in the presence of llama re-immunization and humanized llama re -immunization anti-SMAGPAtorney' Docket No. DEMB-010 / 02WOantibodies. ****: p<0.0001. **: p<0.01; each compared to isotype control, ordinary one-way ANOVA with Dunnett’s multiple comparisons test. FIG. 12B is a bar graph showing the percentage of SW48 tumor cells remaining normalized to tumor cells alone, after an ADCP assay of tumor cells by human macrophages in the presence of llama re-immunization and humanized llama re-immunization anti-SMAGP antibodies. ****: p<0.0001; each compared to isotype control, ordinary’ one-way ANOVA with Dunnett’s multiple comparisons test to isotype control.

[0054] FIG. 13 is a bar graph showing the percentage of RKO tumor cell killing after an ADCC assay of tumor cells by7human NK cells in the presence of Ab022-Gl, Ab042-Gl, or Ab043-Gl or positive control antibody, Cosibelimab biosimilar. ****: pcO. OOOl compared to isotype control, ordinary one-way ANOVA with Dunnett’s multiple comparison test.

[0055] FIG. 14 is a graph showing the percentage of RKO tumor cells remaining normalized to tumor cells alone after an ADCP assay of tumor cells by human macrophages in the presence of anti-SMAGP antibodies or controls at the indicated concentrations. For all antibodies except mIgG2a isotype, lines presented on tlie graph were fit using an asymmetric sigmoidal 5-parameter nonlinear regression. m!gG2a could not be fit using that regression, so no line is shown. Statistical significance was determined by two-way ANOVA with Tukey’s multiple comparisons test to the matched human IgGl or mouse IgG2a isotype control. Above 0.1 nM, all mAbs have a p-value of <0.0001 when compared to their respective isotype control. At 0,03 nM, Ab042-Gl and Ab018-m2a have p-value <0.01 compared to respective matched isotype control. At 0.007 nM, Ab042-Gl and Ab038-Gl have a p-value <0.01 compared to hlgGl isotype control.

[0056] FIGs. 15A-FIG. 15C are graphs showing the percentage of tumor cells remaining normalized to tumor cells alone after an ADCP assay of RKO tumor cells by human macrophages at various Effector: Target ratios in the presence of Ab022-Gl, Ab042-Gl, Ab043-Gl, afticosylated variants thereof, AbO22-Gl-LALAPG, and positive control antibody, Cosibelimab. Data for Ab022-Gl and variants thereof are shown in FIG. ISA, Data for Ab042-G1 and AbO42-Gl-aF are shown in FIG. 15B. Data for Ab043-Gl and AbO43-Gl-aF are shown in FIG. 15C. Above each data point, an ‘a’ signifies p<0.05 in comparison with hlgGl isotype control, a ‘b’ signifies p <0.05 from AbO22-Gl-aF compared with Ab022-Gl (FIG. ISA) or AbO42-Gl-aF compared with Ab042-Gl (FIG. 15B), or AbO43-Gl-aF compared with Ab043-Gl (FIG. 15C), and a “c” signifies p<0.05 compared to AbO22-Gl-LALAPG (FIG.15A). Statistical significance in each figure was determined by 2 -way ANOVA with Tukey’sAttorney Docket No. DEMB-010 / 02WOmultiple comparison tests. Cosibelimab biosimilar, the positive control antibody, is shown compared to isotype control for clarity.

[0057] FIG. 15D is a graph showing the percentage of tumor cells remaining normalized to tumor cells alone after an ADCP assay of RKO tumor cells by human macrophages at an Effector: Target ratio of 1:2 in the presence of Ab042-Gl, AbO42-Gl-aF, and hlgGl isotype control at various concentrations as shown. Near each data point, an ‘a’ signifies p<0.0001 in comparison with hlgGl isotype control, and a ‘b’ signifies p <0.0001 from AbO42-Gl-aF compared with Ab042-Gl. Statistical significance was determined via two-way ANOVA and Tukey’s multiple comparisons test.

[0058] FIG. 16 is a graph showing the percentage of RKO tumor cell killing normalized to tumor cells alone after an ADCC assay of tumor cells by human NK cells in the presence of Ab022-Gl, AbO22-Gl-aF, Ab-042-Gl, AbO42-Gl-aF and negative and positive control antibodies at the indicated concentrations. For all antibodies, lines presented on the graph were fit using an agonist versus response four-parameter nonlinear regression. Statistical significance was determined using two-way AN OVA with Dunnett’s multiple comparisons test to isotype control, “a” indicates a p-value of <0.0001, “b” indicates a p-value of <0.001, and “c” indicates a p-value of <0.05 compared to isotype control. Data shown correspond to one representative donor out of n=3.

[0059] FIG. 17A is a time course showing SW48 tumor volume (mm3) in athymic nude mice treated with isotype control hlgGl, AbOOl-Gl, or positive control cetuximab. FIG. 17B is a time course showing SW48 tumor volume (mm3) in athymic nude mice treated with negative control hlgGl, Ab002-Gl, or positive control cetuximab, each at 10 mg / kg. ***: p < 0.001, 2-way repeat measurement (RM) ANOVA with Dunnett’s multiple comparison test.

[0060] FIG. 18 is a time course showing SW48 tumor volume (mm3) in NOD-SCID mice treated with isotype control hlgGl + h!gG4, Ab002-Gl + hIgG4, hlgGl + anti-human CD47 antibody (Hu5F9-G4, Ichorbio), or Ab002-Gl < Hu5F9-G4, each at 20 mg / kg for hlgGl or Ab002-Gl and at 10 mg / kg for IgG4 or Hu5F9-G4. **: p < 0.01, 2-way RM ANOVA with Dunnett’s multiple comparison test.

[0061] FIG. 19A is a time course showing RKO tumor volume (mm3) in athymic nude mice treated with isotype control hlgGl, Ab004-Gl, Ab005-Gl, Ab007-Gl, Ab009-Gl, AbOlO-Gl, and AbOl 7-GI, each administered at 20 mg / kg. FIG. 19B is atime course showing RKO tumor volume in athymic nude mice treated with negative control hlgGl (20 mg / kg), Ab004-Gl (20 mg / kg), Ab004-Gl (10 mg / kg), and Ab004-Gl (2 mg / kg). FIG. 19C is time course showing RKO tumor volume in athymic nude mice treated with negative control hlgGlAttorney Docket No. DEMB-010 / 02WO(20 mg / kg), AbOlO-Gl (20 mg / kg), AbOlO-Gl (10 mg / kg), and AbOlO-Gl (2 mg / kg). *: p < 0.05, **: p < 0.01, 2-way RM ANOVA with Dunnet’s multiple comparison test.

[0062] FIG. 20A is a time course showing RKO tumor volume (mm3) in athymic nude mice treated with isotype control hlgGl, Ab004-Gl, Ab007-Gl, Ab022-Gl, Ab023-Gl, Ab028-Gl, Ab038-Gl, or Ab042-Gl. FIG. 20B is a time course showing tumor volume in mice treated with hlgGl, Ab022-Gl, or AbO22-Gl-ADE. FIG. 20C is a time course showing tumor volume in mice treated with hlgGl, Ab023-Gl, or AbO23-Gl-ADE. FIG. 20D is a time course showing tumor volume in mice treated with hlgGl, Ab028-Gl, or AbO28-Gl-ADE.FIG. 20E is a time course showing tumor volume in mice treated with hlgGl, Ab038-Gl, or Ab038-Gl -ADE. FIG.20F is a time course showing tumor volume in mice treated with hlgG 1, Ab042-Gl, or AbO42-Gl-ADE. In all cases, treatment was at 20 mg / kg.

[0063] FIG.21A is atime course showing SW48 tumor volume (mm3) in NOD-SCID mice treated with isotype control hlgGl, Cetuximab, Ab002-Gl, Ab004-Gl, Ab022-Gl, Ab023-Gl, Ab028-Gl, or Ab038-Gl. FIG. 21B is a time course showing tumor volume in mice treated with hlgGl, Cetuximab, Ab023-Gl, or AbO23-Gl-ADE. FIG. 21C is a time course showing tumor volume in mice treated with hlgGl, Cetuximab, Ab028-Gl, or AbO28-Gl-ADE. FIG.21 D is a time course showing tumor volume in mice treated with hlgGl, Cetuximab, Ab023-GI-ADE, AbO28-Gl-ADE, Ab038-Gl-ADE, or AbO42-Gl-ADE. FIG. 21E is a time course showing tumor volume in mice treated with hlgGl, Cetuximab, Ab038-Gl, or Ab038-Gl- ADE. In all cases, treatment was at 20 mg / kg. **: p < 0.01, ****: p<0.0001, mixed effects analysis with Dunnet’s multiple comparison test.

[0064] FIG. 22A is a time course showing RKO tumor volume (mm3) in athymic nude mice treated with isotype control hlgGl, Ab022-Gl, Ab023-Gl, Ab042-Gl, or AbO43-m2A.FIG. 22B is a time course showing tumor volume in mice treated with hlgGl, AbO22-Gl, AbO22-Gl-aF, or AbO22-Gl-DE. FIG. 22C is a time course showing tumor volume in mice treated with hlgGl, Ab023-Gl, or AbO23-Gl-aF. FIG. 22D is a time course showing tumor volume in mice treated with hlgG 1, Ab042-Gl, Ab042-Gl -aF, or Ab042-Gl -DE, In all cases, treatment was at 20 mg / kg. *: p<0.05, **: p < 0.01, 2-way RM ANOVA with Dunnet’s multiple comparison test.

[0065] FIG. 23A is a time course showing RKO tumor volume (mm3) in athymic nude mice treated with isot pe control hlgGl (20 mg / kg), Ab022-Gl (20 mg / kg), Ab022-Gl -aF (20 mg / kg), or Ab022-Gl-aF (0.2 mg / kg). FIG. 23B is a time course showing tumor volume in mice treated with isotype control hlgGl (20 mg / kg), Ab042-Gl (20 mg / kg), AbO42-Gl-aF (20 mg / kg), AbO42-Gl-aF (2 mg / kg), or AbO42-Gl-aF (0.2 mg / kg). FIG. 23C is a time courseAttorney Docket No. DEMB-010 / 02WOshowing tumor volume in mice treated with isotype control hlgGl (20 mg / kg), Ab043-m2a, or AbO43-m2a-aF (20 mg / kg in each case).

[0066] FIG. 24 is a time course show ing RKO tumor volume (mm3) in NCG mice treated with isotype control hlgGl or AbOlO-Gl at 20 mg / kg. ****: p < 0.0001, 2-way RM ANOVA with Dunnett’s multiple comparison test.

[0067] FIG. 25A is a time course showing H22 tumor volume (mm3) in BALB / c mice treated with isotype control mIgG2a or Ab018-m2a at 20 mg / kg. *: p<0.05, 2-w'ay RM ANOVA with Dunnett’s multiple comparison test FIG. 25B is a bar chart showing the percentage of CD8+cells detected within H22 tumor samples from mice treated with isotype control mIgG2a or Ab018-m2a, FIG.25C is a bar chart showing the percentage of F4 / 80+cells detected within H22 tumor samples from mice treated with isotype control mIgG2a or Ab018- m2a. FIG. 25D is a bar chart showing tire percentage of NKp46+cells detected within H22 tumor samples from mice treated with isotype control mIgG2a or Ab018-m2a. *: p<0.05, unpaired t-test.

[0068] FIG. 26 is a time course showing Hepal-6 tumor volume (mm3) in C57BL / 6 mice treated with isotype control mIgG2a, Ab018-m2a, or AbO 18-m2a-DE, each at 20 mg / kg. **: p<0,01, 2-way RM ANOVA with Dunnett’s multiple comparison test.

[0069] FIG. 27A is a time course showing tumor volume (mmJ) of an engineered MC38-Cas9-mSMAGP cell line in female BALB / c mice treated with isotype control mIgG2a or Ab018-m2a at 20 mg / kg. Statistical significance was determined via two-way ANOVA with Tukey’s multiple comparison test on log-normalized tumor volumes. *=p-value<0.05.

[0070] FIGs. 27B-FIG. 27F are dot plots showing the number of CD8+ cells (FIG. 27B), IFNg+ CD8+ T cells (FIG. 27C), CD4+ T conventional cells (FIG. 27D), dendritic cells (DC cells) (FIG. 27E), and Ml macrophages (FIG. 27F) per gram tumor at day 13 of the experiment show n in FIG. 27A for each of isotype control mIgG2a and Ab018-m2a. Outliers were removed using ROUT outlier test and statistics were determined using Mann-Whitney. *=p-value<0.05; **=p-value<0.01, ***=p-value<0.001.

[0071] FIG. 28 is a bar chart showing percent of tumor cells remaining after an ADCP assay of MC38-Cas9-mSMAGP tumor cells by primary mouse macrophages in the presence of Ab018-m2a or mIgG2a isotype control. ***= p-value <0.001, as determined by Welch’s t-test,

[0072] FIG.29 is a time course show ing plasma concentrations for Smagp’iECDmice treated with AbO42-Gl-aF dosed three times at 20 mg / kg, 100 mg / kg, or 200 mg / kg IV.Attorney Docket No. DEMB-010 / 02WODETAILED DESCRIPTION

[0073] The instant disclosure provides anti-SMAGP antibodies and polypeptides. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies. The antibodies disclosed herein are particularly useful for diagnosing and / or treating cancer in a subject.Definitions

[0074] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subj ect matter belongs. It is to be understood that the foregoing general description and tire following detailed description are exemplary’ and explanatory only and are not restrictive of any subject matter claimed. In this disclosure, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. In this disclosure, the use of “or” means “and / or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0075] As used herein, the term “SMAGP” refers to Small Cell Adhesion Glycoprotein, a membrane-anchored protein that is highly expressed in cancer cells and tissues. As used herein, the term “human SMAGP” refers to a protein encoded by a wild-ty pe human Small Cell Adhesion Glycoprotein gene (e.g., the gene set forth in NM_00I031628.2). The amino acid sequence of an exemplary' human SMAGP (hSMAGP) protein (as set forth in RefSeq NP 001026798.1) is MTSI TTPSPREELMTTPILQPTEALSPEDGASTALIAVVITVVFLTI SWILIFF YLYKNKGSYVTYEPTEGEPSAIVQMESDLAKGSEKEEYFI (SEQ ID NO: 1).

[0076] The amino acid sequence of an exemplary hSMAGP extracellular domain (ECD) is set forth in amino acids 1-36 of SEQ ID NO: 1.

[0077] As used herein, the terms “antibody” and “antibodies” include full-length antibodies, antigen-binding fragments of full-length antibodies, and molecules comprising antibody CDRs, VH regions, and / or VL regions. Examples of antibodies include, without limitation, monoclonal antibodies, recombinantly produced antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), human antibodies,Attorney Docket No. DEMB-010 / 02WOhumanized antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, an antibody heavy chain monomer, an antibody light chain dimer, an antibody heavy¬ chain dimer, an antibody light chain-antibody heavy chain pair, intrabodies, heteroconjugate antibodies, antibody-drug conjugates, bispecific T cell engagers (BiTEs), chimeric antigen receptors, single domain antibodies, monovalent antibodies, single-chain antibodies or singlechain Fvs (scFv), camelized antibodies, affibodies, Fab fragments, F(ab’)2 fragments, disulfide- linked Fvs (sdFv), anti -idiotypic (anti -Id) antibodies (including, e.g., anti-anti -Id antibodies), and antigen-binding fragments of any of the above. In certain embodiments, antibodies described herein refer to polyclonal antibody populations. Antibodies can be of any ty pe (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any class (e.g., IgGi, IgG?., IgG3, IgGr, IgAi, or IgA?), or any subclass (e.g., IgG?a or IgG2b) of immunoglobulin molecule. In certain embodiments, antibodies described herein are IgG antibodies, or a class (e.g., human IgGi or IgGr) or subclass thereof. In a specific embodiment, the antibody is a humanized monoclonal antibody. In another specific embodiment, the antibody is a human monoclonal antibody.

[0078] “Multispecific antibodies” are antibodies (e.g., bispecific antibodies) that specifically bind to two or more different antigens or two or more different regions of the same antigen. Multispecific antibodies include bispecific antibodies that contain two different antigen-binding sites (exclusive of the Fc region). Multispecific antibodies can include, for example, recombinantly produced antibodies, human antibodies, humanized antibodies, resurfaced antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, heteroconjugate antibodies, linked single-chain antibodies or linked-single-chain Fvs (scFv), camelized antibodies, affybodies, linked Fab fragments, F(ab’)2 fragments, chemically-linked Fvs, and disulfide-linked Fvs (sdFv). Multispecific antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any class (e.g., IgGi, IgG?, IgGs, IgGr, IgAi, or IgA?), or any subclass (e.g., IgG?a or IgG?b) of immunoglobulin molecule. In certain embodiments, multispecific antibodies described herein are IgG antibodies, or a class (e.g., human IgGi, IgG?., or IgGr) or subclass thereof.

[0079] As used herein, the term “CDR” or “complementarity determining region” means the noncontiguous antigen combining sites found within the variable regions of heavy and light chain polypeptides. These particular regions have been described by, for example, Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of protein of immunological interest. (1991), by Chothia etal., J. Mol. Biol. 196: 901-917 (1987), and by MacCallum etal.,Atorney- Docket No. DEMB-010 / 02WOJ. Mol. Biol. 262: 732-745 (1996), all of which are herein incorporated by reference in their entireties, where the definitions include overlapping or subsets of amino acid residues when compared against each other. In certain embodiments, the term “CDR” is a CDR as defined by MacCallum el al., J. Mol. Biol. 262:732-745 (1996) and Martin A. “'Protein Sequence and Structure Analysis of Antibody Variable Domains,’’ in Antibody Engineering, Kontermann and Diibel, eds., Chapter 31, pp. 422-439, Springer- Verlag, Berlin (2001). In certain embodiments, the term “CDR” is a CDR as defined by Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of protein of immunological interest. (1991). In certain embodiments, heavy chain CDRs and light chain CDRs of an antibody are defined using different conventions. In certain embodiments, heavy chain CDRs and / or light chain CDRs are defined by performing structural analysis of an antibody and identifying residues in the variable region(s) predicted to make contact with an epitope region of atarget molecule (e.g., SMAGP). CDRH1, CDRH2, and CDRH3 denote the heavy chain CDRs, and CDRL1, CDRL2, and CDRL3 denote the light chain CDRs.

[0080] As used herein, the terms “variable region” and “variable domain” are used interchangeably and are common in the art. The variable region typically refers to a portion of an antibody, generally, a portion of a light or heavy chain, typically about the amino-terminal 110 to 120 amino acids or 110 to 125 amino acids in the mature heavy chain and about 90 to 115 amino acids in the mature light chain, which differ extensively in sequence among antibodies and are used in the binding and specificity of a particular antibody for its particular antigen. The variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable region are called framework regions (FRs). Without wishing to be bound by any particular mechanism or theory, it is believed that the CDRs of the light and heavy’ chains are primarily responsible for the interaction and specificity of the antibody with antigen. Exemplary'- antibody variable regions are described in Kabat et al., (1991) Sequences of Proteins of Immunological Interest (NIH Publication No, 91-3242, Bethesda), which is herein incorporated by reference in its entirety. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and human framework regions (FRs). In certain embodiments, the variable region is a primate (e.g., non-human primate) variable region. In certain embodiments, the vanable region comprises rodent or murine CDRs and primate (e.g., non-human primate) framework regions (FRs). Further exemplary antibody variable regions include: a variable heavy domain of heavy chain (VHH); and engineered antibody variable regions that comprise one or more camelid CDRs (orAttorney Docket No. DEMB-010 / 02WOengineered variants thereof) grafted into non-camelid framework regions (e.g., human framework regions, or engineered variants thereof). As described herein, the CDR of an antibody can be defined using a variety of numbering systems.

[0081] As used herein, the term “VH” refers to an antibody heavy chain variable region, e. g., as described in Rabat et al., (1991) Sequences of Proteins of Immunological Interest (NIH Publication No. 91-3242, Bethesda), which is herein incorporated by reference in its entirety, and includes, -without limitation, a variable heavy domain of heavy chain (VHH) and engineered antibody variable regions that comprise one or more camelid CDRs (or engineered variants thereof) grafted into non-camelid framework regions (e.g., human framework regions, or engineered variants thereof).

[0082] As used herein, the term “VL” refers to an antibody light chain variable region, e.g., as described in Rabat et al., (1991) Sequences of Proteins of Immunological Interest (NIH Publication No, 91-3242, Bethesda), which is herein incorporated by reference in its entirety.

[0083] As used herein, the term “constant region” is common in the art. The constant region is an antibody portion, e.g., a carboxyl terminal portion of a light and / or heavy chain, which is not directly involved in binding of an antibody to antigen but which can exhibit various effector functions, such as interaction with an Fc receptor (e.g., Fc gamma receptor).

[0084] As used herein, the term “heavy chain” when used in reference to an antibody can refer to any distinct type, e.g., alpha (a), delta (8), epsilon (e), gamma (y), and mu (p), based on the amino acid sequence of the constant region, which give rise to IgA, IgD, IgE, IgG, and IgM classes of antibodies, respectively, including subclasses of IgG, e.g., IgGi, IgG2, IgGs, and IgG4.

[0085] As used herein, the term “light chain” when used in reference to an antibody can refer to any distinct type, e.g., kappa (K) or lambda (X). based on the amino acid sequence of the constant region. Light chain amino acid sequences are well known in the art. In specific embodiments, the light chain is a human light chain.

[0086] As used herein, the term “Ig Fc” refers to the portion of an immunoglobulin heavy chain polypeptide that can dimerize to form an Fc region. As used herein, the term “IgG Fc” refers to an Ig Fc of an IgG subclass (e.g., human IgG). As used herein, the term “IgGl Fc” refers to an Ig Fc of an IgGl subclass (e.g., human IgGl). Ig Fes can comprise wild-type immunoglobulin heavy chain polypeptide sequences or engineered variants of wild-type immunoglobulin heavy chain polypeptide sequences.

[0087] As used herein, the term “specifically binds” refers to the specificity of a binding molecule (e.g., an antibody) for an antigen, as is understood by one skilled in the art. BindingAttorney Docket No. DEMB-010 / 02WOmolecules that specifically bind to an antigen typically bind to the antigen with an equilibrium dissociation constant (KD) of less than 1 106M, as measured by, e.g., ELISA assay, surface plasmon resonance, or other suitable assays known in the art. The skilled worker -will appreciate that, in certain embodiments, a binding molecule can specifically bind to different antigens, e.g., different antigens that share a common epitope that is recognized by the binding molecule.

[0088] As used herein, the term “affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein.

[0089] As used herein, the term “EU numbering system” refers to the EU numbering convention for the constant regions of an antibody, as described in Edelman, G. M. et al.. Proc. Natl. Acad. USA, 63, 78-85 (1969) and Kabat et al, Sequences of Proteins of Immunological Interest, U. S. Dept. Health and Human Services, 5th edition, 1991, each of which is herein incorporated by reference in its entirety. Descriptions herein of an amino acid residue at a particular “EU position” of an antibody heavy chain constant region are with reference to the EU numbering system.

[0090] As used herein, the term “treat,” “treating,” and “treatment” refer to therapeutic or preventative measures described herein. The methods of “treatment” employ administration of an antibody to a subject having a disease or disorder, or predisposed to having such a disease or disorder, in order to prevent, cure, delay, reduce the severity of, or ameliorate one or more symptoms of the disease or disorder or recurring disease or disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.

[0091] As used herein, the term “pharmaceutically active substance” refers to a molecule or moiety that is used to achieve a beneficial outcome in a subject. Beneficial outcomes include, but are not limited to, diagnosis, prognosis, treatment, cure and prevention (prophylaxis) of diseases and / or symptoms and / or health problems.

[0092] As used herein, tire term “effective amount” in the context of the administration of a therapy to a subject refers to the amount of a therapy that achieves a desired prophylactic or therapeutic effect.Attorney Docket No. DEMB-010 / 02WO

[0093] As used herein, the term “subject” includes any human or non-human animal. In certain embodiments, the subject is a human or non-human mammal. In certain embodiments, the subject is a human.

[0094] As used herein with respect to an antibody, polypeptide, or polynucleotide, the term “isolated” refers to an antibody, polypeptide, or polynucleotide that is separated from one or more contaminants (e.g, polypeptides, polynucleotides, lipids, or carbohydrates, etc.) which are present in a natural source (e.g., in a mouse or a human) of the antibody, polypeptide, or polynucleotide. Moreover, an “isolated” antibody, polypeptide, or polynucleotide can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. For example, the language “substantially free” includes preparations of antibody, polypeptide, or polynucleotide having less than about 15%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% (in particular less than about 10%) of other material, e.g., cellular material, culture medium, other nucleic acid molecules, chemical precursors, and / or other chemicals. All instances of “isolated antibodies” described herein are additionally contemplated as antibodies that may be, but need not be, isolated. All instances of “isolated polypeptides” described herein are additionally contemplated as polypeptides that may be, but need not be, isolated. All instances of “isolated polynucleotides” described herein are additionally contemplated as polynucleotides that may be, but need not be, isolated. All instances of “antibodies” described herein are additionally contemplated as antibodies that may be, but need not be, isolated. All instances of “polypeptides” described herein are additionally contemplated as polypeptides that may be, but need not be, isolated. All instances of “polynucleotides” described herein are additionally contemplated as polynucleotides that may be, but need not be, isolated.

[0095] The term “polynucleotide” as used herein refers to a polymer of DNA or RNA. The polynucleotide sequence can be single -stranded or double-stranded; contain natural, non¬ natural, or altered nucleotides; and contain a natural, non-natural, or altered intemucleotide linkage, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified polynucleotide sequence. Polynucleotide sequences include, but are not limited to, all polynucleotide sequences which are obtained by any means available in the art, including, without limitation, recombinant means, e.g., the cloning of polynucleotide sequences from a recombinant library or a cell genome, using ordinary cloning technology and polymerase chain reaction, and the like, and by synthetic means.Attorney Docket No. DEMB-010 / 02WO

[0096] The terms ‘"protein” and “polypeptide” are used interchangeably herein and refer to a polymer of amino acids connected by one or more peptide bonds. As used herein, “amino acid sequence” refers to tire information describing the relative order and identity of amino acid residues which make up a polypeptide.

[0097] The term "about" is used herein to mean approximately, roughly, around, or in the regions of. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below' the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 10 percent, up or down (higher or lower).

[0098] The determination of “percent identity” between two sequences (e.g., amino acid sequences or nucleic acid sequences) can be accomplished using a mathematical algorithm. A specific, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin S & Altschul SF (1990) PNAS 87: 2264-2268, modified as in Karlin S & Altschul SF (1993) PNAS 90: 5873-5877, each of which is herein incorporated by reference in its entirety. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul SF et al., (1990) J Mol Biol 215: 403, which is herein incorporated by reference in its entirety. BLAST nucleotide searches can be performed with the NBLAST nucleotide program parameters set, e.g., for score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid molecule described herein. BLAST protein searches can be performed with the XBLAST program parameters set, e.g., to score 50, wordiength=3 to obtain amino acid sequences homologous to a protein molecule described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul SF et al., (1997) Nuc Acids Res 25: 3389-3402, which is herein incorporated by reference in its entirety. Alternatively, PSI BLAST can be used to perform an iterated search which detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., of XBLA ST and NBLAST) can be used (see, e.g., National Center for Biotechnology Information (NCBI) on the worldwide web, ncbi.nlm.nih.gov). Another specific, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4: 11-17, w'hich is herein incorporated by reference in its entirety. Such an algorithm is incorporated in the ALIGN program (version 2,0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.Attorney Docket No. DEMB-010 / 02WO

[0099] The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.Anti-SMAGP Antibodies

[0100] In one embodiment, the instant disclosure provides antibodies that specifically bind to SMAGP (e.g., human SMAGP). In one embodiment, provided herein, is an antibody that specifically binds to an epitope of SMAGP. In some embodiments, the SMAGP epitope comprises the extracellular domain (ECD) of SMAGP. In some embodiments, the ECD of SMAGP comprises amino acids 1-36 of SEQ ID NO: I. In some embodiments, the epitope of SMAGP comprises amino acids selected from the group consisting of: Leu5; Thr7; Argil; Glul2; GluI3; LeuI4; MetI5; Thrl6; Prol8; Ilel9; Leu20; Gln21; Pro22; Thr23; Glu24; Leu26; Leul4 and MetI5; He 19 and Glu24; and GIn21 and Pro22. In some embodiments, the epitope of human SMAGP ECD comprises amino acids selected from the group consisting of: Gln21, Pro22, and Glu24; Gln21, Pro22, and Thr23; Glul3; Leul4, and MetL5; Glul3, Leul4, and Met15; and GluI2, Leul4, and Metl5, In some embodiments, the epitope of human SMAGP ECD comprises amino acids selected from the group consisting of: Glul2, Glul3; Leul4, and Metl5; Glul2, Glul3, Leul4, and Metl5; and Prol8, lie 19, Leu20, and Gln21. In some embodiments, the epitope of human SMAGP ECD comprises amino acids selected from the group consisting of: Thr7; Glul2; GIul3; Leul4; Metl5; Prol8; Ilel9; Leu20; Gln21; Pro22; Thr23; Glu24; Leu20, Gln21, Pro22, Thr23, and Glu24; IleI9, Gln21, and Glu24; and Thr7 and Leu 14. In some embodiments, the epitope of human SMAGP ECD comprises amino acids selected from the group consisting of: Glul 2; Glul 3; Leu 14; Met! 5; Pro 18; He 19; Leu20; Gln21; Pro22; Thr23; Glu24; lie 19, Gln21, Pro22, Glu24, and Leu26; He 19, Gln21, Glu24, and Leu26; Glul2, Leul4, and Metl5; and Ilel9, Gln21, and Pro22. In some embodiments, the epitope of human SMAGP ECD comprises ammo acids selected from the group consisting of: Leu5, Glul 2, Glul3, Leul4, and Metl5; Glul2, Glul3, Leul4, Metl5, and Thrl6; and Thrl6, He 19, Leu20, Gln21, Pro22, Thr23, and Glu24. In some embodiments, the epitope of human SMAGP ECD comprises amino acids Argil, Glul2, Glul3, Leul4, Metl5, and Thrl6. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Prol8, lie 19, Leu20, Gln21, Pro22, Thr23, Glu24, and Leu26. In some embodiments, the epitope of human SMAGP ECD comprises amino acids Gln21, Pro22, or Thr23. In some embodiments, the epitope of human SMAGP ECD comprises amino acids Gln21 and Pro22. In some embodiments, the epitope of human SMAGP ECD comprises ammoAttorney Docket No. DEMB-010 / 02WOacids He 19, Leu20, Gln21, Pro22, and Thr23. In some embodiments, the epitope of human SMAGP ECD comprises amino acids Gln21, Pro22, and Thr23. In some embodiments, the epitope of human SMAGP ECD comprises amino acids Leu20, Gln21, Pro22, and Thr23. In some embodiments, the epitope of human SMAGP ECD comprises amino acids Leu20, Gln21, Pro22, Thr23, and Glu24. In certain embodiments, the antibody specifically binds to an epitope of human SMAGP ECD comprising ammo acids He 19, Leu20, Gln21, Pro22, Thr23, and Glu24.

[0101] Provided herein are descriptions of the origins of the SMAGP antibodies, as described below in Table 1.Table 1. Exemplary Sequence DescriptionsAntibody Description Light ChainAbOOi-Gl llama IgG (first immunization) LambdaAb002-Gl llama IgG (first immunization) KappaAb003-Gl llama IgG (Boost immunization) KappaAb004-Gl llama IgG (Boost immunization) LambdaAb005-Gl llama IgG (Boost immunization) KappaAb006-Gl llama IgG (Boost immunization) LambdaAb007-Gl llama IgG (Boost immunization) LambdaAb008-Gl llama IgG (Boost immunization) KappaAb()09-Gl llama IgG (Boost immunization) LambdaAbOlO-Gl llama IgG (Boost immunization) LambdaAbOll-Gl llama IgG (Boost immunization) LambdaAb012-Gl Humanized AbOO 1 LambdaAb013-Gl Humanized Ab002 KappaAb014-Gl Affinity-matured Ab012 for hSMAGP LambdaAb015-Gl Affinity-matured Ab012 for hSMAGP LambdaAb016-Gl Affinity-matured Ab013 for hSMAGP KappaAb017-Gl Affinity -matured Ab013 for hSMAGP KappaAb018-Gl Affinity-matured AbOOl for mSMAGP LambdaAb019-Gl Humanized Ab004 LambdaAb()20-Gl Humanized Ab004 LambdaAb021-Gl Humanized Ab004 LambdaAb022-Gl Humanized Ab004 LambdaAb023-Gl Humanized Ab005 KappaAb024-Gl Humanized Ab005 KappaAb025-Gl Humanized Ab005 KappaAttorney Docket No. DEMB-010 / 02WOAntibody Description Light ChainAb()26-Gl Humanized Ab005 KappaAb027-Gl Humanized Ab007 LambdaAb028-Gl Humanized Ab007 LambdaAb029-Gl Humanized Ab007 LambdaAb030-Gl Humanized Ab007 LambdaAb031-G1 Humanized Ab008 KappaAb032-Gl Humanized Ab008 KappaAb033-Gl Humanized Ab008 KappaAb034-Gl Humanized Ab008 KappaAb035-Gl Humanized Ab009 LambdaAb036-Gl Humanized Ab009 LambdaAbO37-Gl Humanized Ab009 LambdaAb038-Gl Humanized Ab009 LambdaAb039-Gl Humanized AbO 10 LambdaAb040-Gl Humanized AbO 10 LambdaAb041-Gl Humanized AbO 10 LambdaAb042-Gl Humanized AbO 10 LambdaAb043-Gl Humanized AbO 18 LambdaAb044-Gl Humanized AbO 18 LambdaAb045-Gl Humanized AbO 18 LambdaAb046-Gl Affinity-matured AbO 12 for hSMAGP LambdaAb047-Gl Affinity-matured AbOl 2 for hSMAGP LambdaAb()48-Gl Affinity-matured Ab012 for hSMAGP LambdaAb049-Gl Affinity-matured AbOl 2 for hSMAGP LambdaAb()50-Gl Affinity-matured Ab012 for hSMAGP LambdaAb05 i-Gl Affinity-matured AbOl 2 for hSMAGP LambdaAb052-Gl Affinity-matured Ab012 for hSMAGP LambdaAb053-Gl Affinity-matured AbO 12 for hSMAGP LambdaAb054-Gl Affinity-matured AbO 12 for hSMAGP LambdaAb055-Gl Affinity-matured AbO 12 for hSMAGP LambdaAb056-Gl Affinity-matured AbO 12 for hSMAGP LambdaAb057-Gl Affinity-matured AbO 12 for hSMAGP LambdaAb058-Gl Affinity-matured AbO 12 for hSMAGP LambdaAb()59-Gl Affinity-matured Ab012 for hSMAGP LambdaAb060-Gl Affinity-matured AbOl 2 for hSMAGP LambdaAb061-Gl Affinity-matured Ab012 for hSMAGP LambdaAb062-Gl Affinity-matured AbOl 2 for hSMAGP LambdaAb063-Gl Affinity-matured Ab012 for hSMAGP LambdaAttorney Docket No. DEMB-010 / 02WOAntibody Description Light ChainAb()64-Gl Affinity-matured Ab012 for hSMAGP LambdaAb065-Gl Affinity-matured AbOl 2 for hSMAGP LambdaAb066-Gl Affinity-matured Ab012 for hSMAGP LambdaAb067-Gl Affinity -matured AbOl 3 for hSMAGP KappaAb068-Gl Affinity-matured Ab013 for hSMAGP KappaAb069-Gl Affinity -matured AbO 13 for hSMAGP KappaAb070-Gl Affinity -matured AbO 13 for hSMAGP KappaAb071-Gl Affinity-matured AbO 13 for hSMAGP KappaAb072-Gl Affinity -matured AbO 13 for hSMAGP KappaAb073-Gl Affinity-matured AbO 13 for hSMAGP KappaAb074-Gl Affinity -matured Ab013 for hSMAGP KappaAb075-Gl Affinity -matured Ab013 for hSMAGP KappaAb076-Gl Affinity -matured Ab013 for hSMAGP KappaAb077-Gl Affinity-matured Ab013 for hSMAGP KappaAb078-Gl Affinity -matured AbOl 3 for hSMAGP KappaAb079-Gl Affinity-matured Ab013 for hSMAGP KappaAb080-Gl Affinity -matured AbO 13 for hSMAGP KappaAb081-Gl Affinity -matured AbO 13 for hSMAGP KappaAb082-Gl Affinity -matured AbO 13 for hSMAGP KappaAb083-Gl Affinity -matured AbO 13 for hSMAGP KappaAb084-Gl Affinity-matured AbO 13 for hSMAGP KappaAb085-Gl Affinity -matured Ab013 for hSMAGP KappaAb()86-Gl Affinity -matured Ab013 for hSMAGP KappaAb087-Gl Affinity -matured Ab013 for hSMAGP KappaAb()88-Gl Affinity -matured Ab013 for hSMAGP KappaAb089-Gl Affinity -matured AbOl 3 for hSMAGP KappaAb090-Gl Affinity-matured Ab013 for hSMAGP KappaAb091-Gl Affinity -matured AbOOl for mSMAGP LambdaAb092-Gl Affinity -matured AbOO 1 for mSMAGP LambdaAb093-Gl Affinity -matured AbOOl for mSMAGP LambdaAb094-Gl Affinity -matured AbOOl for mSMAGP Lambda[001021 The VH, VL, CDRH and CDRL, and constant heavy and light chain region amino acid sequences of exemplary antibodies described above are set forth in Tables 2-8, respectively.Attorney Docket No. DEMB-010 / 02WOTable 2. VH amino acid sequences of exemplary anti-SMAGP antibodies.SEQ ID NO: Description Variable Heavy Chain Sequence EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEWVSAbOOl-GlSEQ ID NO: 2 TINSDGDSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYACAK VH YLRSWALDYWGQGTQVTVSS EVQLVESGGGLVQPGGSLRI. SCAVSGSSFSGWRMNAVVRQAPGKGL. EWV SEQ ID NO: 3 Ab002-Gl VH SFINRDSSITSYVDSVKGRFTISRDNAKNTLYI. QMNSI. NAEDTAVYYCASR DF VLWGQGTQ VT VS S QVQLVESGGGLVEPGGSL. RVSCAASGFTFSNYNMNVVVRQAPGKGGEWV SEQ ID NO: 4 Ab003-Gl VH SVINTGGGSTAYADSVKGRFTTSRDNAKNTVYLQMNSLKPEDTALYYCA TSGYDYWGQGTQVTVSS QVHI. VESGGGI. VQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEWV SEQ ID NO: 5 Ab004-Gl VH SSIPTSGGNTYYADSVKGRFnSRDNAKNTLYLQMNSLKSEDTAVYYCAK NGFGRSYYWDYWGQGTQVTVSS QVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEWVS SEQ ID NO: 6 Ab005-Gl VH DIWSDGTTTYYADSVKGRFQISRDNAKNTLYLQMSSLKSEDTAVYYCVK QGYDSWGQGTQVTVSS QVQLVESGGGLVQPGGSLRVSCAASGFTFSAYYMSWVRQTPGKGLEWVS SEQ ID NO: 7 Ab006-Gl VH AINADGGSTYSTDSVKGRFTISRDNAKNTLYLQMSSLKPEDTALYYCARV PIYYLGDRDFYRYLEIWGQGTLVTVSS EMQLVESGGGLVQPGGSLRLSCVASGFTFASYFMGWVRQAPGKGPEWVS SEQ ID NO: 8 Ab007-Gl VH TINSGGEDTYYSDSVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYACAKY LRNWALDYWGQGTQVTVSS QVHLVESGGGLVQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGLEWLS SEQ ID NO: 9 Ab008-Gl VH SINL. DGSNTYYADSVKGRFTISRDNAKNTLYI. QMNSI. KSEDTAKYYCAKP QPGNSIATYDYWGQGTQVTVSS EMQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQTPGKGPEWVS SEQ ID NO: 10 Ab009-Gl VH AINADGGDTYYADSVKGRFTISRDNAKNMLYLQMNSLKPEDTAVYTCAK YLSYWALDHWGQGTQVTVSS QVQLVESGGGFVQPGGSI. RLSCASSGFPFSSYWMFWVRQAPGKGLEWVS SEQ ID NO: 11 AbOJO-Gl VH HIKPGGGSTYYADSVKGRFTISRDDTKNTLYI. QMNNLKSEDTALYYCARQ GYGTTWYVDYWGQGTQVTVSS EMQLVESGGGLVQPGGSI. RLSCAASGFTFGSFFMGWVRQAPGKGPEWVS SEQ ID NO: 12 AbOll-Gl VH TINSGGDSTYYEDSVKGRFTISRDNAKNTLHLQMNSLKPEDTAVYACAKY LRNWALDFWGQGTQVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 13 Ab012-Gl VH TINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEWV SEQ ID NO: 14 Ab013-Gl VH SFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR DFVI. WGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 15 Ab014-Gl VH TINSDGRSTYYA DS VKGRFTISRDN AKNTLYLQMNSLRAEDTA VYYC AKYL. RSWAL. DYWGQGTLVTVSSAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Heavy Chain Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ IDNO: 16 Ab015-Gl VH TINSDGDSTY YADS VKGRFTISRDNAKN TL YLQMN SLRAEDTA V Y YCAK YLRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEWV SEQ ID NO: 17 AbO16-GI VH SFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVY YCASR D V VLWGQGTL VT VS S EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEWV SEQ IDNO: 18 Ab017-Gl VH SFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR DFVLWGQGTLVTVSS EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEWVS SEQ IDNO: 19 Ab018-Gl VH TINSDGSSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYACAKY IRRWALDYWGQGTQVTVSS EVQLVESGGGLVQPGGSL. RLSCAASGFTFSSYWMYWVRQAPGKGL. EWVS SEQ ID NO: 20 Ab019-Gl VH SIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKN GFGRSYYWDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRL. SC AASGFTFGSYVVMSWVRQAPGKGLEWVS SEQ ID NO: 21 Ab020-Gl VH SIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKN GFGRSYYWDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEWV SEQ ID NO: 22 Ab021-Gl VH SSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK NGFGRSY Y WDYWGQGTL VTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEWV SEQ ID NO: 23 Ab022-Gl VH SSIPTSGGNTYYADSVKGRFT1SRDNSKNTLYLQMNSLRAEDTAVYYCAK NGFGRSYYWDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEWV SSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK SEQ ID NO: 24 Ab022-Gl VH X 1X2FGR S YYWDYWGQGTL. VTVSSWherein X 1 can be selected from N, Q, H, or SWherein Xz can be selected from G, V, or A EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEWVS SEQ ID NO: 25 Ab023-Gl VH DIWSDGTTTYYADSVKGRFTISRDNAK. NTLYLQMSSLRAEDTAVYYCVK QGYDSWGQGTL VTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEWVS SEQ ID NO: 26 Ab024-Gl VH YIWSDGTTTYYADSVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYYCVK QGYDSWGQGTL VTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEWVS SEQ ID NO: 27 Ab025-Gl VH YIWSDGTTTYYADSVKGRFT1SRDNAKNTLYLQMSSLRAEDTAVYYCVK QGYDSWGQGTL VTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEWVS SEQ ID NO: 28 Ab026-Gl VH DIWSDGTTTYYADSVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYYCVK QGYDSWGQGTL. VTVSSAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Heavy Chain Sequence EVQLVESGGGLVQPGGSLRLSCVASGFTFSSYFMGWVRQAPGKGLEWVS SEQ ID NO: 29 Ab027-Gl VH TINSGGEDTYYSDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCAKY LRNWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCVASGFTFASYFMGWVRQAPGKGLEWVS SEQ ID NO: 30 Ab028-Gl VH TINSGGEDTYYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCAKY LRNWALDYWGQGTLVTVSS E VQL VESGGGL VQPGGSLRLSC VASGFTFASY FMG W VRQAPGKGLEWVS SEQ ID NO: 31 Ab029-Gl VH TINSGGEDTYYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYACAKY LRNWALDYWGQGTLVTVSSF. VQL VESGGGL. VQPGGSLRLSC AASGFTFASYFMGWVRQAPGKGPEWVS SEQ ID NO: 32 Ab030-Gl VH TINSGGEDTYYSDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYACAKY LRNWALDYWGQGTLVTVSS EVQL VESGGGL VQPGGSL. RLSCAASGFTFNTYYLNWVRQAPGKGL. EWVS SEQ ID NO: 33 Ab031-Gl VH SINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKP QPGNSIATYDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRLSC AASGFTFNTYYMNWVRQAPGKGLEWVS SEQ ID NO: 34 Ab032-Gl VH SINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKP QPGNSIATYDYWGQGTLVTVSS EVQL VESGGGL VQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGLEWLS SEQ ID NO: 35 Ab033-Gl VH SINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKP QPGNSIATYDYWGQGTLVTVSS EVQL VESGGGL VQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGLEWVS SEQ ID NO: 36 Ab034-Gl VH SINLDGSNTY Y ADS VKGRFTISRDNAKN TL YLQMN SLRAEDTA V YYCAKP QPGNSIATYDYWGQGTL. VTVSSEVQL VESGGGL VQPGGSLRLSCAASGFTFGSSFMSWVRQAPGKGLEWVS SEQ ID NO: 37 Ab035-Gl VH AINADGGDTYYADSVKGRFTISRDNSKNTL. YLQMNSLRPEDTAVYYCAK YLSYWALDHWGQGTLVTVSS E VQL VESGGGL VQPGGSLRLSCAASGFTFGS SFMSW VRQAPGKGLEW VS SEQ ID NO: 38 Ab036-Gl VH AINADGGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCAK YLSYWALDHWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQAPGKGLEWVS SEQ ID NO: 39 Ab037-Gl VH AINADGGDTYYADSVKGRFTISRDNSKNTL. YLQMNSLRPEDTAVYTCAK YLSYWALDHWGQGTLVTVSS EVQL. VESGGGL. VQPGGSL. RLSCAASGFTFGSSFMSWVRQAPGKGPF. WVS SEQ ID NO: 40 Ab038-Gl VH AINADGGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYTCAK YLSYWALDHWGQGTLVTVSS EVQLVESGGGLVQPGGSLRL. SCAASGFTFSSYWMFWVRQAPGKGLEWVS SEQ ID NO: 41 Ab039-Gl VH HIKPGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARQ GYGTTWYVDYWGQGTLVTVSS EVQL VESGGGL VQPGGSLRLSCAASGFPFSSYWMHWVRQAPGKGLEWVS SEQ ID NO: 42 Ab040-Gl VH HIKPGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARQGYGTTWYVDYWGQGTLVTVSSAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Heavy Chain Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMFWVRQAPGKGLEWVS SEQ ID NO: 43 Ab041-Gl VH HIKPGGGST YYADS VKGRFTISRDNSKNTLY LQMNSLRAEDTALYYCARQ GYGTTWYVDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFPFSSYWMFWVRQAPGKGLEWVS SEQ ID NO: 44 AbO42-GI VH HIKPGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARQ GYGTTWYVDYWGQGTLVTVSSEVQL VESGGGLVQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 45 Ab043-Gl VH TINSDG SSTYYA DS VKGRFTISRDN AKNTLYLQMNSLRAEDTA VYYC AKY IRRWALDYWGQGTLVTVSS EVQL VESGGGL. VQPGGSLRL. SC AASGFTFSSYTMSWVRQAPGKGLEWVS SEQ ID NO: 46 Ab044-Gl VH TINSDGSSTYYADSVKGRFTISRDNAKNTL. YLQMNSLRAEDTAVYYCAKY IRRWALDYWGQGTLVTVSS EVQI. VESGGGLVQPGGSL. RLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 47 Ab045-Gl VH RINSDGSSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKY IRRWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 48 Ab012-Gl VH TINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRS WALD YWGQGTLVTV SS EVQL VESGGGLVQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 49 AbO12-VHal VH TIGSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 50 AbO12-VHa2 VH TIN VDGDSTYY ADS VKGRFTISRDN AKNTLY LQMNSLRAEDTAVY YCAK YLRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 51 AbO12-VHa3 VH TINLDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YL. RSWAL. DYWGQGTLVTVSSEVQL VESGGGLVQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 52 AbOl 2-VHa4 VH TINSVGDSTYYADSVKGRFTISRDNAKNTLYI. QMNSL. RAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQL VESGGGL. VQPGGSLRL. SC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 53 AbO12-VHa5 VH TINSLGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKY LRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 54 AbOl 2-VHa6 VH TINSDVDSTYYADSVKGRFTISRDNAKNTLYI. QMNSL. RAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRL. SC AASGFTFGSYFMSWVRQAPGKGLEW'VS SEQ ID NO: 55 AbO12-VHa7 VH TINSDGSSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKY LRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 56 AbO12-VHa8 VH TTNSDGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKYLRSWALDYWGQGTLVTVSSAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Heavy Chain Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 57 AbO12-VHa9 VH TINSDGV STY Y ADS VKGRFTISRDNAKN TL YLQMN SLRAEDTA V Y YCAK YLRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 58 AbO12-VHalO VH TINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS E VQLVESGGGLVQPGGSLRLSCAASGFTFGSY TMSW VRQAPGKGLEW V S SEQ ID NO: 59 A bOl 2-VHal l VH TINSDGDSTYYADSVKGRFTISRDNAKNTLYI. QMNSL. RAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNAVVRQAPGKGLEWV SEQ ID NO: 60 Ab013-Gl VH SFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEWW SEQ ID NO: 61 Ab013-VHal VH SFINRGSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYWCASR DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRL. SCAVSGSSFSGWRMNYV’VRQAPGKGLEW’V SEQ ID NO: 62 AbO13-VHa2 VH SFINRVSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEWV SEQ ID NO: 63 AbO13-VHa3 VH SFINRPSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR DFVLWGQGI'LVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQA. PGKGLEWV SEQ ID NO: 64 AbO13-VHa4 VH SFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEWV SEQ ID NO: 65 Ab013-VHa5 VH SFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEWVAb022 HCDR3SEQ ID NO: 66 SSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK variant VHQGFGRSYYWDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRL. SCAASGFTFGSYAVMYWVRQAPGKGLEWV Ab022 HCDR3SEQ ID NO: 67 SSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK variant VHHGFGRSYYWDYWGQGTLVTVSS EVQI. VESGGGI. VQPGGSL. RLSCAASGFTFGSYYVMYWVRQAPGKGLEW’V Ab022 HCDR3SEQ ID NO: 68 SSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK variant VHSGFGRSYYWDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEWVAb022 HCDR3SEQ ID NO: 69 SSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK variant VHNVFGRSYYWDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEWVAb022 HCDR3SEQ ID NO: 70 SSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK variant VHNAFGRSY YWDYWGQGTLVTVSSAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Heavy Chain Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEWV SEQ ID NO: 71 Ab022-Gl VH SSIPTSGGN TY Y ADS VKGRFT1SRDNSKNTLYLQMN SLRAEDTAVYYCAK NGFGRSYYWDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEWVS SEQ ID NO: 72 AbO23-GI VH DIWSDGTTTYYADSVKGRFT1SRDNAKNTLYLQMSSLRAEDTAVYYCVK QGYDSWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFPFSSYWMFWVRQAPGKGLEWVS SEQ ID NO: 73 Ab042-Gl VH HIKPGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARQ GYGTTWYVDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRL. SC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 74 Ab043-Gl VH TINSDGSSTYYADSVKGRFTISRDNAKNTL. YLQMNSLRAEDTAVYYCAKY IRRWALDYWGQGTLVTVSS EVQI. VESGGGLVQPGGSL. RLSCAASGFTFGSYFMSVVVRQAPGKGLEWVS SEQ ID NO: 75 Ab046-Gl VH TINPRGGSTYYADSVKGRFTISRDNAKNTL. YLQMNSLRAEDTAVYYCAKY LRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRL. SC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 76 Ab047-Gl VH TINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRS WALD YWGQGTLVTV SS EVQL VESGGGLVQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 77 Ab048-Gl VH TINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKY LRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 78 Ab049-Gl VH TINSDGDSTY Y ADS VKGRFTISRDNAKN TL YLQMN SLRAEDTAVY YCAK YLRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 79 Ab050-Gl VH TINPRGGSTYYA DS VKGRFTISRDN AKNTLYLQMNSLRAEDTA VYYC AKY LRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 80 AbO5J-Gl VH TINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRL. SC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 81 Ab052-Gl VH TINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQL. VESGGGI. VQPGGSL. RLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 82 Ab053-Gl VH TINPRGGSTYYADSVKGRFTISRDNAKNTL. YLQMNSLRAEDTAVYYCAKY LRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRL. SC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 83 Ab054-Gl VH TINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 84 Ab055-Gl VH TINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKYLRSWALDYWGQGTLVTVSSAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Heavy Chain Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 85 Ab056-Gl VH TINPRGGSTY Y ADS VKGRFT1SRDNAKNTLY LQMNSLRAEDTA V Y YCAK Y LRSWALDYWGQGTI. VTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 86 AbO57-GI VH TINPDGDRTY Y ADS VKGRFTISRDNAKN TL YLQMN SLRAEDTA V Y YCAK YI. RSW'AI. DYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 87 Ab058-Gl VH TINSDGRSTYYADSVKGRFTISRDNAKNTI. YLQMNSLRAEDTAVYYCAKY LRSWALDYWGQGTI. VTVSSEVQL VESGGGLVQPGGSLRI. SC AASGFTFGSYFMSWVRQAPGKGL. EWVS SEQ ID NO: 88 Ab059-Gl VH TINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQI. VESGGGLVQPGGSL. RLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 89 Ab060-Gl VH TINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKY LRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRI. SC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 90 Ab061-Gl VH TINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAK YLRS WALD YWGQGTLVTV SS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 91 Ab062-Gl VH TINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKY LRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 92 AbO63-GI VH TINSDGDSTY Y ADS VKGRFTISRDNAKN TL YLQMN SLRAEDTA VY YCAK YLRSWALDYWGQGTLVTVSS EVQL VESGGGLVrQPGGSLRLSC AASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 93 Ab064-Gl VH TINPRGGSTYYA DS VKGRFTISRDN AKNTLYLQMNSLRAEDTA VYYC AKY LRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEWVS SEQ ID NO: 94 Ab065-Gl VH TINPDGDRTYYADSVKGRFTISRDNAKNTL. YLQMNSLRAEDTAVYYCAK YLRSWALDYWGQGTLVTVSS EVQL VESGGGLVQPGGSLRI. SC AASGFTFGSYFMSWVRQAPGKGL. EWVS SEQ ID NO: 95 Ab066-Gl VH TINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKY LRSWALDYWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEWV SEQ ID NO: 96 Ab067-Gl VH SFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRL. SCAVSGTSFGGWRMNWVRQAPGKGLEWV SEQ ID NO: 97 Ab068-Gl VH SFINRRQSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDI'AVYYCASR DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEWV SEQ ID NO: 98 Ab069-Gl VH SFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASRDVVLWGQGTLVTVSSAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Heavy Chain Sequence EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEWV SEQ ID NO: 99 Ab070-Gl VH SFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR DVVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab071-GI VH SFIGRASS1TSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 100DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab072-Gl VH SFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 101DFVLWGQGTLVTVSSF. VQLVESGGGLVQPGGSLRLSCAVSGSSFSGVVrRMN’W?VRQAPGKGLEWV SEQ ID NO:Ab073-Gl VH SFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 102DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEWW SEQ ID NO:Ab074-Gl VH SFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 103DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRL. SCAVSGTSFGGWRMNWVRQAPGKGLEW’V SEQ ID NO:Ab075-Gl VH SFINRRQSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 104DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEVVV SEQ ID NO:Ab076-Gl VH SFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 105DVVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab077-Gl VH SFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 106DVVTWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab078-Gl VH SFIGRDVSITSYADSVKGRFTISRDNAKNTI. YLQMNSLRAEDTAVYYCASR 107DVVLWGQGTLVTVS S EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab079-Gl VH SFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 108DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWWRQAPGKGLEWV SEQ ID NO:Ab080-Gl VH SFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 109DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab081-Gl VH SFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 110DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRL. SCAVSGSSFSCAVRMNAVVRQAPGKGLEW’V SEQ ID NO:Ab082-Gl VH SFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 111DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGVVRMNWVRQAPGKGLEVVV SEQ ID NO:Ab083-Gl VH SFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 112DFVLWGQGTLVTVSSAttorney Docket No. DEMB-010 / 02WO SEQ ID NO: Description Variable Heavy Chain Sequence EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab084-Gl VH SFINRRQS1TSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 113DFVLWGQGTLVTVSS EVQLVTSGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab085-Gl VH SFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 114D V VLWGQGTL VT VS S EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab086-Gl VH SFIGRDVSITSYADSVKGRFTISRDNAKNTLYI. QMNSLRAEDTAVYYCASR 115DVVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab087-Gl VH SFIGRDVSITSYADSVKGRFTISRDNAKNTI. YLQMNSLRAEDTAVYYCASR 116D V VLWGQGTL VT VS S EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab088-Gl VH SFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 117DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab089-Gl VH SFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 118DFVLWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEWV SEQ ID NO:Ab090-Gl VH SFIGRASS1TSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASR 119DFVLWGQGTLVTVSS EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEWVS SEQ ID NO:Ab091-Gl VH TINSDGKRTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYACAK 120YIRRWALDYWGQGTQVTVSS EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEWVS SEQ ID NO:Ab092-Gl VH TINSTGDKTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYACAK 121YIRRW7AI. DYWGQGTQVTVSS EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEWVS SEQ ID NO:Ab093-Gl VH TINSDGDRTYYADSVKGRFTISRDNAKNTVYI. QMNSI. KPEDTAVYACAK 122YIRRWALDYWGQGTQVTVSS EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGK. GPEWVS SEQ ID NO:Ab094-Gl VH TINPDGRSTYYADSVKGRFTISRDNAKNTVYTQMNSLKPEDTAVYACAKY 123IRRWALDYWGQGTQVTVSSTable 3. VL amino acid sequences of exemplary anti-SMAGP antibodies.SEQ ID NO: Description Variable Light Chain Sequence QSALTQPPSVSGTLGKTVTISCAGTSSDIGGYNSVSWYQHLPGTAPKLLI SEQ ID NO: 124 AbOOl-Gl VL YAVNARASGIPDRFSGSKSGNTASLIISGLQSEDEGDYYCASYRRVNNHVFGGGTHLTVLAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Light Chain Sequence NVVLTQTPGSLSVVPGESASISCKASQSLVYTDGKTYLCWLLQKPGQRP SEQ IDNO: 125 Ab002-Gl VL QLLIYQVSNRGSGVPGRFTGSGSGTDFTLKISGVKAEDAGVYYCGQGIY YPPTFGQGTKLEIK DLVLTQTPGSLS VVPGES ASISCKASQSL VHTDGKT YLS WLLQKPGQRP SEQ ID NO: 126 Ab003-Gl VL QLLIYQLSNRGSGVPDRFAGSGSGTDFTLKISGVKAEDAGVYYCAQTIY YPDYPRTFGQGTKI. EIKQS ALTQPPS VSGTLGKTLTISCAGT VSDIGG YNGV SW YQQLPGTAPKLLI SEQ IDNO: 127 Ab004-GJ VL. YEVNARASGIPDRFSGSKSGNTASLNISGLQSEDEGDYYCASYRKTNNA VFGSGTHVTVL DVVLTQTPGSLSVVPGDSASISCKASHSLVHTDGTTYLSWFL. QKPGQRP SEQ IDNO: 128 Ab005-Gl VL QLLIYRLSYRSSGVPDRFTGSGSGTDFTLKISGMKAF. DAGVYYCAQTKY YPTTFGQGTKLEIK QSALTQPPSVSGSPGKTVTISCAGTSSDVGYGNFVSWYQQLPGMAPKLL SEQ IDNO: 129 Ab006-Gl VL. IYDVNKRASGIADRFSGSKSGNTASLTISGI. QSEDEADYYCASYRSSNNY VFGGGTTLTVL QSALTQPPSVSGTLGKTVTISCAGTDSDIGGYNHVSWYQHLPGTAPKLLI SEQ IDNO: 130 Ab007-Gl VL YAVTARASGIPDRFSGSKSGNTASLI1AGLQAEDEGLYYCASYRRVNKH VFGGGTHLTVL DRVMTQSPSSVTASVGEKVTINCKSSQSVVFGSNQKSYLNWYQQRPGQ SEQ ID NO: 131 Ab008-Gl VL SPRLLIYYASTQESEIPDRFSGSGSTTDFTLTISSVQPEDAAVYYCQQAYS PPYSFGSGTRLEIK QSALTQNPSVSGALGKTVTISCAGTSSDIGDYNHVSWYQHLPGTAPKLL SEQ IDNO: 132 Ab009-Gl VL IFAVNLRASG1PDRFSGSKSGTTASLTISGLQSEDEGDYYCASYRRYNNH VFGGGTHLTVL QSALTQPPSVSGTLGKTVTISCAGTSSDIGAYNSVSW YQQLPGTAPKLLI SEQ IDNO: 133 AbOlO-Gl VL YEVNKRPSGIPDRFSGSKSGNTASI. TISGLQSEDEQDYYCASYTRNNNF MIGGGTHLTVL QSALTQPPSVSGTLGKTVTISCAGTSSD1GDYNHVSWYQHLPGTAPKLLI SEQ IDNO: 134 AbOll-GJ VL YAVNARASGIPDRFSGSKSGNTASL. IISGLQSEDEGDYYCASYRRVNTH VFGGGTHLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLIJ SEQ IDNO: 135 Ab012-Gl VL YAV7LARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL FJVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ IDNO: 136 Ab013-Gl VL LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK QSALTQPPSVSGSPGQSVTISCTGTSSDVGNYNIVSWYQQHPGKAPKLLI SEQ IDNO: 137 Ab014-Gl VL YAVNARPSG1PDRFSGSKSGNTASLT1SGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ ID NO: 138 Ab015-Gl VL YPTVARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNHVFGGGTKLTVLAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Light Chain Sequence EIVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ IDNO: 139 Ab016-Gl VL LL1YQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ ID NO: 140 Ab017-Gl VL LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQG1YYP PTFGQGTKLEIK QSALTQPPSVSGTLGKTVTISCAGTSSD1GGYNHVSWYQHLPGTAPKLLI SEQ IDNO: 141 Ab018-GJ VL YAVNARASGIPDRFSGSKSGNTASL.il SGLQSF. DEGDYYCASY’RRVNNH VFGGGTHLTVL QSALTQPPSVSGSPGQSVTISCAGTVSDIGGYNGVSWYQQLPGTAPKLLI SEQ IDNO: 142 Ab019-Gl VL YEVNARASGVPDRFSGSKSGNTASLTISGLQSEDEADYYCASYRKTNNA VFGSGTKVTVL QSALTQPPSVSGSPGQSVTISCTGTVSDIGGYNGVSWYQQLPGTAPKLLI SEQ IDNO: 143 Ab020-Gl VL YEVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRKTNNA VFGGGTKVTVL QSALTQPPSVSGSPGQSVTISCAGTVSDIGGYNGVSWYQQLPGTAPKLLI SEQ IDNO: 144 AL021-G1 VL YEVNARASGVPDRFSGSKSGNTASLTISGLQSEDEADYYCASYRKTNNA VFGSGTKVTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGGYNGVSWYQQLPGTAPKLLI SEQ ID NO: 145 Ab022-Gl VL YEVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRKTNNA VFGSGTKVTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGGYX1X2VSWYQQLPGTAPKLL IYEVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRKTNN SEQ IDNO: 146 Ab022-Gl VL AVFGSGTKVTVLWherein Xi can be selected from N, Q, H, or SWherein Xi can be selected from G, or A DVVLTQTPLSLSVTPGQSASISCKASHSLVHTDGTTYLSWFLQKPGQSPQ SEQ IDNO: 147 Ab023-Gl VL LLIYRLSYRSSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQTKYYP TTFGQGTKLEIK DVVLTQTPLSLSVTPGQPASISCKSSHSLVHTDGTTYLYWFLQKPGQSPQ SEQ ID NO: 148 Ab024-Gl VL LLIYRLSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQTKYYP TTFGQGTKLEIK DVVLTQTPLSLSVTPGQSAS1SCKASHSLVHTDGTTYLSWFLQKPGQSPQ SEQ IDNO: 149 AL025-G1 VL LL1YRLSYRSSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQTKYYP TTFGQGTKLEIK DVVLTQTPLSLSVTPGQPASISCKASHSLVHTDGTTYLSWFLQKPGQSPQ SEQ ID NO: 150 Ab026-Gl VL LLIYRLSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQTKYYP TTFGQGTKLEIK QS ALTQPPS VSGSPGQS V T1SCAGTDSD1GG YNHVSW YQHLPGT APKLLI SEQ IDNO: 151 Ab027-GJ VL. YAVTARASGVPDRFSGSKSGNTASL. TISGLQAEDEADYYCASYRRVNKHVFGGGTKLTVLAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Light Chain Sequence QSALTQPPSVSGSPGQSVT1SCTGTDSDIGGYNHVSWYQHLPGTAPKLLI SEQ IDNO: 152 Ab028-Gl VL YAVTNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNK HVFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTDSDIGGYNHVSWYQHLPGTAPKLLI SEQ ID NO: 153 Ab029-Gl VL YAVTNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNK HVFGGGTKLTVL.QSALTQPPSVSGSPGQSVT1SCTGTSSDIGGYNHVSWYQQPPGTAPKLLI SEQ IDNO: 154 Ab030-GJ VL. YAVTNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNK HVFGGGTKLTVL DIVMTQSPDSLAVSLGERATINCKSSQSVVFGSNQKSYI. NWYQQKPGQP SEQ IDNO: 155 Ab031-Gl VL PRLLIYYASTQESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQAYS PPYSFGQGTKLEIK DIVMTQSPDSL. AVSLGERATINCKSSQSVVFGSNQKSYLAWYQQKPGQP SEQ IDNO: 156 Ab032-Gl VL. PKLLIYYASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQAYS PPYSFGQGTKLEIK DIVMTQSPDSLAVSLGERATINCKSSQSVVFGSNQKSYI. NWYQQKPGQP SEQ IDNO: 157 Ab033-Gl VL PRLLIYYASTQESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQAYS PPYSFGQGTKLEIK DIVMTQSPDSLAVSLGERATINCKSSQSVLFSSNQKSYLNWYQQKPGQP SEQ ID NO: 158 Ab034-Gl VL PRLLIYYASTQESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQAYS PPYSFGQGTKLEIK QSALTQPPSVSGAPGQTVTISCAGTSSDIGDYNHVSWYQHLPGTAPKLLI SEQ IDNO: 159 Ab035-Gl VL FAVNLRASGVPDRFSGSKSGTTASLTISGLQSEDEADYYCASYRRYNNH VFGGGTKLTVL QSALTQPPSVSGAPGQSVTISCTGTSSD1GDYNHVSWYQHLPGTAPKLLI SEQ IDNO: 160 Ab036-Gl VL FAVNNRPSGVPDRFSGSKSGTTASLTISGLQAF. DEADYYCASYRRYNNH VFGGGTKLTVL.QSALTQPPSVSGAPGQTVTISCAGTSSDIGDYNHVSWYQHLPGTAPKLLI SEQ IDNO: 161 AbO37-GJ VL. FAVNLRASGVPDRFSGSKSGTTASLTISGL. QSEDEADYYCASYRRYNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGDYNHVSWYQQPPGTAPKLI. I SEQ IDNO: 162 Ab038-Gl VL YAV74L. RASGIPDRFSGSKSGNTASLTISGL. QAEDEADYYCASYRRYNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCAGTSSDIGAYNSVSWYQQLPGTAPKLLI SEQ IDNO: 163 Ab039-Gl VL YEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDF. ADYYCASYTRNNNF MFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGAYNSVSWYQQLPGTAPKLLI SEQ IDNO: 164 Ab040-Gl VL YEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYI'RNNNF MFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGAYNSVSWYQQLPGTAPKLLI SEQ ID NO: 165 Ab041-Gl VL YEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYTRNNNFMFGGGTKLTVLAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Light Chain Sequence QSALTQPPSVSGSPGQSVT1SCTGTSSDIGAYNSVSWYQQPPGTAPKLLI SEQ IDNO: 166 Ab042-Gl VL YEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYTRNNNF VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGAYX)X2VSWYQQPPGTAPKLL IYEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYTRNNN SEQ ID NO: 167 AbO42-GJ VL. FVFGGGTKLTVLWherein Xi can be selected from N, Q, H, or S,Wherein X?. can be selected from S, V, L, or 1 QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNHVSWYQQHPGKAPKLL SEQ ID NO: 168 Ab043-Gl VL IYAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNN H VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCAGTSSDIGGYNHVSWYQHLPGTAPKLLI SEQ IDNO: 169 Ab044-Gl VL YAVNARASGVPDRFSGSKSGNTASLTISGLQSEDEADYYCASYRRVNN HVFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGGYNHVSWYQHLPGTAPKLLI SEQ ID NO: 170 Ab045-Gl VL YAVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNN HVFGGGTKLTVL.QSALTQPPSVSGSPGQSVT1SCTGTSSDVGGYNSVSWYQQHPGKAPKLL1 SEQ IDNO: 171 AbO12-GJ VL YAVNARPSGIPDRFSGSKSGNTASI. TISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ IDNO: 172 AbO12-VHal VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL.QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ IDNO: 173 AbO12-VHa2 VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ IDNO: 174 AbO12-VHa3 VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ ID NO: 175 AbO12-VHa4 VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVT1SCTGTSSDVGGYNSVSWYQQFIPGKAPKLL1 SEQ IDNO: 176 AbO12-VHa5 VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ ID NO: 177 AbO12-VHa6 VL Y A VNARPSGIPDRFSGSKSGNTASLTISGLQAEDEAD Y YC AS Y RRVNN H VFGGGTKLTVL.QSALTQPPSVSGSPGQSVT1SCTGTSSDVGGYNSVSWYQQHPGKAPKLL1 SEQ IDNO: 178 AbO12-VHa7 VL. YAVNARPSGIPDRFSGSKSGNTASI. TISGI. QAEDEADYYCASYRRVNNHVFGGGTKLTVLAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Light Chain Sequence QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ IDNO: 179 AbO12-VHa8 VL YAVNARPSG1PDRFSGSKSGNTASLT1SGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ ID NO: 180 AbO12-VHa9 VL Y A VNARPSGIPDRFSGSKSGNTASLTISGLQAEDEAD Y YC AS Y RRVNN H VFGGGTKLTVL.QSALTQPPSVSGSPGQSVT1SCTGTSSDVGGYGSVSWYQQHPGKAPKLL1 SEQ IDNO: 181 AbO12-VHalO VI. YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYSSVSWYQQHPGKAPKLLI SEQ IDNO: 182 AbO12-VHall VL YAV74ARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL.EIVL. TQTPI. SI. SVVPGQPASISCKASQSLVYTDGKTYL. AWLLQKPGQSPQ SEQ IDNO: 183 Ab013-Gl VL. LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ IDNO: 184 AbO13-VHal VL LL1YQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ ID NO: 185 AbO13-VHa2 VL LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ IDNO: 186 Ab013-VHa3 VL LL1YQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYTGGKTYLAWLLQKPGQSPQ SEQ IDNO: 187 AbO13-VHa4 VL LLI YQVSNRGSG VPSR FSGSG SGTDFTLKISR VEAEDVGVYYCGQGI YYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYT'VGKT'YLAWLLQKPGQSPQ SEQ IDNO: 188 Ab013-VHa5 VL. LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK QSALTQPPSVSGSPGQSVTISCTGTSSDIGGWGVSWYQQLPGTAPKLLI SEQ IDNO: 189 Ab022-Gl VL YEVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRKTNNA VFGSGTKVTVL DVVLTQTPLSLSVTPGQSASISCKASHSI. VHTDGTTYI. SWFLQKPGQSPQ SEQ IDNO: 190 Ab023-Gl VL. I. LIYRLSYRSSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQTKYYP TTFGQGTKLEIK QSALTQPPSVSGSPGQSVTISCTGTSSDIGAYNSVSWYQQPPGTAPKLLI SEQ IDNO: 191 Ab042-Gl VL YEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYT'RNNNF VFGGGTKLTVL QSALT'QPPSVSGSPGQSVTISCTGTSSDVGGYNHVSWYQQHPGKAPKLL SEQ ID NO: 192 Ab043-Gl VL IYAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNHVFGGGTKLTVLAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Light Chain Sequence QSALTQPPSVSGSPGQSVT1SCTGTSSDIGGYQGVSWYQQLPGTAPKLLI Ab022- VL LCDR1SEQ IDNO: 193 YEVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRKTNNA variant V'LVFGSGTKVTVL QSALTQPPSVSGSPGQSV'TISCTGTSSDIGGYHGVSWYQQLPGTAPKLLI \b022- VL LCDR1SEQ ID NO: 194 YEVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRKTNNA variant VLVFGSGTKVTVL QSALTQPPSVSGSPGQSVT1SCTGTSSDIGGYSGVSWYQQLPGTAPKLLI Ab022- VL LCDR1SEQ IDNO: 195 YEVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRKTNNA variant V'LVFGSGTKVTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGGYNVVSWYQQLPGTAPKLLIAb022- VL LCDR1SEQ IDNO: 196 YEVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRKTNNA variant VLVFGSGTKVTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGGYNAVSWYQQLPGTAPKLLIAb022- VL LCDR1SEQ IDNO: 197 YEVNNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRKTNNA variant V'LVFGSGTKVTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGAYQSVSWYQQPPGTAPKLLIAb042- VL LCDR1SEQ IDNO: 198 YEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYTRNNNF variant VLVFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGAYHSVSWYQQPPGTAPKLLIAb042- VL LCDR1SEQ ID NO: 199 YEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYTRNNNF variant VI.VFGGGTKLTVL QSALTQPPSVSGSPGQSVT1SCTGTSSDIGAYSSVSWYQQPPGTAPKLLIY Ab042- VL LCDR1SEQ ID NO: 200 EVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYTRNNNFV variant VLFGGGTKLTVL QSALTQPPSVSGSPGQSV'TISCTGTSSDIGAYNVVSWYQQPPGTAPKLLI Ab042- VL LCDR1SEQ IDNO: 201 YEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYTRNNNF variant VLVFGGGTKLTVL.QS ALTQPPS VSGSPGQS V T1SCTGTSSDIGAY NLV S VV YQQPPGTAPKLLI Ab042- VL LCDR1SEQ ID NO: 202 YEVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCASYTRNNNF variant V'LVFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDIGAYNIVSWYQQPPGTAPKLLIYAb042- VL LCDR1SEQ ID NO: 203 EVNKRPSGVPDRFSGSKSGNTASLTISGL. QAEDEADYYCASYTRNNNFV variant VLFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ ID NO: 204 Ab046-Gl VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLIJ SEQ ID NO: 205 Ab047-Gl VL YAVNARPSG1PDRFSGSKSGNTASLT1SGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ ID NO: 206 Ab048-Gl VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNHVFGGGTKLTVLAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Light Chain Sequence QSALTQPPSVSGSPGQSVTISCTGTSSDVGNYNIVSWYQQHPGKAPKLLI SEQ ID NO: 207 Ab049-Gl VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGNYNIVSWYQQHPGKAPKLLI SEQ ID NO: 208 Ab050-Gl VL Y A VNARPSGIPDRFSGSKSGNTASLTISGLQAEDEAD Y YC AS Y RRVNN H VFGGGTKLTVL.QSALTQPPSVSGSPGQSVT1SCTGTSSDVGNYNIVSWYQQHPGKAPKLL1 SEQ ID NO: 209 AbO51-GJ VL YAVNARPSGIPDRFSGSKSGNTASL. TISGI. QAEDEADYYCAS YRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGHYNIVSWYQQHPGKAPKLLI SEQ ID NO: 210 Ab052-Gl VL YAV7LARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL.QSALTQPPSVSGSPGQSVTISCTGTSSDVGHYNIVSWYQQHPGKAPKLLI SEQ ID NO: 211 Ab053-Gl VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCAS YRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGHYNIVSWYQQHPGKAPKLLI SEQ ID NO: 212 Ab054-Gl VL YA VNARPSG1PDRFSGSKSGNTASLT1SGLQAEDEADYYCAS YRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGHYNIVSWYQQHPGKAPKLLI SEQ ID NO: 213 Ab055-Gl VL YAVNARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ ID NO: 214 Ab056-Gl VL YPTVARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCAS YRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ ID NO: 215 Ab057-Gl VL YPTVARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL.QSALTQPPSVSGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLLI SEQ ID NO: 216 AbO58-GJ VL. YPTVAR PSGIPDRFSGSK SGNT ASLTISGLQAEDEADYYC AS YRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGNYNIVSWYQQHPGKAPKLLI SEQ ID NO: 217 Ab059-Gl VL YPTVARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGNYNIVSWYQQHPGKAPKLLI SEQ ID NO: 218 Ab060-Gl VL YPTVARPSGIPDRFSGSKSGNTASL. TISGL. QAEDEADYYCASYRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGNYNIVSWYQQHPGKAPKLLI SEQ ID NO: 219 Ab061-Gl VL YPTVARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCAS YRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGNYNIVSWYQQHPGKAPKLLI SEQ ID NO: 220 Ab062-Gl VL YPTVARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNHVFGGGTKLTVLAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Light Chain Sequence QSALTQPPSVSGSPGQSVTISCTGTSSDVGHYNIVSWYQQHPGKAPKLLI SEQ ID NO: 221 Ab063-Gl VL YPTVARPSGIPDRFSGSKSGNTASLTTSGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL QS ALTQPPS VSGSPGQS VTISCTGTSSDV GH YNI V SW YQQHPGKAPKLLI SEQ ID NO: 222 Ab064-Gl VL YPTVARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL.QSALTQPPSVSGSPGQSVT1SCTGTSSDVGHYNIVSW YQQHPGKAPKLLI SEQ ID NO: 223 AbO65-GJ VL. YPTVAR PSGIPDRFSGSK SGNT ASLTISGLQAEDEADYYC AS YRRVNNH VFGGGTKLTVL QSALTQPPSVSGSPGQSVTISCTGTSSDVGHYNIVSWYQQHPGKAPKLLI SEQ ID NO: 224 Ab066-Gl VL YPTVARPSGIPDRFSGSKSGNTASLTISGLQAEDEADYYCASYRRVNNH VFGGGTKLTVL.EIVL. TQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ ID NO: 225 Ab067-Gl VL. LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSL. VYTDGKTYLAWLLQKPGQSPQ SEQ ID NO: 226 Ab068-Gl VL LL1YQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ ID NO: 227 Ab069-Gl VL LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ ID NO: 228 Ab070-Gl VL LL1YQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ ID NO: 229 Ab071-Gl VL LLI YQVSNRGSG VPSR FSGSG SGTDFTLKISR VEAEDVGVYYCGQGI YYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVYTDGKTYLAWLLQKPGQSPQ SEQ ID NO: 230 AbO72-GJ VL. LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSL. VGTDRKTYLAWL. LQKPGQSPQ SEQ ID NO: 231 Ab073-Gl VL LLIYQGHNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYY PPTFGQGTKLEIK FHVLTQTPLSLSVVPGQPASISCKASQSLVGTDRKTYLAWLLQKPGQSPQ SEQ ID NO: 232 Ab074-Gl VL LLIYQGHNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYY PPTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSL. VGTDRKTYLAWL. LQKPGQSPQ SEQ ID NO: 233 Ab075-Gl VL LL1YQGHNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYY PPTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVGTDRKTYLAWLLQKPGQSPQ SEQ ID NO: 234 Ab076-Gl VL LLIYQGHNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYPPTFGQGTKLEIKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Variable Light Chain Sequence EIVLTQTPLSLSVVPGQPASISCKASQSLVGTDRKTYLAWLLQKPGQSPQ SEQ ID NO: 235 Ab077-Gl VL LL1YQGHNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVG VYYCGQGI Y Y PPTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLVGTDRKTYLAWLLQKPGQSPQ SEQ ID NO: 236 Ab078-Gl VL LLI YQGHN RGSG VPSRFSGSGSGTDFTLKISRVEAEDVGV Y Y CGQGI Y Y PPTFGQGTKLEIKE1VLTQTPLSLSVVPGQPASISCKASQSLVGTDRKTYLAWLLQKPGQSPQ SEQ ID NO: 237 AbO79-GJ VL. LLIYQGHNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYY PPTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSL. VGTDRKTYLAWL. LQKPGQSPQ SEQ ID NO: 238 Ab080-Gl VL LIJYQGHNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYY PPTFGQGTKLEIK EIVLTQTPI. SI. SVVPGQPASISCKASQSLVGTDRKTYLAWLI. QKPGQSPQ SEQ ID NO: 239 Ab081-Gl VL. LLIYQGHNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYY PPTFGQGTKLEIK FJVLTQTPLSLSVVPGQPASISCKASQSLRYTGGKTYLAWLLQKPGQSPQ SEQ ID NO: 240 Ab082-Gl VL LL1YQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLRYTGGKTYLAWLLQKPGQSPQ SEQ ID NO: 241 Ab083-Gl VL LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIKE1VLTQTPLSLSVVPGQPASISCKASQSLRYTGGKTYLAWLLQKPGQSPQ SEQ ID NO: 242 Ab084-Gl VL LL1YQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLRYTGGKTYLAWLLQKPGQSPQ SEQ ID NO: 243 Ab085-Gl VL LLI YQVSNRGSGVPSR FSGSG SGTDFTLKISR VEAEDVG VYYCGQGI YYP PTFGQGTKLEIKE1VLTQTPLSLSVVPGQPASISCKASQSLRYTGGKTYLAWLLQKPGQSPQ SEQ ID NO: 244 AbO86-GJ VL. LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLRYTGGKTYLAWLLQKPGQSPQ SEQ ID NO: 245 Ab087-Gl VL LIJYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAF. DVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLRYTGGKTYI. AWLLQKPGQSPQ SEQ ID NO: 246 Ab088-Gl VL LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK FJVLTQTPLSLSVVPGQPASISCKASQSLRYTGGKTYLAWLLQKPGQSPQ SEQ ID NO: 247 Ab089-Gl VL LL1YQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYP PTFGQGTKLEIK EIVLTQTPLSLSVVPGQPASISCKASQSLRYTGGKTYLAWLLQKPGQSPQ SEQ ID NO: 248 Ab090-Gl VL LLIYQVSNRGSGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGIYYPPTFGQGTKLEIKAttorney Docket No. DEMB-010 / 02WO SEQ ID NO: Description Variable Light Chain Sequence QSALTQPPSVSGTLGKTVTISCAGTSSD1GGYNHVSWYQHLPGTAPKLLI SEQ ID NO: 249 Ab091-Gl VL YAVNARASGIPDRFSGSKSGNTASLIISGLQSEDEGDYYCASYRRVNNH VFGGGTHLTVL QSALTQPPSVSGTLGKTVTISCAGTSSDIGGYNHVSWYQHLPGTAPKLLI SEQ ID NO: 250 Ab092-Gl VL YAVNARASGIPDRFSGSKSGNTASLI1SGLQSEDEGDYYCASYRRVNNH VFGGGTHLTVL.QSALTQPPSVSGTLGKTVTISCAGTSSDIGGYNSVSWYQHLPGTAPKLLI SEQ ID NO: 251 Ab093-Gl VL YAVNARASGIPDRFSGSKSGNTASLI1SGLQSEDEGDYYCASYRRVNNH VFGGGTHLTVL QSALTQPPSVSGTLGKTVTISCAGTSSDIGGYNHVSWYQHLPGTAPKLLI SEQ ID NO: 252 AbO94-GJ VL. YAVNARASGIPDRFSGSKSGNTASL.il SGLQSEDEGDYYCASYRRVNL’JHVFGGGTHLTVLTable 4. CDRH amino acid sequences of exemplary anti-SMAGP antibodies.Description CDRH1 CDRH2 CDRH3AbOOl-Gl GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 441) 540) NO: 656) Ab002-Gl GSSFSGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 657)442) 541)Ab003-Gl GFTFSN YN (SEQ ID NO: INTGGGST (SEQ ID NO: ATSGYDY (SEQ ID NO: 658)443) 542)Ab004-Gl GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKNGFGRSYYWDY (SEQ 444) 543) ID NO: 659) Ab005-Gl GFTFSESR (SEQ ID NO: IWSDGTTTV (SEQ ID NO: KQGYDS (SEQ ID NO: 660)445) 544)Ab006-Gl GFTFSAYY (SEQ ID NO: INADGGST (SEQ ID NO: ARVPIYYLGDRDFYRYLEI 446) 545) (SEQ ID NO: 661)Ab007-G 1 GFTFASYF (SEQ ID NO: INSGGEDT (SEQ ID NO: AKYLRNWALDY (SEQ ID 447) 546) NO: 662) Ab008-GJ GFTFNTYY (SEQ ID NO: INL. DGSNT (SEQ ID NO: AKPQPGNSIATYDY (SEQ 448) 547) ID NO: 663) Ab009-GJ GFTFGSSF (SEQ ID NO: INADGGDT (SEQ ID NO: AKYL. SYWAI. DH (SEQ ID 449) 548) NO: 664) AbOlO-Gl GFPFSSYW (SEQ ID NO: IKPGGGST (SEQ ID NO: ARQGYGTTWYVDY (SEQ 450) 549) ID NO: 665) AbOll-Gl GFTFGSFF (SEQ ID NO: INSGGDST (SEQ ID NO: ACAKYLRNWALDF (SEQ 451) 550) ID NO: 666) Ab012-Gl GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSW ALDY (SEQ ID 452) 551) NO: 667) Ab013-Gl GSSFSGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 668)453) 552)Attorney Docket No. DEMB-010 / 02WODescription CDRH1 CDRH2 CDRH3Ab014-Gl GFTFGSYF (SEQ ID NO: INSDGRST (SEQ ID NO: AKYLRSWALDY (SEQ ID 454) 553) NO: 669) Ab015-Gl GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 455) 554) NO: 670) Ab016-Gl GTSFGGWR (SEQ ID NO: IGRDVS1T (SEQ ID NO: ASRDVVL (SEQ ID NO: 671)456) 555)Ab017-Gl GTSFGGWR (SEQ ID NO: IGRASSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 672)457) 556)Ab018-Gl GFTFGSYF (SEQ ID NO: INSDGSST (SEQ ID NO: AKYIRRWALDY (SEQ ID 458) 557) NO: 673) Ab019-Gl GFTFSSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKNGFGRSYYWDY (SEQ 459) 558) ID NO: 674)Ab020-Gl GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKNGFGRSYYWDY (SEQ 460) 559) ID NO: 675)Ab021-Gl GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKNGFGRSYYWDY (SEQ 461) 560) ID NO: 676)Ab022-Gl GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKNGFGRSYYWDY (SEQ 462) 561) ID NO: 677)Ab023-Gl GFTFSESR (SEQ ID NO: IWSDGTTT (SEQ ID NO: VKQGYDS (SEQ ID NO:463) 562) 678) Ab024-Gl GFTFSESR (SEQ ID NO: IWSDGTTT (SEQ ID NO: VKQGYDS (SEQ ID NO:464) 563) 679) Ab025-Gl GFTFSESR (SEQ ID NO: IWSDGTTT (SEQ ID NO: VKQGYDS (SEQ ID NO:465) 564) 680) Ab026-Gl GFTFSESR (SEQ ID NO: IWSDGTTT (SEQ ID NO: VKQGYDS (SEQ ID NO:466) 565) 681) Ab027-Gl GFTFSSYF (SEQ ID NO: INSGGEDT (SEQ ID NO: AKYLRNWALDY (SEQ ID 467) 566) NO: 682) Ab028-Gl GFTFASYF (SEQ ID NO: INSGGEDT (SEQ ID NO: AKYLRNWALD Y (SEQ ID 468) 567) NO: 683) Ab029-Gl GFTFASYF (SEQ ID NO: INSGGEDT (SEQ ID NO: AKYLRNWALDY (SEQ ID 469) 568) NO: 684) Ab030-Gl GFTFASYF (SEQ ID NO: INSGGEDT (SEQ ID NO: AKYLRNWALDY (SEQ ID 470) 569) NO: 685) Ab031-Gl GFTFNTYY (SEQ ID NO: INLDGSNT (SEQ ID NO: AKPQPGNSIATYDY (SEQ 471) 570) ID NO: 686)Ab032-Gl GFTFNTYY (SEQ ID NO: INLDGSNT (SEQ ID NO: AKPQPGNSIATYDY (SEQ 472) 571) ID NO: 687)Ab033-Gl GFTFNTYY (SEQ ID NO: INLDGSNT (SEQ ID NO: AKPQPGNSIATYDY (SEQ 473) 572) ID NO: 688)Ab034-Gl GFTFNTYY (SEQ ID NO: INLDGSNT (SEQ ID NO: AKPQPGNSIATYDY (SEQ 474) 573) ID NO: 689)Attorney Docket No. DEMB-010 / 02WODescription CDRH1 CDRH2 CDRH3Ab035-Gl GFTFGSSF (SEQ ID NO: INADGGDT (SEQ ID NO: AKYLSYWALDH (SEQ ID 475) 574) NO: 690) Ab036-Gl GFTFGSSF (SEQ ID NO: INADGGDT (SEQ ID NO: AKYLSYWALDH (SEQ ID 476) 575) NO: 691) Ab037-Gl GFTFGSSF (SEQ ID NO: INADGGDT (SEQ ID NO: AKYLSYWALDH (SEQ ID 477) 576) NO: 692) Ab038-Gl GFTFGSSF (SEQ ID NO: INADGGDT (SEQ ID NO: AKYLSYWALDH (SEQ ID 478) 577) NO: 693) Ab039-Gl GFTFSSYW (SEQ ID NO: IKPGGGST (SEQ ID NO: ARQGYGTTWYVDY (SEQ 479) 578) ID NO: 694)Ab040-Gl GFPFSSYW (SEQ ID NO: IKPGGGST (SEQ ID NO: ARQGYGTTWYVDY (SEQ 480) 579) ID NO: 695)Ab041-Gl GFTFSSYW (SEQ ID NO: IKPGGGST (SEQ ID NO: ARQGYGTTWYVDY (SEQ 481) 580) ID NO: 696)Ab042-Gl GFPFSSYW (SEQ ID NO: IKPGGGST (SEQ ID NO: ARQGYGTTWYVDY (SEQ 482) 581) ID NO: 697)Ab043-Gl GFTFGSYF (SEQ ID NO: INSDGSST (SEQ ID NO: AKYIRRWALDY (SEQ ID 483) 582) NO: 698) Ab044-Gl GFTFSSYF (SEQ ID NO: INSDGSST (SEQ ID NO: AKYIRRWALDY (SEQ ID 484) 583) NO: 699) Ab045-Gl GFTFGSYF (SEQ ID NO: INSDGSST (SEQ ID NO: AKYIRRWALDY (SEQ ID 485) 584) NO: 700) AbO12-VHa-Gl GFTFGSYF (SEQ ID NO: NSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 585) NO: 667) AbO12-VHal-Gl GFTFGSYF (SEQ ID NO: GSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 586) NO: 667) AbO12-VHa2-Gl GFTFGSYF (SEQ ID NO: NVDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 587) NO: 667) AbO12-VHa3-Gl GFTFGSYF (SEQ ID NO: NLDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 588) NO: 667) AbO12-VHa4-Gl GFTFGSYF (SEQ ID NO: NSVGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 589) NO: 667) AbO12-VHa5-Gl GFTFGSYF (SEQ ID NO: NSLGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 590) NO: 667) AbO12-VHa6-Gl GFTFGSYF (SEQ ID NO: NSDVDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 591) NO: 667) AbO12-VHa7-Gl GFTFGSYF (SEQ ID NO: NSDGSST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 592) NO: 667) AbO12-VHa8-Gl GFTFGSYF (SEQ ID NO: NSDGGST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 593) NO: 667) AbO12-VHa9-Gl GFTFGSYF (SEQ ID NO: NSDGVST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 594) NO: 667)Attorney Docket No. DEMB-010 / 02WODescription CDRH1 CDRH2 CDRH3AbO12-VHalO-Gl GFTFGSYF (SEQ ID NO: NSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 595) NO: 667) AbO12-VHall-Gl GFTFGSYF (SEQ ID NO: NSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 596) NO: 667) Ab013-Gl GSSFSGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 668)486) 597)AbO13-VHal GFTFGSYW (SEQ ID NO: INRGSSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 668)487) 598)AbO13-VHa2 GFTFSESR (SEQ ID NO: INRVSSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 668)488) 599)AbO13-VHa3 GSSFSGWR (SEQ ID NO: INRPSSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 668)486) 600)AbO13-VHa4 GSSFSGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 668)486) 601)AbO13-VHa5 GSSFSGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 668)486) 602)Ab022-Gl GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKNGFGRSYYWDY (SEQ 487) 603) ID NO: 677)Ab022-Gl CDRH3 GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKNGFGRSYYWDY (SEQ variant 487) 603) ID NO: 701)Ab023-Gl GFTFSESR (SEQ ID NO: IWSDGTTT (SEQ ID NO: VKQGYDS (SEQ ID NO:488) 604) 702) Ab023-Gl GFTFSESR (SEQ ID NO: IWSDGTTT (SEQ ID NO: VKQGYDS (SEQ ID NO:488) 604) 678) Ab042-Gl GFPFSSYW (SEQ ID NO: IKPGGGST (SEQ ID NO: ARQGYGTTWY VDY (SEQ 489) 605) ID NO: 703)Ab043-Gl GFTFGSYF (SEQ ID NO: INSDGSST (SEQ ID NO: AKYIRRW'ALDY (SEQ ID 490) 606) NO: 704) Ab022-Gl CDRH3 GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKXXFGRSYYWDY (SEQ variant 487) 603) ID NO: 705)Ab022-Gl CDRH3 GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKQGFGRSYYWDY (SEQ variant 487) 603) ID NO: 706)Ab022-Gl CDRH3 GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKHGFGRSYYWDY (SEQ variant 487) 603) ID NO: 707)Ab022-Gl CDRH3 GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKSGFGRSYY V'. DY (SEQ variant 487) 603) ID NO: 708)Ab022-Gl CDRH3 GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKNVFGRSYYWDY (SEQ variant 487) 603) ID NO: 709)Ab022-Gl CDRH3 GFTFGSYW (SEQ ID NO: IPTSGGNT (SEQ ID NO: AKNAFGRSYYWDY (SEQ variant 487) 603) ID NO: 710)Ab046-Gl GFTFGSYF (SEQ ID NO: INPRGGST (SEQ ID NO: AKYLRSWALDY (SEQ ID 491) 607) NO: 711)Attorney Docket No. DEMB-010 / 02WODescription CDRH1 CDRH2 CDRH3Ab047-Gl GFTFGSYF (SEQ ID NO: INPDGDRT (SEQ ID NO: AKYLRSWALDY (SEQ ID 492) 608) NO: 712) Ab048-Gl GFTFGSYF (SEQ ID NO: INSDGRST (SEQ ID NO: AKYLRSWALDY (SEQ ID 493) 609) NO: 713) Ab049-Gl GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 494) 610) NO: 714) Ab050-Gl GFTFGSYF (SEQ ID NO: INPRGGST (SEQ ID NO: AKYLRSWALDY (SEQ ID 495) 611) NO: 715) Ab051-Gl GFTFGSYF (SEQ ID NO: INPDGDRT (SEQ ID NO: AKYLRSWALDY (SEQ ID 496) 612) NO: 716) Ab052-Gl GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 497) 613) NO: 717) Ab053-Gl GFTFGSYF (SEQ ID NO: INPRGGST (SEQ ID NO: AKYLRSWALDYSEQ ID 498) 614) NO: 718) Ab054-Gl GFTFGSYF (SEQ ID NO: INPDGDRT (SEQ ID NO: AKYLRSWALDY (SEQ ID 499) 615) NO: 719) Ab055-Gl GFTFGSYF (SEQ ID NO: INSDGRST (SEQ ID NO: AKYLRSWALDY (SEQ ID 500) 616) NO: 720) Ab056-Gl GFTFGSYF (SEQ ID NO: INPRGGST (SEQ ID NO: AKYLRSWALDY (SEQ ID 501) 617) NO: 721) Ab057-Gl GFTFGSYF (SEQ ID NO: INPDGDRT (SEQ ID NO: AKYLRSWALDY (SEQ ID 502) 618) NO: 722) Ab058-Gl GFTFGSYF (SEQ ID NO: INSDGRST (SEQ ID NO: AKYLRSWALDY (SEQ ID 503) 619) NO: 723) Ab059-Gl GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 504) 620) NO: 724) Ab060-Gl GFTFGSYF (SEQ ID NO: INPRGGST (SEQ ID NO: AKYLRSWALDY (SEQ ID 505) 621) NO: 725) Ab061-Gl GFTFGSYF (SEQ ID NO: INPDGDRT (SEQ ID NO: AKYLRSWALDY (SEQ ID 506) 622) NO: 726) Ab062-Gl GFTFGSYF (SEQ ID NO: INSDGRST (SEQ ID NO: AKYLRSWALDY (SEQ ID 507) 623) NO: 727) Ab063-Gl GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 508) 624) NO: 728) Ab064-Gl GFTFGSYF (SEQ ID NO: INPRGGST (SEQ ID NO: AKYLRSWALDY (SEQ ID 509) 625) NO: 729) Ab065-Gl GFTFGSYF (SEQ ID NO: INPDGDRT (SEQ ID NO: AKYLRSWALDY (SEQ ID 510) 626) NO: 730) Ab066-Gl GFTFGSYF (SEQ ID NO: INSDGRST (SEQ ID NO: AKYLRSWALDY (SEQ ID 511) 627) NO: 731) Ab067-Gl GLSFGGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 732)512) 628)Attorney Docket No. DEMB-010 / 02WODescription CDRH1 CDRH2 CDRH3Ab068-Gl GTSFGGWR (SEQ ID NO: INRRQSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 733)513) 629)Ab069-Gl GSSFSGWR (SEQ ID NO: IGRDVSIT (SEQ ID NO: ASRDVVL (SEQ ID NO: 734)514) 630)Ab070-Gl GLSFGGWR (SEQ ID NO: IGRDVSIT (SEQ ID NO: ASRDVVL (SEQ ID NO: 735)515) 631)Ab071-Gl GSSFSGWR (SEQ ID NO: IGRASSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 736)516) 632)Ab072-Gl GLSFGGWR (SEQ ID NO: IGRASSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 737)517) 633)Ab073-Gl GSSFSGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 738)518) 634)Ab074-Gl GLSFGGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 739)519) 635)Ab075-Gl GTSFGGWR (SEQ ID NO: INRRQSIT (SEQ ID NO: ASRDFVL. (SEQ ID NO: 740)520) 636)Ab076-Gl GSSFSGWR (SEQ ID NO: IGRDVSIT (SEQ ID NO: ASRDVVL. (SEQ ID NO: 741 )521) 637)Ab077-Gl GLSFGGWR (SEQ ID IGRDVSIT (SEQ ID NO: ASRDVVL. (SEQ ID NO: 742)522) 638)Ab078-Gl GTSFGGWR (SEQ ID NO: IGRDVSIT (SEQ ID NO: ASRDVVL. (SEQ ID NO: 743)523) 639)Ab079-Gl GSSFSGWR (SEQ ID NO: IGRASSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 744)524) 640)Ab080-Gl GLSFGGWR (SEQ ID NO: IGRASSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 745)525) 641)Ab081-Gl GTSFGGWR (SEQ ID NO: IGRASSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 746)526) 642)Ab082-Gl GSSFSGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 747)527) 643)Ab083-Gl GLSFGGWR (SEQ ID NO: INRDSSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 748)528) 644)Ab084-Gl GTSFGGWR (SEQ ID NO: INRRQSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 749)529) 645)Ab085-Gl GSSFSGWR (SEQ ID NO: IGRDVSIT (SEQ ID NO: ASRDVVL (SEQ ID NO: 750)530) 646)Ab086-Gl GLSFGGWR (SEQ ID NO: IGRDVSIT (SEQ ID NO: ASRDVVL (SEQ ID NO: 751)531) 647)Ab087-Gl GTSFGGWR (SEQ ID NO: IGRDVSIT (SEQ ID NO: ASRDVVL (SEQ ID NO: 752)532) 648)Ab088-Gl GSSFSGWR (SEQ ID NO: IGRASSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 753)533) 649)Attorney Docket No. DEMB-010 / 02WO Description CDRH1 CDRH2 CDRH3Ab089-Gl GLSFGGWR (SEQ ID NO: IGRASSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 754)534) 650)Ab090-Gl GTSFGGWR (SEQ ID NO: IGRASSIT (SEQ ID NO: ASRDFVL (SEQ ID NO: 755)535) 651)Ab091-Gl GFTFGSYF (SEQ ID NO: INSDGKRT (SEQ ID NO: AKYIRRWALDY (SEQ ID 536) 652) NO: 756) Ab092-Gl GFTFGSYF (SEQ ID NO: INSTGDKT (SEQ ID NO: AKYIRRWALDY (SEQ ID 537) 653) NO: 757) Ab093-Gl GFTFGSYF (SEQ ID NO: INSDGDRT (SEQ ID NO: AKYIRRWALDY (SEQ ID 538) 654) NO: 758) Ab094-Gl GFTFGSYF (SEQ ID NO: INPDGRST (SEQ ID NO: AKYIRRWALDY (SEQ ID 539) 655) NO: 759) Ab012-Gl GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 551) NO: 667) AbO12-VHal GFTFGSYF (SEQ ID NO: IGSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 1198) NO: 667) AbO12-VHa2 GFTFGSYF (SEQ ID NO: INVDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 1199) NO: 667) AbO12-VHa3 GFTFGSYF (SEQ ID NO: INLDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 1200) NO: 667) AbO12-VHa4 GFTFGSYF (SEQ ID NO: INSVGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 1201) NO: 667) AbO12-VHa5 GFTFGSYF (SEQ ID NO: INSLGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 1202) NO: 667) AbO12-VHa6 GFTFGSYF (SEQ ID NO: INSDVDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 1203) NO: 667) AbO12-VHa7 GFTFGSYF (SEQ ID NO: INSDGSST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 1204) NO: 667) AbO12-VHa8 GFTFGSYF (SEQ ID NO: INSDGGST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 1205) NO: 667) AbO12-VHa9 GFTFGSYF (SEQ ID NO: INSDGVST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 1206) NO: 667) AbO12-VHalO GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 551) NO: 667) AbO12-VHall GFTFGSYF (SEQ ID NO: INSDGDST (SEQ ID NO: AKYLRSWALDY (SEQ ID 452) 551) NO: 667)Table 5. CDRL amino acid sequences of exemplary anti-SMAGP antibodies.Description CDRLI CDRL 2 CDRL3AbOOl-Gl SSD1GGYNS (SEQ ID NO: A V NARAS (SEQ ID NO: ASYRRVNNHV (SEQ ID 760) 878) NO: 972)Attorney Docket No. DEMB-010 / 02WODescription CDRL1 CDRL2 CDRL3Ab002-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 879) GQGIYYPPT (SEQ ID NO:NO: 761) 973) Ab003-Gl QSLVHTDGKTY (SEQ ID QLSNRGS (SEQ ID NO: 880) AQTIYYPDYPRT (SEQ ID NO: 762) NO: 974) Ab004-Gl VSDIGGYNG (SEQ ID NO: EVNARAS (SEQ ID NO: 881) ASYRKTNNAV (SEQ ID 763) NO: 975) Ab005-Gl HSLVHTDGTTY (SEQ ID RLSYRSS (SEQ ID NO: 882) AQTKYYPTT (SEQ ID NO:NO: 764) 976) Ab006-Gl SSDVGYGNF (SEQ ID NO: DVNKRAS (SEQ ID NO: ASYRSSNNYV (SEQ ID 765) 883) NO: 977) Ab007-Gl DSDIGGYNH (SEQ ID NO: AVTARAS (SEQ ID NO: 884) ASYRRVNKHV (SEQ ID 766) NO: 978) Ab008-Gl QSVVFGSNQKSY (SEQ ID YASTQES (SEQ ID NO: 885) QQAYSPPYS (SEQ ID NO:NO: 767) 979) Ab009-Gl SSDIGDYNH (SEQ ID NO: A VNLRAS (SEQ ID NO: 886) ASYRRYNNHV (SEQ ID 768) NO: 980) AbOlO-Gl SSDIGAYNS (SEQ ID NO: EVNKRPS (SEQ ID NO: 887) ASYTRNNNFM (SEQ ID 769) NO: 981) AbOU-Gl SSDIGDYNH (SEQ ID NO: A VNARAS (SEQ ID NO: ASYRRVNTHV (SEQ ID 770) 888) NO: 982) Ab012-Gl SSDVGGYNS (SEQ ID NO: A VNARPS (SEQ ID NO: 889) ASYRRVNNHV (SEQ ID 771) NO: 983) Ab013-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 890) GQGIYYPPT (SEQ ID NO:NO: 772) 984) Ab014-Gl SSDVGNYN1 (SEQ ID NO: A VNARPS (SEQ ID NO: 891) ASYRRVNNHV (SEQ ID 773) NO: 985) Ab015-Gl SSDVGGYNS (SEQ ID NO: PTVARPS (SEQ ID NO: 892) ASYRRVNNHV (SEQ ID 774) NO: 986) Ab016-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 893) GQGIYYPPT (SEQ ID NO:NO: 775) 987) Ab017-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 894) GQGIYYPPT (SEQ ID NO:NO: 776) 988) Ab018-Gl SSDIGGYNH (SEQ ID NO: AVNARAS (SEQ ID NO: ASYRRVNNHV (SEQ ID 777) 895) NO: 989) Ab019-Gl VSDIGGYNG (SEQ ID NO: EVNARAS (SEQ ID NO: 896) ASYRKTNNAV (SEQ ID 778) NO: 990) Ab020-Gl VSDIGGYNG (SEQ ID NO: EVNNRPS (SEQ ID NO: 897) ASYRKTNNAV (SEQ ID 779) NO: 991) Ab021-Gl VSDIGGYNG (SEQ ID NO: EVNARAS (SEQ ID NO: 898) ASYRKTNNAV (SEQ ID 780) NO: 992) Ab022-Gl SSDIGGYNG (SEQ ID NO: EVNNRPS (SEQ ID NO: 899) ASYRKTNNAV (SEQ ID 781) NO: 993)Attorney Docket No. DEMB-010 / 02WODescription CDRL1 CDRL2 CDRL3AE023-G1 HSLVTITDGTTY (SEQ ID RLSYRSS (SEQ ID NO: 900) AQTKYYPTT (SEQ ID NO:NO: 782) 994) AE024-G1 HSLVTITDGTTY (SEQ ID RLSNRFS (SEQ ID NO: 901) AQTKYYPTT (SEQ ID NO:NO: 783) 995) AE025-G1 HSLVTITDGTTY (SEQ ID RLSYRSS (SEQ ID NO: 902) AQTKYYPTT (SEQ ID NO:NO: 784) 996) Ab026-Gl HSLVTITDGTTY (SEQ ID RLSNRFS (SEQ ID NO: 903) AQTKYYPTT (SEQ ID NO:NO: 785) 997) Ab027-Gl DSDIGGYNH (SEQ ID NO: AVTARAS (SEQ ID NO: 904) ASYRRVNKHV (SEQ ID 786) NO: 998) Ab028-Gl DSDIGGYNH (SEQ ID NO: A VTNRPS (SEQ ID NO: 905) ASYRRVNKHV (SEQ ID 787) NO: 999) Ab029-Gl DSDIGGYNH (SEQ ID NO: A VTNRPS (SEQ ID NO: 906) ASYRRVNKHV (SEQ ID 788) NO: 1000)Ab030-Gl SSDIGGYNH (SEQ ID NO: A VTNRPS (SEQ ID NO: 907) ASYRRVNKHV (SEQ ID 789) NO: 1001)Ab031-Gl QSVVFGSNQKSY (SEQ ID YASTQES (SEQ ID NO: 908) QQAYSPPYS (SEQ ID NO:NO: 790) 1002) Ab032-Gl QSVVFGSNQKSY (SEQ ID YASTRES (SEQ ID NO: 909) QQAYSPPYS (SEQ ID NO:NO: 791) 1003) Ab033-Gl QSVVFGSNQKSY (SEQ ID YASTQES (SEQ ID NO: 910) QQAYSPPYS (SEQ ID NO:NO: 792) 1004) Ab034-Gl QSVLFSSNQKSY (SEQ ID YASTQES (SEQ ID NO: 911) QQAYSPPYS (SEQ ID NO:NO: 793) 1005) Ab035-Gl SSDIGDYNH (SEQ ID NO: AVNLRAS (SEQ ID NO: 912) ASYRRYNNHV (SEQ ID 794) NO: 1006)Ab036-Gl SSDIGDYNH (SEQ ID NO: AVNNRPS (SEQ ID NO: 913) ASYRRYNNHV (SEQ ID 795) NO: 1007)Ab037-Gl SSDIGDYNH (SEQ ID NO: AVNLRAS (SEQ ID NO: 914) ASYRRYNNHV (SEQ ID 796) NO: 1008)Ab038-Gl SSDIGDYNH (SEQ ID NO: AVNLRAS (SEQ ID NO: 915) ASYRRYNNHV (SEQ ID 797) NO: 1009)Ab039-Gl SSDIGAYNS (SEQ ID NO: EVNKRPS (SEQ ID NO: 916) ASYTRNNNFM (SEQ ID 798) NO: 1010)Ab040-Gl SSDIGAYNS (SEQ ID NO: EVNKRPS (SEQ ID NO: 917) ASYTRNNNFM (SEQ ID 799) NO: 1011)Ab041-Gl SSDIGAYNS (SEQ ID NO: EVNKRPS (SEQ ID NO: 918) ASYTRNNNFM (SEQ ID 800) NO: 1012)Ab042-Gl SSDIGAYNS (SEQ ID NO: EVNKRPS (SEQ ID NO: 919) ASYTRNNNFV (SEQ ID 801) NO: 1013)Ab043-Gl SSDVGGYNH (SEQ ID NO: AVNARPS (SEQ ID NO: 920) ASYRRVNNHV (SEQ ID 802) NO: 1014)Attorney Docket No. DEMB-010 / 02WODescription CDRLl CDRL2 CDRL3Ab044-Gl SSD1GGYNH (SEQ ID NO: AVNARAS (SEQ ID NO: ASYRRVNNHV (SEQ ID 803) 921) NO: 1015)Ab045-Gl SSDIGGYNH (SEQ ID NO: AVNNRPS (SEQ ID NO: 922) ASYRRVNNHV (SEQ ID 804) NO: 1016)Ab012-Gl SSDVGGYNS (SEQ ID NO: AVNARPS (SEQ ID NO: 889) ASYRRVNNHV (SEQ ID 805) NO: 983) AbO12-VHalO SSDVGGYGS (SEQ ID NO: A VNARPS (SEQ ID NO: 889) ASYRRVNNHV (SEQ ID CDRLl 806) NO: 983)AbO12-VHall SSDVGGYSS (SEQ ID NO: AVNARPS (SEQ ID NO: 889) ASYRRVNNHV (SEQ ID CDRLl 807) NO: 983)Ab013-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 890) GQGIYYPPT (SEQ ID NO:NO: 808) 984) AbO13-VHal QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 890) GQGIYYPPT (SEQ ID NO:NO: 809) 984) AbO13-VHa2 QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 890) GQGIYYPPT (SEQ ID NO:NO: 810) 984) AbO13-VHa3 QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 890) GQGIYYPPT (SEQ ID NO:NO: 811) 984) AbO13-VHa4 QSLVYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 890) GQGIYYPPT (SEQ ID NO:NO: 812) 984) AbO13-VHa5 QSLVYTVGKTY (SEQ ID QVSNRGS (SEQ ID NO: 890) GQGIYYPPT (SEQ ID NO:NO: 813) 984) Ab022-Gl SSDIGGYNG (SEQ ID NO: EVNNRPS (SEQ ID NO: 899) ASYRKTNNAV (SEQ ID 814) NO: 993) Ab023-Gl HSLVHTDGTTY (SEQ ID RLSYRSS (SEQ ID NO: 900) AQTKYYPTT (SEQ ID NO:NO: 815) 994) Ab042-Gl SSDIGAYNS (SEQ ID NO: EVNKRPS (SEQ ID NO: 919) ASYTRNNNFV (SEQ ID 816) NO: 1013)Ab043-Gl SSDVGGYNH (SEQ ID NO: AVNARPS (SEQ ID NO: 920) ASYRRVNNHV (SEQ ID 817) NO: 1014)Ab022- CDRLl SSDIGGYQG (SEQ ID NO: EVNNRPS (SEQ ID NO: 899) ASYRKTNNAV (SEQ ID variant 818) NO: 993)Ab022- CDRLl SSDIGGYHG (SEQ ID NO: EVNNRPS (SEQ ID NO: 899) ASYRKTNNAV (SEQ ID variant 819) NO: 993)Ab022- CDRLl SSDIGGYSG (SEQ ID NO: EVNNRPS (SEQ ID NO: 899) ASYRKTNNAV (SEQ ID variant 820) NO: 993)Ab022- CDRLl SSDIGGYNV (SEQ ID NO: EVNNRPS (SEQ ID NO: 899) ASYRKTNNAV (SEQ ID variant 821) NO: 993)Ab022- CDRLl SSDIGGYNA (SEQ ID NO: EVNNRPS (SEQ ID NO: 899) ASYRKTNNAV (SEQ ID variant 822) NO: 993)Ab042- CDRLl SSDIGAYQS (SEQ ID NO: EVNKRPS (SEQ ID NO: 919) ASYTRNNNFV (SEQ ID variant 823) NO: 1013)Attorney Docket No. DEMB-010 / 02WODescription CDRL1 CDRL2 CDRL3Ab042- CDRL1 SSDIGAYHS (SEQ ID NO: EVNKRPS (SEQ ID NO: 919) ASYTRNNNFV (SEQ ID variant 824) NO: 1013)Ab042- CDRL1 SSD1GAYSS (SEQ ID NO: EVNKRPS (SEQ ID NO: 919) ASYTRNNNFV (SEQ ID variant 825) NO: 1013)Ab042- CDRL1 SSDIGAYNV (SEQ ID NO: EVNKRPS (SEQ ID NO: 919) ASYTRNNNFV (SEQ ID variant 826) NO: 1013)Ab042- CDRL1 SSDIGAYNL (SEQ ID NO: EVNKRPS (SEQ ID NO: 919) ASYTRNNNFV (SEQ ID variant 827) NO: 1013)Ab042- CDRL1 SSDIGAYNI (SEQ ID NO: EVNKRPS (SEQ ID NO: 919) ASYTRNNNFV (SEQ ID variant 828) NO: 1013)Ab046-Gl SSDVGGYNS (SEQ ID NO: AVNARPS (SEQ ID NO: 923) ASYRRVNNHV (SEQ ID 829) NO: 1017)Ab047-Gl SSDVGGYNS (SEQ ID NO: A VNARPS (SEQ ID NO: 924) ASYRRVNNHV (SEQ ID 830) NO: 1018)Ab048-Gl SSDVGGYNS (SEQ ID NO: AVNARPS (SEQ ID NO: 925) ASYRRVNNHV (SEQ ID 831) NO: 1019)Ab049-Gl SSDVGNYNI (SEQ ID NO: AVNARPS (SEQ ID NO: 926) ASYRRVNNHV (SEQ ID 832) NO: 1020)Ab050-Gl SSDVGNYNI (SEQ ID NO: AVNARPS (SEQ ID NO: 927) ASYRRVNNHV (SEQ ID 833) NO: 1021)Ab051-Gl SSDVGNYNI (SEQ ID NO: AVNARPS (SEQ ID NO: 928) ASYRRVNNHV (SEQ ID 834) NO: 1022)Ab052-Gl SSDVGHYN1 (SEQ ID NO: AVNARPS (SEQ ID NO: 929) ASYRRVNNHV (SEQ ID 835) NO: 1023)Ab053-Gl SSDVGHYN1 (SEQ ID NO: AVNARPS (SEQ ID NO: 930) ASYRRVNNHV (SEQ ID 836) NO: 1024)Ab054-Gl SSDVGHYN1 (SEQ ID NO: AVNARPS (SEQ ID NO: 931) ASYRRVNNHV (SEQ ID 837) NO: 1025)Ab055-Gl SSDVGHYN1 (SEQ ID NO: AVNARPS (SEQ ID NO: 932) ASYRRVNNHV (SEQ ID 838) NO: 1026)Ab056-Gl SSDVGGYNS (SEQ ID NO: PTVARPS (SEQ ID NO: 933) ASYRRVNNHV (SEQ ID 839) NO: 1027)Ab057-Gl SSDVGGYNS (SEQ ID NO: PTVARPS (SEQ ID NO: 934) ASYRRVNNHV (SEQ ID 840) NO: 1028)Ab058-Gl SSDVGGYNS (SEQ ID NO: PTVARPS (SEQ ID NO: 935) ASYRRVNNHV (SEQ ID 841) NO: 1029)Ab059-Gl SSDVGNYN1SEQ ID NO: PTVARPSSEQ ID NO: 936) ASYRRVNNHVSEQ ID NO:842) 1030) Ab060-Gl SSDVGNYNI (SEQ ID NO: PTVARPS (SEQ ID NO: 937) ASYRRVNNHV (SEQ ID 843) NO: 1031)Ab061-Gl SSDVGNYNI (SEQ ID NO: PTVARPS (SEQ ID NO: 938) ASYRRVNNHV (SEQ ID 844) NO: 1032)Attorney Docket No. DEMB-010 / 02WODescription CDRL1 CDRL2 CDRL3Ab062-Gl SSDVGNYNI (SEQ ID NO: PTVARPS (SEQ ID NO: 939) ASYRRVNNHV (SEQ ID 845) NO: 1033)Ab063-Gl SSDVGHYNI (SEQ ID NO: PTVARPS (SEQ ID NO: 940) ASYRRVNNHV (SEQ ID 846) NO: 1034)Ab064-Gl SSDVGHYNI (SEQ ID NO: PTVARPS (SEQ ID NO: 941) ASYRRVNNHV (SEQ ID 847) NO: 1035)Ab065-Gl SSDVGHYNI (SEQ ID NO: PTVARPS (SEQ ID NO: 942) ASYRRVNNHV (SEQ ID 848) NO: 1036)Ab066-Gl SSDVGHYNI (SEQ ID NO: PTVARPS (SEQ ID NO: 943) ASYRRVNNHV (SEQ ID 849) NO: 1037)Ab067-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 944) GQGIYYPPT (SEQ ID NO:NO: 850) 1038) Ab068-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 945) GQGIYYPPT (SEQ ID NO:NO: 851) 1039) Ab069-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 946) GQGIYYPPT (SEQ ID NO:NO: 852) 1040) Ab070-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 947) GQGIYYPPT (SEQ ID NO:NO: 853) 1041) Ab071-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 948) GQGIYYPPT (SEQ ID NO:NO: 854) 1042) Ab072-Gl QSLVYTDGKTY (SEQ ID QVSNRGS (SEQ ID NO: 949) GQGIYYPPT (SEQ ID NO:NO: 855) 1043) Ab073-Gl QSLVGTDRKTY (SEQ ID QGHNRGS (SEQ ID NO: GQGIYYPPT (SEQ ID NO:NO: 856) 950) 1044) Ab074-Gl QSLVGTDRKTY (SEQ ID QGHNRGS (SEQ ID NO: GQGIYYPPT (SEQ ID NO:NO: 857) 951) 1045) Ab075-Gl QSLVGTDRKTY (SEQ ID QGHNRGS (SEQ ID NO: GQGIYYPPT (SEQ ID NO:NO: 858) 952) 1046) Ab076-Gl QSLVGTDRKTY (SEQ ID QGHNRGS (SEQ ID NO: GQGIYYPPT (SEQ ID NO:NO: 859) 953) 1047) Ab077-Gl QSLVGTDRKTY (SEQ ID QGHNRGS (SEQ ID NO: GQGIYYPPT (SEQ ID NO:NO: 860) 954) 1048) Ab078-Gl QSLVGTDRKTY (SEQ ID QGHNRGS (SEQ ID NO: GQGIYYPPT (SEQ ID NO:NO: 861) 955) 1049) Ab079-Gl QSLVGTDRKTY (SEQ ID QGHNRGS (SEQ ID NO: GQGIYYPPT (SEQ ID NO:NO: 862) 956) 1050) Ab080-Gl QSLVGTDRKTY (SEQ ID QGHNRGS (SEQ ID NO: GQGIYYPPT (SEQ ID NO:NO: 863) 957) 1051) Ab081-Gl QSLVGTDRKTY (SEQ ID QGHNRGS (SEQ ID NO: GQGIYYPPT (SEQ ID NO:NO: 864) 958) 1052) Ab082-Gl QSLRYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 959) GQGIYYPPT (SEQ ID NO:NO: 865) 1053)Attorney Docket No. DEMB-010 / 02WODescription CDRL1 CDRL2 CDRL3Ab083-Gl QSLRYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 960) GQGIYYPPT (SEQ ID NO:NO: 866) 1054) Ab084-Gl QSLRYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 961) GQGIYYPPT (SEQ ID NO:NO: 867) 1055) Ab085-Gl QSLRYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 962) GQGIYYPPT (SEQ ID NO:NO: 868) 1056) Ab086-Gl QSLRYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 963) GQGIYYPPT (SEQ ID NO:NO: 869) 1057) Ab087-Gl QSLRYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 964) GQGIYYPPT (SEQ ID NO:NO: 870) 1058) Ab088-Gl QSLRYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 965) GQGIYYPPT (SEQ ID NO:NO: 871) 1059) Ab089-Gl QSLRYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 966) GQGIYYPPT (SEQ ID NO:NO: 872) 1060) Ab090-Gl QSLRYTGGKTY (SEQ ID QVSNRGS (SEQ ID NO: 967) GQGIYYPPT (SEQ ID NO:NO: 873) 1061) Ab091-Gl SSDIGGYNH (SEQ ID NO: A VNARAS (SEQ ID NO: ASYRRVNNHV (SEQ ID 874) 968) NO: 1062) Ab092-Gl SSDIGGYNH (SEQ ID NO: A VNARAS (SEQ ID NO: ASYRRVNNHV (SEQ ID 875) 969) NO: 1063) Ab093-Gl SSDIGGYNS (SEQ ID NO: A VNARAS (SEQ ID NO: ASYRRVNNHV (SEQ ID 876) 970) NO: 1064) Ab094-Gl SSDIGGYNH (SEQ ID NO: A VNARAS (SEQ ID NO: ASYRRVNNHV (SEQ ID 877) 971) NO: 1065)

[0103] The individual CDRs of an antibody disclosed herein can be determined according to any CDR numbering scheme known in the art.

[0104] In certain embodiments, one or more of the CDRs of an antibody disclosed herein can be determined according to Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat el al., Sequences of protein of immunological interest (1991), each of which is herein incorporated by reference in its entirety.

[0105] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), the antibody provided herein comprises the CDRH1, CDRH2, and / or CDRH3 of a VH amino acid sequence set forth in any of SEQ ID NOs: 2-123 as determined by the Kabat numbering scheme. In certain embodiments, an antibody provided herein comprises the CDRL1, CDRL2, and / or CDRL3 of a VL amino acid sequence set forth in any of SEQ ID NOs: 124-252 as determined by the Kabat numbering scheme.Attorney Docket No. DEMB-010 / 02WO

[0106] In certain embodiments, one or more of the CDRs of an antibody disclosed herein can be determined according to the Chothia numbering scheme, which refers to the location of immunoglobulin structural loops (see, e.g., Chothia C & Lesk AM, (1987), J Mol Biol 196: 901-917; Al-Lazikani B et al., (1997) J Mol Biol 273: 927-948; Chothia C et al., (1992) J Mol Biol 227: 799-817; Tramontane A et al., (1990) J Mol Biol 215(1): 175-82; and U. S. Patent No. 7,709,226, all of which are herein incorporated by reference in their entireties).

[0107] In certain embodiments, an antibody provided herein comprises the CDRH1, CDRH2, and / or CDRH3 of a VH amino acid sequence set forth in any of SEQ ID NOs: 2-123 as determined by the Chothia numbering system. In certain embodiments, an antibody provided herein comprises the CDRL1, CDRL2, and / or CDRL3 of a VL amino acid sequence set forth in any of SEQ ID NOs: 124-252 as determined by the Chothia numbering system.

[0108] In certain embodiments, one or more of the CDRs of an antibody disclosed herein can be determined according to MacCallum RM et al., (1996) J Mol Biol 262: 732-745, herein incorporated by reference in its entirety. See also, e.g., Martin A. “Protein Sequence and Structure Analysis of Antibody Variable Domains,” in Antibody Engineering, Kontermann and Diibel, eds., Chapter 31, pp. 422-439, Springe r-Verlag, Berlin (2001), herein incorporated by reference in its entirety,

[0109] In certain embodiments, an antibody provided herein comprises the CDRII1, CDRH2, and / or CDRH3 of a VH amino acid sequence set forth in any of SEQ ID NOs: 2-123 as determined by the MacCallum numbering system. In certain embodiments, an antibody provided herein comprises the CDRL1, CDRL2, and / or CDRL3 of a VL amino acid sequence set forth in any of SEQ ID NOs: 124-252 as determined by the MacCallum numbering system.

[0110] In certain embodiments, the CDRs of an antibody disclosed herein can be determined according to the IMGT numbering system as described in: Lefranc M-P, (1999) The Immunologist 7: 132-136; Lefranc M-P etal., (1999) Nucleic Acids Res 27: 209-212, each of which is herein incorporated by reference in its entirety; and Lefranc M-P et al., (2009) Nucleic Acids Res 37: D1006-D1012.

[0111] In certain embodiments, an antibody provided herein comprises the CDRH1, CDRH2, and / or CDRH3 of a VH amino acid sequence set forth in any of SEQ ID NOs: 2-123 as determined by the IMGT numbering system. In certain embodiments, an antibody provided herein comprises the CDRL1, CDRL2, and / or CDRL3 of a VL amino acid sequence set forth in any of SEQ ID NOs: 124-252 as determined by the IMGT numbering system.

[0112] In certain embodiments, the CDRs of an antibody disclosed herein can be determined according to the AbM numbering scheme, which refers to AbM hypervariableAttorney Docket No. DEMB-010 / 02WOregions, which represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular’s AbM antibody modeling software (Oxford Molecular Group, Inc.), herein incorporated by reference in its entirety.[00113| In certain embodiments, an antibody provided herein comprises the CDRH1, CDRH2, and / or CDRH3 of a VH amino acid sequence set forth in any of SEQ ID NOs: 2-123 as determined by the AbM numbering scheme. In certain embodiments, an antibody provided herein comprises the CDRL1, CDRL2, and / or CDRL3 of a VL amino acid sequence set forth in any of SEQ ID NOs: 124-252 as determined by the AbM numbering scheme.

[0114] In certain embodiments, the CDRs of an antibody disclosed herein can be determined according to the AHo numbering system, as described in Honegger and Pliickthun, A., J. Mol. Biol. 309:657-670 (2001), herein incorporated by reference in its entirety.

[0115] In certain embodiments, an antibody provided herein comprises the CDRH1, CDRH2, and / or CDRH3 of a VH amino acid sequence set forth in any of SEQ ID NOs: 2-123 as determined by the AHo numbering system. In certain embodiments, an antibody provided herein comprises the CDRL1, CDRL2, and / or CDRL3 of a VL amino acid sequence set forth in any of SEQ ID NOs: 124-252 as determined by tire AHo numbering system.

[0116] In certain embodiments, the individual CDRs of an antibody disclosed herein are each independently determined according to one of the Kabat, Chothia, MacCallum, IMGT, AHo, or AbM numbering schemes, or by structural analy sis of the multispecific molecule, wherein the structural analysis identifies residues in the variable region(s) predicted to make contact with an epitope region of SMAGP.

[0117] In certain embodiments, the instant disclosure provides an antibody that specifically binds SMAGP (e.g., human SMAGP) comprising a VH comprising the CDRH1, CDRH2, and CDRH3 of a VH amino acid sequence set forth in any one of SEQ ID NOs: 2-123, and a VL comprising the CDRL1, CDRL2, and CDRL3 of a VL amino acid sequence set forth in any¬ one of SEQ ID NOs: 124-252, wherein each CDR is independently determined according to one of the Kabat, Chothia, MacCallum, IMGT, AHo, or AbM numbering schemes, or by structural analysis of the multispecific molecule, wherein the structural analysis identifies residues in the variable region(s) predicted to make contact with an epitope region of SMAGP (e.g., human SMAGP).

[0118] In certain embodiments, the instant disclosure provides an antibody that specifically binds SMAGP (e.g., human SMAGP) comprising a VH comprising the CDRH1, CDRH2, and CDRH3 of a VH amino acid sequence set forth in any one of SEQ ID NOs: 2-123, and a VL comprising the CDRL1, CDRL2, and CDRL3 of a VL amino acid sequence set forth in anyAttorney Docket No. DEMB-010 / 02WOone of SEQ ID NOs: 124-252, wherein the VH amino acid sequence and the VL amino acid sequence are from the same antibody ( / . e., as shown in Tables 2 and 3), and wherein each CDR is independently determined according to one of the Kabat, Chothia, MacCallum, IMGT, Allo, or AbM numbering schemes, or by structural analysis of the multispecific molecule, wherein the structural analysis identifies residues in the variable region(s) predicted to make contact with an epitope region of SMAGP (e.g., human SMAGP).

[0119] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), wherein the antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the VH and VL amino acid sequences set forth in SEQ ID NOs: 44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, 70 and 197, 2 and 124, 3 and 125, 4 and 126, 5 and 127, 6 and 128, 7 and 129, 8 and 130, 9 and 131, 10 and 132, 11 and 133, 12 and 134, 13 and 135, 14 and 136, 15 and 137, 16 and 138, 17 and 139, 18 and 140, 19 and 141, 20 and 142, 21 and 143, 22 and 144, 24 and 146, 25 and 147, 26 and 148, 27 and 149, 28 and 150, 29 and 151, 30 and 152, 31 and 153, 32 and 154, 33 and 155, 34 and 156, 35 and 157, 36 and 158, 37 and 159, 38 and 160, 39 and 161, 40 and 162, 41 and 163, 42 and 164, 43 and 165, 45 and 168, 46 and 169, 47 and 170, 48 and 171, 49 and 172, 50 and 173, 51 and 174, 52 and 175, 53 and 176, 54 and 177, 55 and 178, 56 and 179, 57 and 180, 58 and 181, 59 and 182, 60 and 183, 61 and 184, 62 and 185, 63 and 186, 64 and 187, 65 and 188, 71 and 189, 72 and 190, 73 and 191, 74 and 192, 75 and 204, 76 and 205, 77 and 206, 78 and 207, 79 and 208, 80 and 209, 81 and 210, 82 and 211, 83 and 212, 84 and 213, 85 and 214, 86 and 215, 87 and 216, 88 and 217, 89 and 218, 90 and 219, 91 and 220, 92 and 221, 93 and 222, 94 and 223, 95 and 224, 96 and 225, 97 and 226, 98 and 227, 99 and 228, 100 and 229, 101 and 230, 102 and 231, 103 and 232, 104 and 233, 105 and 234, 106 and 235, 107 and 236, 108 and 237, 109 and 238, 110 and 239, 111 and 240, 112 and 241, 113 and 242, 114 and 243, 115 and 244, 116 and 245, 117 and 246, 118 and 247, 119 and 248, 120 and 249, 121 and 250, 122 and 251, or 123 and 252, respectively. In some embodiments, the antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the VH and VL amino acid sequences set forth in SEQ ID NOs: 44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23Attorney Docket No. DEMB-010 / 02WOand 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, or 70 and 197, respectively

[0120] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), wherein the antibody comprises a VH comprising a CDRH1, CDRH2, and / or CDRH3 set forth in Table 4. In certain embodiments, the antibody comprises a VH comprising a CDRH1 comprising the amino acid sequence of any one of SEQ ID NOs: 441-539. In certain embodiments, the antibody comprises a VH comprising a CDRH2 comprising the amino acid sequence of any one of SEQ ID NOs: 540-655. In certain embodiments, the antibody comprises a VH comprising a CDRH3 comprising the amino acid sequence of any one of SEQ ID NOs: 656-759.

[0121] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), wherein the antibody comprises a VH comprising the CDRH1, CDRH2, and CDRH3 amino acid sequences set forth in Table 4. In certain embodiments, the antibody comprises a VH comprising CDRH1, CDRH2, and CDRH3 comprising the amino acid sequences of SEQ ID NOs: 482, 581, and 697; 489, 605, and 703; 487, 603, and 677; 487, 603, and 701; 487, 603, and 705; 487, 603, and 706; 487, 603, and 707; 487, 603, and 708; 487, 603, and 709; 487, 603, and 710; 462, 561, and 677; 441, 540, and 656; 442, 541, and 657; 443, 542, and 658; 444, 543, and 659; 445, 544, and 660; 446, 545, and 661; 447, 546, and 662; 448, 547, and 663; 449, 548, and 664; 450, 549, and 665; 451, 550, and 666; 452, 5 1, and 667; 453, 552, and 668; 454, 553, and 669; 455, 554, and 670; 456, 555, and 671; 457, 556, and 672; 458, 557, and 673; 459, 558, and 674; 460, 559, and 675; 461, 560, and 676; 463, 562, and 678; 464, 563, and 679; 465, 564, and 680; 466, 565, and 681; 467, 566, and 682; 468, 567, and 683; 469, 568, and 684; 470, 569, and 685; 471, 570, and 686; 472, 571, and 687; 473, 572, and 688; 474, 573, and 689; 475, 574, and 690; 476, 575, and 691; 477, 576, and 692; 478, 577, and 693; 479, 578, and 694; 480, 579, and 695; 481, 580, and 696; 483, 582, and 698; 484, 583, and 699; 485, 584, and 700; 452, 585, and 667; 452, 586, and 667; 452, 587, and 667; 452, 588, and 667; 452, 589, and 667; 452, 590, and 667; 452, 591, and 667; 452, 592, and 667; 452, 593, and 667; 452, 594, and 667; 452, 595, and 667; 452, 596, and 667; 452, 1198, and 667; 452, 1199, and 667; 452, 1200, and 667; 452, 1201, and 667; 452, 1202, and 667; 452, 1203, and 667; 452, 1204, and 667; 452, 1205, and 667; 452, 1206, and 667; 486, 597, and 668; 486, 598, and 668; 486, 599, andAttorney Docket No. DEMB-010 / 02WO668; 486, 600, and 668; 486, 601, and 668; 486, 602, and 668; 488, 604, and 702; 488, 604, and 678; 490, 606, and 704; 491, 607, and 711; 492, 608, and 712; 493, 609, and 713; 494, 610, and 714; 495, 611, and 715; 496, 612, and 716; 497, 613, and 717; 498, 614, and 718; 499, 615, and 719; 500, 616, and 720; 501, 617, and 721; 502, 618, and 722; 503, 619, and 723; 504, 620, and 724; 505, 621, and 725; 506, 622, and 726; 507, 623, and 727; 508, 624, and 728; 509, 625, and 729; 510, 626, and 730; 511, 627, and 731; 512, 628, and 732; 513, 629, and 733; 514, 630, and 734; 515, 631, and 735; 516, 632, and 736; 517, 633, and 737; 518, 634, and 738; 519, 635, and 739; 520, 636, and 740; 521, 637, and 741; 522, 638, and 742; 523, 639, and 743; 524, 640, and 744; 525, 641, and 745; 526, 642, and 746; 527, 643, and 747; 528, 644, and 748; 529, 645, and 749; 530, 646, and 750; 531, 647, and 751; 532, 648, and 752; 533, 649, and 753; 534, 650, and 754; 535, 651, and 755; 536, 652, and 756; 537, 653, and 757; 538, 654, and 758; or 539, 655, and 759, respectively. In certain embodiments, the CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, and 697, respectively. In certain embodiments, the CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 462, 561, and 677, respectively.

[0122] In certain embodiments, tire instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), wherein the antibody comprises a VL comprising a CDRL1, CDRL2, and / or CDRL3 amino acid sequence set forth in Table 5. In certain embodiments, the antibody comprises a VL comprising a CDRL1 comprising the amino acid sequence of any one of SEQ ID NOs: 760-877. In certain embodiments, the antibody comprises a VL comprising a CDRL2 comprising the amino acid sequence of any one SEQ ID NOs: 878-971. In certain embodiments, the antibody comprises a VL comprising a CDRL3 comprising the amino acid sequence of any one of SEQ ID NOs: 972-1065.

[0123] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), wherein the antibody comprises a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences set forth in Table 5. In certain embodiments, the antibody comprises a VI, comprising CDRL1, CDRL2, and CDRL3 comprising the amino acid sequences of SEQ ID NOs: 801, 919, and 1013; 823, 919, and 1013; 824, 919, and 1013; 825, 919, and 1013; 826, 919, and 1013; 827, 919, and 1013; 828, 919, and 1013; 781, 899, and 993; 814, 899, and 993; 818, 899, and 993; 819, 899, and 993; 820, 899, and 993; 821, 899, and 993; 822, 899, and 993: 760, 878, and 972; 761, 879, and 973; 762, 880, and 974; 763, 881, and 975; 764, 882, and 976; 765, 883, and 977; 766, 884, and 978; 767, 885, and 979; 768, 886, and 980; 769, 887, and 981; 770, 888, and 982; 771, 889, and 983; 772, 890, and 984; 773, 891, and 985; 774, 892, and 986; 775, 893, and 987; 776,Attorney Docket No. DEMB-010 / 02WO894, and 988; 777, 895, and 989; 778, 896, and 990; 779, 897, and 991; 780, 898, and 992; 782, 900, and 994; 783, 901, and 995; 784, 902, and 996; 785, 903, and 997; 786, 904, and 998; 787, 905, and 999; 788, 906, and 1000; 789, 907, and 1001; 790, 908, and 1002; 791, 909, and 1003; 792, 910, and 1004; 793, 911, and 1005; 794, 912, and 1006; 795, 913, and 1007; 796, 914, and 1008; 797, 915, and 1009; 798, 916, and 1010; 799, 917, and 1011; 800, 918, and 1012; 802, 920, and 1014; 803, 921, and 1015; 804, 922, and 1016; 805, 889, and 983; 806, 889, and 983; 807, 889, and 983; 808, 890, and 984; 809, 890, and 984; 810, 890, and 984; 811, 890, and 984; 812, 890, and 984; 813, 890, and 984; 815, 900, and 994; 816, 919, and 1013; 817, 920, and 1014; 829, 923, and 1017; 830, 924, and 1018; 831, 925, and 1019; 832, 926, and 1020; 833, 927, and 1021; 834, 928, and 1022; 835, 929, and 1023; 836, 930, and 1024; 837, 931, and 1025; 838, 932, and 1026; 839, 933, and 1027; 840, 934, and 1028; 841, 935, and 1029; 842, 936, and 1030; 843, 937, and 1031; 844, 938, and 1032; 845, 939, and 1033; 846, 940, and 1034; 847, 941, and 1035; 848, 942, and 1036; 849, 943, and 1037; 850, 944, and 1038; 851, 945, and 1039; 852, 946, and 1040; 853, 947, and 1041; 854, 948, and 1042; 855, 949, and 1043; 856, 950, and 1044; 857, 951, and 1045; 858, 952, and 1046; 859, 953, and 1047; 860, 954, and 1048; 861, 955, and 1049; 862, 956, and 1050; 863, 957, and 1051; 864, 958, and 1052; 865, 959, and 1053; 866, 960, and 1054; 867, 961, and 1055; 868, 962, and 1056; 869, 963, and 1057; 870, 964, and 1058; 871, 965, and 1059; 872, 966, and 1060; 873, 967, and 1061; 874, 968, and 1062; 875, 969, and 1063; 876, 970, and 1064; or 877, 971, and 1065, respectively. In certain embodiments, the CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 801, 919, and 1013, respectively. In certain embodiments, the CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 781, 899, and 993, respectively.

[0124] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), wherein the antibody comprises a VH comprising a CDRH1, CDRH2, and / or CDRH3 amino acid sequence set forth in Table 4 and a VL comprising a CDRL1, CDRL2, and / or CDRL3 amino acid sequence set forth in Table 5, wherein 1, 2, 3, 4, 5, or 6 of the CDRII1, CDRII2, CDRH3, CDRL1, CDRL2, and CDRL3 amino acid sequences are from the same antibody (i.e., as shown in Tables 4 and 5). In certain embodiments, the antibody comprises a VH comprising CDRH1, CDRH2, and CDRH3, and a VL comprising CDRL1, CDRL2, and CDRL3, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, 697, 801, 919, and 1013; 489, 605, 703, 823, 919, and 1013; 489, 605, 703, 824, 919, and 1013; 489, 605, 703, 825, 919, and 1013; 489, 605, 703, 826, 919, and 1013; 489, 605, 703, 827, 919,Attorney Docket No. DEMB-010 / 02WOand 1013; or 489, 605, 703, 828, 919, and 1013; 462, 561, 677, 781, 899, and 993; 462, 561, 677, 818, 899, and 993; 462, 561, 677, 819, 899, and 993; 462, 561, 677, 820, 899, and 993; 462, 561, 677, 821, 899, and 993; 462, 561, 677, 822, 899, and 993; 487, 603, 705, 781, 899, and 993; 487, 603, 705, 818, 899, and 993; 487, 603, 705, 819, 899, and 993; 487, 603, 705, 820, 899, and 993; 487, 603, 705, 821, 899, and 993; 487, 603, 705, 822, 899, and 993; 487, 603, 706, 781, 899, and 993; 487, 603, 706, 818, 899, and 993; 487, 603, 706, 819, 899, and 993; 487, 603, 706, 820, 899, and 993; 487, 603, 706, 821, 899, and 993; 487, 603, 706, 822, 899, and 993; 487, 603, 707, 781, 899, and 993; 487, 603, 707, 818, 899, and 993; 487, 603, 707, 819, 899, and 993; 487, 603, 707, 820, 899, and 993; 487, 603, 707, 821, 899, and 993; 487, 603, 707, 822, 899, and 993; 487, 603, 708, 781, 899, and 993; 487, 603, 708, 818, 899, and 993; 487, 603, 708, 819, 899, and 993; 487, 603, 708, 820, 899, and 993; 487, 603, 708, 821, 899, and 993; 487, 603, 708, 822, 899, and 993; 487, 603, 709, 781, 899, and 993; 487, 603, 709, 818, 899, and 993; 487, 603, 709, 819, 899, and 993; 487, 603, 709, 820, 899, and 993; 487, 603, 709, 821, 899, and 993; 487, 603, 709, 822, 899, and 993; 487, 603, 710, 781, 899, and 993; 487, 603, 710, 818, 899, and 993; 487, 603, 710, 819, 899, and 993; 487, 603, 710, 820, 899, and 993; 487, 603, 710, 821, 899, and 993; 487, 603, 710, 822, 899, and 993; 441, 540, 656, 760, 878, and 972; 442, 541, 657, 761, 879, and 973; 443, 542, 658, 762, 880, and 974; 444, 543, 659, 763, 881, and 975; 445, 544, 660, 764, 882, and 976; 446, 545, 661, 765, 883, and 977; 447, 546, 662, 766, 884, and 978; 448, 547, 663, 767, 885, and 979; 449, 548, 664, 768, 886, and 980; 450, 549, 665, 769, 887, and 981; 451, 550, 666, 770, 888, and 982; 452, 551, 667, 771, 889, and 983; 453, 552, 668, 772, 890, and 984; 454, 553, 669, 773, 891, and 985; 455, 554, 670, 774, 892, and 986; 456, 555, 671, 775, 893, and 987; 457, 556, 672, 776, 894, and 988; 458, 557, 673, 777, 895, and 989; 459, 558, 674, 778, 896, and 990; 460, 559, 675, 779, 897, and 991; 461, 560, 676, 780, 898, and 992; 463, 562, 678, 782, 900, and 994; 464, 563, 679, 783, 901, and 995; 465, 564, 680, 784, 902, and 996; 466, 565, 681, 785, 903, and 997; 467, 566, 682, 786, 904, and 998; 468, 567, 683, 787, 905, and 999; 469, 568, 684, 788, 906, and 1000; 470, 569, 685, 789, 907, and 1001; 471, 570, 686, 790, 908, and 1002; 472, 571, 687, 791, 909, and 1003; 473, 572, 688, 792, 910, and 1004; 474, 573, 689, 793, 911, and 1005; 475, 574, 690, 794, 912, and 1006; 476, 575, 691, 795, 913, and 1007; 477, 576, 692, 796, 914, and 1008; 478, 577, 693, 797, 915, and 1009; 479, 578, 694, 798, 916, and 1010; 480, 579, 695, 799, 917, and 1011; 481, 580, 696, 800, 918, and 1012; 483, 582, 698, 802, 920, and 1014; 484, 583, 699, 803, 921, and 1015; 485, 584, 700, 804, 922, and 1016; 452, 585, 667, 805, 889, and 983; 452, 586, 667, 805, 889, and 983; 452, 587, 667, 805, 889, and 983; 452, 588, 667, 805, 889, and 983; 452, 589, 667, 805, 889, and 983; 452, 590, 667,Attorney Docket No. DEMB-010 / 02WO805, 889, and 983; 452, 591, 667, 805, 889, and 983; 452, 592, 667, 805, 889, and 983; 452, 593, 667, 805, 889, and 983; 452, 594, 667, 805, 889, and 983; 452, 595, 667, 806, 889, and 983; 452, 596, 667, 807, 889, and 983; 452, 1198, 667, 805, 889, and 983; 452, 1199, 667, 805, 889, and 983; 452, 1200, 667, 805, 889, and 983; 452, 1201, 667, 805, 889, and 983; 452, 1202, 667, 805, 889, and 983; 452, 1203, 667, 805, 889, and 983; 452, 1204, 667, 805, 889, and 983; 452, 1205, 667, 805, 889, and 983; 452, 1206, 667, 805, 889, and 983; 452, 551, 667, 806, 889, and 983; 452, 551, 667, 807, 889, and 983; 486, 597, 668, 808, 890, and 984; 486, 598, 668, 809, 890, and 984; 486, 599, 668, 810, 890, and 984; 486, 600, 668, 811, 890, and 984; 486, 601, 668, 812, 890, and 984; 486, 602, 668, 813, 890, and 984; 488, 604, 702, 782, 900, and 994; 483, 582, 698, 817, 920, and 1014; 490, 606, 704, 817, 920, and 1014; 491, 607, 711, 829, 923, and 1017; 492, 608, 712, 830, 924, and 1018; 493, 609, 713, 831, 925, and 1019; 494, 610, 714, 832, 926, and 1020; 495, 611, 715, 833, 927, and 1021; 496, 612, 716, 834, 928, and 1022: 497, 613, 717, 835, 929, and 1023; 498, 614, 718, 836, 930, and 1024; 499, 615, 719, 837, 931, and 1025; 500, 616, 720, 838, 932, and 1026; 501, 617, 721, 839, 933, and 1027; 502, 618, 722, 840, 934, and 1028; 503, 619, 723, 841, 935, and 1029; 504, 620, 724, 842, 936, and 1030; 505, 621, 725, 843, 937, and 1031; 506, 622, 726, 844, 938, and 1032; 507, 623, 727, 845, 939, and 1033; 508, 624, 728, 846, 940, and 1034: 509, 625, 729, 847, 941, and 1035; 510, 626, 730, 848, 942, and 1036; 511, 627, 731, 849, 943, and 1037; 5512, 628, 732, 850, 944, and 1038; 513, 629, 733, 851, 945, and 1039; 514, 630, 734, 852, 946, and 1040; 515, 631, 735, 853, 947, and 1041: 516, 632, 736, 854, 948, and 1042; 517, 633, 737, 855, 949, and 1043: 518, 634, 738, 856, 950, and 1044; 5519, 635, 739, 857, 951, and 1045; 520, 636, 740, 858, 952, and 1046; 521, 637, 741, 859, 953, and 1047; 522, 638, 742, 860, 954, and 1048; 523, 639, 743, 861, 955, and 1049; 524, 640, 744, 862, 956, and 1050; 525, 641, 745, 863, 957, and 1051; 526, 642, 746, 864, 958, and 1052; 527, 643, 747, 865, 959, and 1053; 528, 644, 748, 866, 960, and 1054; 529, 645, 749, 867, 961, and 1055; 530, 646, 750, 868, 962, and 1056; 531, 647, 751, 869, 963, and 1057; 532, 648, 752, 870, 964, and 1058; 533, 649, 753, 871, 965, and 1059; 534, 650, 754, 872, 966, and 1060; 535, 651, 755, 873, 967, and 1061; 536, 652, 756, 874, 968, and 1062; 537, 653, 757, 875, 969, and 1063; 538, 654, 758, 876, 970, and 1064; or 539, 655, 759, 877, 971, and 1065, respectively.

[0125] In certain embodiments, the antibody comprises a VH comprising CDRH1, CDRH2, and CDRH3, and a VL comprising CDRL1, CDRL2, and CDRL3, wherein the CDRII1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, 697, 801, 919, and 1013; 489, 605, 703, 823, 919, and 1013; 489, 605, 703, 824, 919, and 1013; 489, 605, 703, 825, 919, and 1013; 489, 605, 703, 826, 919, andAttorney Docket No. DEMB-010 / 02WO1013; 489, 605, 703, 827, 919, and 1013; or 489, 605, 703, 828, 919, and 1013; 462, 561, 677, 781, 899, and 993; 462, 561, 677, 818, 899, and 993; 462, 561, 677, 819, 899, and 993; 462, 561, 677, 820, 899, and 993; 462, 561, 677, 821, 899, and 993; 462, 561, 677, 822, 899, and 993; 487, 603, 705, 781, 899, and 993; 487, 603, 705, 818, 899, and 993; 487, 603, 705, 819, 899, and 993; 487, 603, 705, 820, 899, and 993; 487, 603, 705, 821, 899, and 993; 487, 603, 705, 822, 899, and 993; 487, 603, 706, 781, 899, and 993; 487, 603, 706, 818, 899, and 993; 487, 603, 706, 819, 899, and 993; 487, 603, 706, 820, 899, and 993; 487, 603, 706, 821, 899, and 993; 487, 603, 706, 822, 899, and 993; 487, 603, 707, 781, 899, and 993; 487, 603, 707, 818, 899, and 993; 487, 603, 707, 819, 899, and 993; 487, 603, 707, 820, 899, and 993; 487, 603, 707, 821, 899, and 993; 487, 603, 707, 822, 899, and 993; 487, 603, 708, 781, 899, and 993; 487, 603, 708, 818, 899, and 993; 487, 603, 708, 819, 899, and 993; 487, 603, 708, 820, 899, and 993; 487, 603, 708, 821, 899, and 993; 487, 603, 708, 822, 899, and 993; 487, 603, 709, 781, 899, and 993; 487, 603, 709, 818, 899, and 993; 487, 603, 709, 819, 899, and 993; 487, 603, 709, 820, 899, and 993; 487, 603, 709, 821, 899, and 993; 487, 603, 709, 822, 899, and 993; 487, 603, 710, 781, 899, and 993; 487, 603, 710, 818, 899, and 993; 487, 603, 710, 819, 899, and 993; 487, 603, 710, 820, 899, and 993; 487, 603, 710, 821, 899, and 993; or 487, 603, 710, 822, 899, and 993, respectively.

[0126] In certain embodiments, the antibody comprises a VH comprising CDRH1, CDRH2, and CDRH3, and a VL comprising CDRL1, CDRL2, and CDRL3, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, 697, 801, 919, and 1013, respectively.

[0127] In certain embodiments, the antibody comprises a VH comprising CDRH1, CDRH2, and CDRH3, and a VL comprising CDRL1, CDRL2, and CDRL3, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 462, 561, 677, 781, 899, and 993, respectively.

[0128] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP) comprising a VH comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 2-123. In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), comprising a VH comprising an amino acid sequence of any one of SEQ ID NOs: 2-123. In certain embodiments, the amino acid sequence ofthe VH consists of the amino acid sequence of any one of SEQ ID NOs: 2- 123. In certain embodiments,Atorney- Docket No. DEMB-010 / 02WOthe VH comprises the amino acid sequence of SEQ ID NOs: 23, 66, 67, 68, 69, and 70. In certain embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 23. In certain embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 44.[00129| In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), comprising a VL comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100 identical to the amino acid sequence of any one of SEQ ID NOs: 124-252. In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), comprising a VL comprising an amino acid sequence of any one of SEQ ID NOs: 124-252. In certain embodiments, the amino acid sequence of the VL consists of the amino acid sequence of any one of SEQ ID NOs: 124-252. In certain embodiments, the VL comprises the amino acid sequences of 166, 198, 199, 200, 201, 202, and 203. In certain embodiments, the VL comprises the amino acid sequence of SEQ ID NOs: 145, 193, 194, 195, 196, and 197.

[0130] In certain embodiments, tire instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), comprising a VH comprising an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95?% or I00?zo (e.g., at least 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 2-123, and a VL comprising an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% (e.g., at least 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 124-252. In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), comprising a VH comprising an ammo acid sequence of any one of SEQ ID NOs: 2-123, and a VL comprising an amino acid sequence of any one of SEQ ID NOs: 124-252. In certain embodiments, the amino acid sequence of the VH consists of the amino acid sequence of any¬ one of SEQ ID NOs: 2-123, and the amino acid sequence of the VI, consists of the ammo acid sequence of any one of SEQ ID NOs: 124-252.

[0131] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), comprising a VH comprising an amino acid sequence that is at least 75?% 80%, 85%, 90%, 95%, or 100?-o (e.g., at least 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%) identical to an amino acid sequence of any one of SEQ ID NOs: 2- 123, and a VL comprising an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95?% or 100% (e.g., at least 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%) identical to anAttorney Docket No. DEMB-010 / 02WOamino acid sequence of any one of SEQ ID NOs: 124-252, wherein the amino acid sequences of any one of SEQ ID NOs: 2-123 and any one of SEQ ID NOs: 124-252 are from the same antibody (i.e., as shown in Tables 2 and 3). In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), comprising a VH comprising an amino acid sequence of any one of SEQ ID NOs: 2-123, and a VL comprising an amino acid sequence of any one of SEQ ID NOs: 124-252, wherein the ammo acid sequences of any one of SEQ ID NOs: 2-123 and any one of SEQ ID NOs: 124-252 are from the same antibody (i.e., as shown in Tables 2 and 3). In certain embodiments, the amino acid sequence of the VH consists of the amino acid sequence of any one of SEQ ID NOs: 2-123, and the amino acid sequence of the VL consists of the amino acid sequence of any one of SEQ ID NOs: 124-252, wherein the amino acid sequences of any one of SEQ ID NOs: 2-123 and any one of SEQ ID NOs: 124-252 are from the same antibody (i.e., as shown in Tables 2 and 3).

[0132] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), wherein the antibody comprises a VH and VL comprising the amino acid sequences of SEQ ID NOs: 44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, 70 and 197, 2 and 124, 3 and 125, 4 and 126, 5 and 127, 6 and 128, 7 and 129, 8 and 130, 9 and 131, 10 and 132, 11 and 133, 12 and 134, 13 and 135, 14 and 136, 15 and 137, 16 and 138, 17 and 139, 18 and 140, 19 and 141, 20 and 142, 21 and 143, 22 and 144, 24 and 146, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 25 and 147, 26 and 148, 27 and 149, 28 and 150, 29 and 151, 30 and 152, 31 and 53, 32 and 154, 33 and 155, 34 and 156, 35 and 157, 36 and 158, 37 and 159, 38 and 160, 39 and 161, 40 and 162, 41 and 163, 42 and 164, 43 and 165, 45 and 168, 46 and 169, 47 and 170, 48 and 171, 49 and 172, 50 and 173, 51 and 174, 52 and 175, 53 and 176, 54 and 177, 55 and 178, 56 and 179, 57 and 180, 58 and 181, 59 and 182, 60 and 183, 61 and 184, 62 and 185, 63 and 186, 64 and 187, 65 and 188, 71 and 189, 72 and 190, 73 and 191, 74 and 192, 75 and 204, 76 and 205, 77 and 206, 78 and 207, 79 and 208, 80 and 209, 81 and 210, 82 and 211, 83 and 212, 84 and 213, 85 and 214, 86 and 215, 87 and 216, 88 and 217, 89 and 218, 90 and 219, 91 and 220, 92 and 221, 93 and 222, 94 and 223, 95 and 224,Attorney Docket No. DEMB-010 / 02WO96 and 225, 97 and 226, 98 and 227, 99 and 228, 100 and 229, 101 and 230, 102 and 231, 103 and 232, 104 and 233, 105 and 234, 106 and 235, 107 and 236, 108 and 237, 109 and 238, 110 and 239, 111 and 240, 112 and 241, 113 and 242, 114 and 243, 115 and 244, 116 and 245, 117 and 246, 118 and 247, 119 and 248, 120 and 249, 121 and 250, 122 and 251, or 123 and 252, respectively.

[0133] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), wherein the antibody comprises a VII and VL consisting of the amino acid sequences of SEQ ID NOs: 44 and 166, 23 and 145, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, or 70 and 197, respectively. In certain embodiments, tire VII amino acid sequence and the VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs: 44 and 166, respectively. In certain embodiments, the VH amino acid sequence and the VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs: 23 and 145, respectively.

[0134] In certain embodiments, the instant disclosure provides an antibody that cross¬ competes for binding to SMAGP (e.g., human SMAGP) with any of the antibodies described above. In certain embodiments, the instant disclosure provides an antibody that binds to the same or an overlapping epitope of SMAGP (e.g., an epitope of human SMAGP) as an antibody described above.

[0135] In certain embodiments, the epitope of an antibody can be determined by, e.g., NMR spectroscopy, surface plasmon resonance (BIAcore®), X-ray diffraction crystallography studies, ELISA assays, hydrogen / deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo-peptide scanning assays, and / or mutagenesis mapping (e.g., site-directed mutagenesis mapping). For X-ray crystallography, crystallization may be accomplished using any of the known methods in the art (e.g., Giege R et al.. (1994) Acta Crystallogr D Biol Crystallogr 50(Pt 4): 339-350; McPherson A (1990) Eur J Biochem 189: 1-23; Chayen NE (1997) Structure 5: 1269-1274; McPherson A (1976) J Biol Chem 251: 6300-6303, all of which are herein incorporated by reference in their entireties). Antibody: antigen crystals may be studied using well known X- ray diffraction techniques and may be refined using computer software such as X-PLOR (YaleAttorney Docket No. DEMB-010 / 02WOUniversity, 1992, distributed by Molecular Simulations, Inc.; see, e.g., Meth Enzymol (1985) volumes 114 & 115, eds. Wyckoff HW etal.; U. S. Patent Application No. 2004 / 0014194), and BUSTER (Bricogne G (1993) Acta Crystallogr D Biol Crystallogr 49(Pt 1): 37-60; Bricogne G (1997) Meth Enzymol 276A: 361-423, ed Carter CW; Roversi P et al., (2000) Acta Crystallogr D Biol Crystallogr 56(Pt 10): 1316-1323, all of which are herein incorporated by reference in their entireties). Mutagenesis mapping studies may be accomplished using any method known to one of skill in the art. See, e.g., Champe M et al., (1995) supra and Cunningham BC & Wells JA (1989) supra for a description of mutagenesis techniques, including alanine scanning mutagenesis techniques. In a specific embodiment, the epitope of an antibody is determined using alanine scanning mutagenesis studies. In addition, antibodies that recognize and bind to the same or overlapping epitopes of SMAGP (e.g., human SMAGP) can be identified using routine techniques such as an immunoassay, for example, by showing the ability of one antibody to block the binding of another antibody to a target antigen, i.e., a competitive binding assay. Competition binding assays also can be used to determine whether two antibodies have similar binding specificity for an epitope. Competitive binding can be determined in an assay in which the immunoglobulin under test inhibits specific binding of a reference antibody to a common antigen, such as SMAGP (e.g., human SMAGP). Numerous types of competitive binding assays are known, for example: solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay see Stalili C et al., (1983) Methods Enzymol 9: 242-253); solid phase direct biotin-avidin EIA (see Kirkland TN et al., (1986) J Immunol 137: 3614-9); solid phase direct labeled assay, solid phase direct labeled sandwich assay (see Harlow E & Lane D, (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Press); solid phase direct label RIA using 1-125 label (see Morel GA et al., (1988) Mol Immunol 25(1): 7-15); solid phase direct biotin-avidin EIA (see Cheung RC et al., (1990) Virology 176: 546-52); and direct labeled RIA (see Moldenhauer G et al., (1990) Scand J Immunol 32: 77-82), all of which are herein incorporated by reference in their entireties. Typically, such an assay involves the use of purified antigen (e.g., such as human SMAGP) bound to a solid surface or cells bearing either of these, an unlabeled test immunoglobulin and a labeled reference immunoglobulin. Competitive inhibition can be measured by determining the amount of label bound to the solid surface or cells in the presence of the test immunoglobulin. Usually, the test immunoglobulin is present in excess. Usually, when a competing antibody is present in excess, it will inhibit specific binding of a reference or antibody to a common antigen by at least 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, or more. A competition binding assay can be configured in a largeAtorney’ Docket No. DEMB-010 / 02WOnumber of different formats using either labeled antigen or labeled antibody. In a common version of this assay, the antigen is immobilized on a 96-well plate. The ability of unlabeled antibodies to block the binding of labeled antibodies to the antigen is then measured using radioactive or enzyme labels. For further details see, e.g., Wagener C et al., (1983) J Immunol 130: 2308-2315; Wagener C et al., (1984) J Immunol Methods 68: 269-274; Kuroki M et al., (1990) Cancer Res 50: 4872-4879; Kuroki M et al., (1992) Immunol Invest 21: 523-538; Kuroki M et al., (1992) Hybridoma 11: 391-407 and Antibodies: A Laboratory' Manual, Ed Harlow E & Lane D editors supra, pp. 386-389, all of which are herein incorporated by reference in their entireties.

[0136] In certain embodiments, an antibody disclosed herein is conjugated to a pharmaceutically active substance. Pharmaceutically active substances include, but are not limited to, cytotoxic agents, cytostatic agents, toxins, radionuclides (e.g., radioisotopes), polypeptides, polynucleotides, detectable labels, and combinations thereof. In certain embodiments, pharmaceutically active substance is a cytotoxic agent. In certain embodiments, the cytotoxic agent is able to induce death or destruction of a cell in contact therewith. In certain embodiments, the pharmaceutically active substance is a cytostatic agent. In certain embodiments, the cytostatic agent is able to prevent or substantially reduce proliferation and / or inhibits the activity or function of a cell in contact therewith. In certain embodiments, the cytotoxic agent or cytostatic agent is a chemotherapeutic agent.

[0137] In certain embodiments, the pharmaceutically active substance is a radionuclide. Suitable radionuclides include, but are not limited to, beta emitters, auger emitters, converted electron emitters, alpha emitters, and low' photon energy emitters. In certain embodiments, the radionuclide is selected from3H,14C,32P,37S,36C1,45Ca,5!Cr,57Co,78Co,59Fe,67Cu,6 / Ga,76As,77As,89Sr,90Y, " Tc,99mTc,105Rh,I1]In,II4mIn,117Lu,, 21I,1231,124I,!25I,,311,149Tb,153Sm,161Tb,166Ho,177Lu,198Au,2O1T1,211At,212Pb,213Bi,225Ac,186Re,188Re,212Bi,213Bi,221At,223Ac,223Ra,225Ac,z55Fm, and combinations thereof.

[0138] In certain embodiments, the pharmaceutically active substance is a detectable label. In certain embodiments, the detectable label comprises a fluorescent moiety, a click chemistry handle, or a combination thereof.

[0139] In certain embodiments, the pharmaceutically active substance is a drug. Suitable drugs include, but are not limited to, anti-cancer agents, anti-inflammatory’ agents, and anti-infective (e.g., anti-fungal, antibacterial, anti -parasitic, antiviral) agents. Suitable anti-cancer agents include, but are not limited to, alkylating agents, antimetabolites, spindle poison plant alkaloids, cytotoxic / antitumor antibiotics, topoisomerase inhibitors, photosensitizers, kinaseAttorney Docket No. DEMB-010 / 02WOinhibitors, anti-hormonal agents, aromatase inhibitors, anti-androgens, protein kinase inhibitors, lipid kinase inhibitors, antisense oligonucleotides (e.g., those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation), ribozymes, (e.g., VEGF expression inhibitors and HER2 expression inhibitors), vaccines (e.g., gene therapy vaccines), topoisomerase 1 inhibitors, anti-angiogenic agents, microtubule-disrupting agents (e.g., maytansine derivatives), pharmaceutically acceptable salts, acids, solvates and derivatives of any of the above, and any combination thereof.

[0140] In certain embodiments the pharmaceutically active substance includes, but is not limited to, an anti-PD-1 antibody, an antagonist anti-PD-Ll antibody, an antagonist anti-PD-L2 antibody, an antagonist anti-PD-l / VEGF antibody, an antagonist anti-CTLA-4 antibody, an anti-HERl antibody, an anti -FIERI -LGR5 antibody, an anti-HERl-MET antibody, an anti- HER2 antibody, an anti-EGFR antibody, an anti-CMET antibody, an anti-VEGF antibody, an anti-VEGFR antibody, an anti-VEGFR-2 antibody, a TROP-2 directed antibody, an anti-Nectin-4 antibody, an antagonist anti-TIM-3 antibody, an antagonist anti-LAG-3 antibody, an antagonist anti-VISTA antibody, an antagonist tyrosine kinase inhibitor antibody, an antagonist anti-TIGIT antibody, antagonist anti-SIRPa antibody, an antagonist BRAF inhibitor antibody, a BRAF inhibitor, an anti-Claudin 18.2 antibody, an MEK inhibitor, an antagonist anti-CD96 antibody, an antagonist anti-CEACAMl antibody, an agonist anti-CD137 antibody, an mTOR inhibitor, a tropomyosin kinase receptor inhibitor, a CDK4 / 6 inhibitor, a PIK3CA inhibitor, an AKT inhibitor, a KRAS inhibitor, a pan-RAS inhibitor, an agonist anti-GITR antibody, or an agonist anti -0X40 antibody.

[0141] In certain embodiments, the pharmaceutically active substance is a toxin. Suitable toxins include, but are not limited to, proteinaceous toxins (e.g., bacterial-derived toxins, and plant-derived toxins), toxins targeting tubulin filaments, toxins targeting DNA, toxins targeting RNA. Examples of proteinaceous toxins include saporin, dianthin, ricin, modeccin, abrin, volkensin, viscumin, shiga toxin, shiga-like toxin, pseudomonas exotoxin (PE, also known as exotoxin A), diphtheria toxin (DT), and cholera toxin. Examples of toxins targeting tubulin filaments include maytansinoids (e.g. DM1 and DM4), auristatins (e.g., Monomethyl auristatin E (MMAE) and Monomethyl auristatin F (MMAF)), toxoids, tubulysins, cryptophycins, rhizoxin. Examples of DMA-targeting toxins include calicheamicins: N-Acetyl- y- calicheamicm, CC-1065 analogs, duocarmycins, doxorubicin, methotrexate, benzodiazepines, camptothecin analogues, and anthracy clines. Examples of RNA-targeting toxins are amanitins, spliceostatins, and thailanstatins.Attorney Docket No. DEMB-010 / 02WO

[0142] In certain embodiments, the pharmaceutically active substance is a polypeptide. Suitable polypeptides include, but are not limited to, Cas9; toxins (e.g., saporin, dianthin, gelonin, (de)bouganin, agrostin, ricin (toxin A chain); pokeweed antiviral protein, apoptin, diphtheria toxin, pseudomonas exotoxin); metabolic enzymes (e.g., argininosuccinate lyase, argininosuccinate synthetase); enzymes of the coagulation cascade; repairing enzymes; enzymes for cell signaling; cell cycle regulation factors; gene regulating factors (e.g., transcription factors such as NF-KB or gene repressors such as methionine repressor).

[0143] In certain embodiments, the pharmaceutically active substance is a polynucleotide. In certain embodiments, the polynucleotide comprises coding information. In certain embodiments, the polynucleotide is a gene or an open reading frame encoding a protein. In certain embodiments, the polynucleotide comprises regulatory information. In certain embodiments, the polynucleotide is a promoter, a regulatory element binding region, or a sequence encoding a micro-RNA. Suitable polynucleotides include natural and artificial nucleic acids. Artificial nucleic acids include, but are not limited to, peptide nucleic acids (PNA), Morpholines and locked nucleic acids (LNA), glycol nucleic acids (GNA), and threose nucleic acids (TN A). Each of these is distinguished from naturally occurring DNA or RNA by changes to the backbone of the molecule. Suitable polynucleotides include, but are not limited to, a vector; a gene (e.g., a cell suicide-inducing transgene); single stranded DNA; linear double stranded DNA; circular double stranded DNA (e.g., a plasmid); mini-circle DNA; a DNA aptamer; single stranded RNA; linear double stranded RNA; mRNA; tRNA; rRNA; short interfering RNA (siRNA); microRNA (miRNA); antisense RNA; anti-sense oligonucleotides; peptide nucleic acid (PNA); phosphoramidate morpholino oligomer (PMO); locked nucleic acid (LNA); bridged nucleic acid (BNA); 2 ’-deoxy-2’ -fluoroarabino nucleic acid (FANA); 2'- O-methoxyethyl-RNA (MOE); 2'-0, 4' -aminoethylene bridged nucleic acid; 3 ’-fluoro hexitol nucleic acid (FIINA); an RNA aptamer; and combinations thereof.

[0144] Any immunoglobulin (Ig) constant region can be used in the antibodies disclosed herein. In certain embodiments, the Ig region is a human IgG, IgE, IgM, IgD, IgA, or IgY immunoglobulin molecule, any class (e.g., IgGi, IgG?, IgGs, IgGr, IgAi, and IgAz), or any subclass (e.g., IgGzaand IgG?b) of immunoglobulin molecule.

[0145] In certain embodiments, tire instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), the antibody comprising a heavy chain constant region. In certain embodiments, the heavy chain region is selected from the group consisting of human IgGi, IgG?., IgG.% IgGr, IgAi, and IgA?. In certain embodiments, the heavy chain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%,Attorney Docket No. DEMB-010 / 02WOat least 89%, at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, or 1074.[001461 In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), the antibody comprising a heavy chain constant region, of human IgGi. In certain embodiments, the IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1066.

[0147] In certain embodiments, the instant disclosure provides an antibody that comprises an IgGi-DE heavy chain constant region comprising amino acids Asp239 and Glu332, wherein the amino acid position is indicated according to the EU numbering system. In certain embodiments, the IgGi-DE heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1067.

[0148] In certain embodiments, the instant disclosure provides an antibody that comprises an IgGi-ADE heavy chain constant region comprising amino acids Ala236, Asp239, and Glu332, wherein the amino acid position is indicated according to the EU numbering system. In certain embodiments, the IgGi-ADE heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1068.

[0149] In certain embodiments, the instant disclosure provides an antibody that comprises an IgGi-LALA PG heavy chain constant region comprising amino acids Ala234, Ala235, and Gly329, wherein the amino acid position is indicated according to the EU numbering system. In certain embodiments, the IgGi-LALA PG heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1069.

[0150] In certain embodiments, the instant disclosure provides an antibody that comprises an afucosylated IgGi heavy chain constant region. In certain embodiments, the afucosylated IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1074.

[0151] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), the antibody comprising a heavy chain constant region that is a variant of a wild-type heavy chain constant region, wherein the variant heavy chain constant region binds to an FcyR with lower affinity than the wild-type heavy chain constant region binds to the FcyR.

[0152] In certain embodiments, the instant disclosure provides an antibody that specifically binds to SMAGP (e.g., human SMAGP), the antibody comprising a heavy chain comprising an amino acid sequence shown in Table 6. In certain embodiments, the heavy chain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at leastAttorney Docket No. DEMB-010 / 02WO89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 253-346, 1080-1173, or 1175-1184. In certain embodiments, the antibody comprises a heavy chain amino acid sequence of any one of SEQ ID NOs: 253-346, 1080-1173, or 1175- 1184. In certain embodiments, the heavy chain comprises an amino acid sequence identical to any one of SEQ ID NOs: 253-346, 1080-1173, or 1175-1184, except that the heavy chain lacks the C-terminal lysine.

[0153] In certain embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NOs: 1066-1074. In certain embodiments, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 1066-1074.Table 6, Heavy chain amino acid sequences of exemplary anti-SMAGP antibodies.SEQ ID NO: Description SequenceSEQ ID NO: AbOOl-Gl Full Heavy EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEW 253 Chain VSTINSDGDSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYA CAKYLRSWALDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPF. VKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYK1TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab002-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 254 Chain VSFINRDSSITSYVDSVKGRFTISRDNAKNTL. YLQMNSLNAEDTAVYYC ASRDFVLWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLM1SRTPEV TC VVVDV SHEDPEVKFNW Y V DGVEV HNAKTKPREEQ YNSTYRVVSVLTVL. HQDWL. NGKEYKCKVSNKAI. PAPIEKTISKAKGQP RF. PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab003-Gl Full Heavy- QVQLVESGGGLVEPGGSLRVSCAASGFTFSNYNMNWVRQAPGKGGEW 255 Chain VSVINTGGGSTAYADSVKGRFTTSRDNAKNTVYLQMNSLKPEDTALYY CATSGYDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL. SSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPF. LLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK SEQ ID NO: Ab004-Gl Full Heavy QVHLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEW 256 Chain VSSIPTSGGNTYYADSVKGRFTISRDNAKNTLYLQMNSLKSEDTAVYYC AKNGFGRSY YWDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYTPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPS SSLGTQTYICNWHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYN STY RVVS VLTVLHQDWLNGKE YKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDEIH’KNQVSLTCLVK. GFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG K SEQ ID NO: Ab005-Gl Full Heavy QVQLVESGGGIA7QPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEW 257 Chain VSDIWSDGTTTYYADSVKGRFQISRDNAKNTLYLQMSSLKSEDTAVYY CVKQGYDSWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK SEQ ID NO: Ab006-Gl Full Heavy- QVQLVESGGGLVQPGGSLRVSCAASGFTFSAYYMSWVRQTPGKGLEW 258 Chain VSAINADGGSTYSTDSVKGRFTISRDNAKNTLYLQMSSLKPEDTALYYC ARVPIYYLGDRDFYRYLEIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVS’ft'NSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL GGPS VFLFPPKPKDTLMISRTPEVTCV V VDVSHEDPEV KFNWY VDGV E VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKI. TVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK SEQ ID NO: Ab007-Gl Full Heavy- EMQLVESGGGLVQPGGSLRLSCVASGFTFASYFMGWVRQAPGKGPEW 259 Chain VSTINSGGEDTYYSDSVKGRFT1SRDNAKNTLYLQMNSLKPEDTAVYAC AKYLRNWALDYWGQGT'QVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CIA7KDYFPEPY7TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSI. GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSVFL. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQV YTLPPSRDELTKNQV SLTCLVKGFYPSD1A VEW ESN GQP ENNYKTTPPVLDSDGSFFI. YSKLTVDKSRWQQGNV’FSCSVMHEALHNH YTQKSLSLSPGKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description SequenceSEQ ID NO: Ab008-Gl Full Heavy QVHLVESGGGLVQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGLEW 260 Chain LSSINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLKSEDTAKYYC AKPQPGNSIATYDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SSLGTQTYICNWHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYN STY RVVS VLTVLHQDWLNGKE YKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKI. TVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG K SEQ ID NO: Ab009-Gl Full Heavy EMQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQTPGKGPEWV 261 Chain SAINADGGDTYYADSVKGRFTISRDNAKNMLYLQMNSLKPEDTAVYTC AKYLSYWALDHWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTxAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK SEQ ID NO: AbOlO-Gl Full Heavy- QVQLVESGGGFVQPGGSLRLSCASSGFPFSSYWMFWVRQAPGKGLEW 262 Chain VSHIKPGGGSTYYADSVKGRFTISRDDTKNTLYLQMNNLKSEDTALYY CARQGYGTTWYVDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK SEQ ID NO: AbOll-Gl Full Heavy- EMQLVESGGGLVQPGGSLRLSCAASGFTFGSFFMGWVRQAPGKGPEW 263 Chain VSTINSGGDSTYYEDSVKGRFTISRDNAKNTLHLQMNSLKPEDTAVYAC AKYLRNWALDFWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSI. GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSVFL. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQV YTLPPSRDELTKNQV SLTCLVKGFYPSD1A VEW ESN GQP ENNYKTTPPVL. DSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK SEQ ID NO: AbOJ 2-G1 Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 264 Chain VSTINSDGDSTYYADSVKGRFTISRDNAKNTI. YL. QMNSL. RAEDTAVYYCAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL.Attorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV'TVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL. PAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab013-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 265 Chain VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVA’TVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVY’TLPPSRDELTKNQVSLTCL. VKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab0l4-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 266 Chain VSTINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CA. KYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTT'PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab015-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 267 Chain VSTINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSW'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEY’KCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDEI. TKNQVSI. TCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVI. DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab016-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW 268 Chain VSFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDVVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEJ> VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL. LGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTKPREEQAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab017-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW 269 Chain VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVtVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVS’WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCWVDVSHEDPEVKFNWWDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWI, NGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEVVESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab018-Gl Full Heavy EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEW 270 Chain VSTINSDGSSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYAC AKYIRRWALDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CL. VKDYFPEPVTVSWNSGALTSGVHTFPAVI. QSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ Y NST YRV VS VLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVK4HEALHNH YTQKSLSLSPGK SEQ ID NO: Ab0l9-Gl Full Heavy EVQL. VESGGGL. VQPGGSLRLSCAASGFTFSSYAVMYWVRQAPGKGLEW 271 Chain VSSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKNGFGRSYYWDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTL. MISRTPEVTCVVVDVSHEDPEVKFNVVYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVI. HQDWI. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTV'DKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Ab020-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMSWVRQAPGKGLEW Chain VSSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKNGFGRSYYVVDYWGQGTLVTVSSASTKGPSVFPL. APSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL. YSI. SSVVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVL. TVI. HQDWI. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK.SEQ ID NO: Ab021-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEW 273 Chain VSSIPTSGGNTY YADSVKGRFTISRDNSKNTLYTQMNSLRAEDTAVYYC AKNGFGRSYYWDYWGQGTLXTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SSLGTQTYHCNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYN STY RVVS VLTVLHQDWLNGKE YKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG K SEQ ID NO: Ab022-Gl Full Heavy EVQL. VESGGGL. VQPGGSL. RLSCAASGFTFGSYAVMYWVRQAPGKGLEW 274 Chain VSSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKNGFGRSYYWDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVI. HQDWI. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYK’n'PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Ab023-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEW 7*75 Chain VSDIWSDGTTTYYADSVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYY CVKQGYDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVI. QSSGLYSLSSVV7TVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVT'CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYXCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCJA'XGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK SEQ ID NO: Ab024-Gl Full Heavy- EVQIAT. SGGGLVQPGGSLRLSCAASGFTFSESRMNft'VRQAPGKGLEW 276 Chain VSYIWSDGTTTYYADSVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYY CVKQGYDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVS’ftT’JSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVA’VDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVL. DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description SequenceSEQ ID NO: Ab025-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEW 277 Chain VS Y I WSDGTTTY YADS VKGRFHSRDN AKN TL YLQMSSLRAEDTAV Y Y CVKQGYDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEI. LGGPSVFLFPP KPKDTLM1SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYTSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK SEQ ID NO: Ab026-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEW 278 Chain VSDIWSDGTTTYYADSVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYY CVKQGYDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYTPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK SEQ ID NO: Ab027-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCVASGFTFSSYFMGWVRQAPGKGLEW 279 Chain VSTINSGGEDTYYSDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYC AKYLRNWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF'NWYVDGVEVHNAKTK PREEQ YNSTYRVVSVI. TVLHQDWLNGKEYKCKVSNKAL. PAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK SEQ ID NO: Ab028-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCVASGFTFASYFMGWVRQAPGKGLEW 280 Chain VSTINSGGEDTYYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYY CAKYLRNWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGV7HTFPAVL. QSSGLYSLSSVVTVPSS SLGTQTYICNV'NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNYVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab029-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCVASGFTFASYFMGWVRQAPGKGLEW 281 Chain VSTINSGGEDTYYADSVKGRFTISRDNAKNTLYI. QMNSI. RPEDTAVYACAKYLRNWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab030-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCA. ASGFTFASYFMGWVRQAPGKGPEW 282 Chain VSTIN SGGEDTYY SDS VKGRFTISRDN AKN' FL YLQMNSLRAEDTAV Y A CAKYLRNWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVTQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCL. VKGFYPSDIAVFAVESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab031-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGLEW 283 Chain VSSINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKPQPGNSIATYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA AXGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTL. MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVI. HQDWI. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTX'DKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Ab032-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYYMNWVRQAPGKGLEW 284 Chain VSSINL. DGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKPQPGNSIATYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGAL. TSGVHTFPAVLQSSGL. YSI. SSVVTVP SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVL. TVI. HQDVvT. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN G QPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFSCS VMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Ab033-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGI. EW 285 Chain LSSINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKPQPGNSIATYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFI. FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVFINAAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA. LPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Ab034-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGLEW 286 Chain VSSINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKPQPGNSIATYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFI. FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Ab035-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQAPGKGLEWV 287 Chain SAINADGGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYC AKYLSYWALDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CL. VKDYFPEPVTVSWNSGALTSGVHTFPAVI. QSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ Y NST YRV VS VLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVK4HEALHNH YTQKSLSLSPGK SEQ ID NO: Ab036-Gl Full Heavy EVQL. VESGGGL. VQPGGSLRLSCAASGFTFGSSFMSVVVRQAPGKGLEWV 288 Chain SAINADGGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYC AKYLSYWALDHWGQG'I'LVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL. LGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVI. TVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK SEQ ID NO: Ab037-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQAPGKGLEWV 289 Chain SAINADGGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYTC AKYLSYVVALDHVVGQGTLV'TVSSASTKGPSVFPLAPSSKSTSGGTAAL. G CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSI. GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVI. TVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK SEQ ID NO: Ab038-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQAPGKGPEWV 290 Chain SAINADGGDTYYADSVKGRFT1SRDNSKNTLYLQMNSLRAEDTAVYTC AKYLSYWALDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYTPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQY NST YRV VS VLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVK4HEALHNH YTQKSLSLSPGK SEQ ID NO: Ab039-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAVMFWVRQAPGKGLEW 291 Chain VSHIKPGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYC ARQGYGTTWYVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVI. HQDWI. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTV'DKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Ab040-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFPFSSYWMHWVRQAPGKGLEW 292 Chain V SHIKPGGGSTY Y ADS VKGRFT1SRDNSKNTL YLQMN SLRAEDTALY YC ARQGYGTTWYVDYWGQGTIA'TVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL. YSI. SSVVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVL. TVI. HQDVvT. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN G QPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFSCS VMHEAL HNHYTQKSLSLSPGK SEQ ID NO: Ab041-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVVMFWVRQAPGKGLEW 293 Chain VSHIKPGGGSTYYADSVKGRI'TISRDNSKNTLYLQMNSLRAED'I'ALYYC ARQGYGTTWYVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVS\VNSGAL. TSGVHTFPAVLQSSGL. YSI. SSVVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFI. FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEV.'ESN GQPENNYKTTPPVLDSDGSFFLYSKL. TVDKSRWQQGNVFSCSVMHEAL. HNHYTQKSLSLSPGKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description SequenceSEQ ID NO: Ab042-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFPFSSYWMFW'VRQAPGKGLEW 294 Chain VSHIKPGGGSTY YADS V KGRFTISRDN SKNTLYLQMNSLRAEDTAL YYC ARQGYGTTWYVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAI. GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SSLGTQTYICNWHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYN STY RVVS VLTVLHQDWLNGKE YKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKI. TVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG K SEQ ID NO: Ab043-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 295 Chain VSTINSDGSSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC AKYIRRWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK SEQ ID NO: Ab044-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYFMSWVRQAPGKGLEWV 296 Chain STINSDGSSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA KYIRRWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVL. TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLTCL. VKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK SEQ ID NO: Ab045-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 297 Chain VSRINSDGSSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYIRRV.'ALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL. QSSGLY’SLSSVVTVPSS SLGTQTYICNX'NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab046-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 298 Chain VSTINPRGGSTYYADSVKGRFTISRDNAKNTL. YLQMNSLRAEDTAVYYCAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL.Attorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV'TVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQV" YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab047-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 299 Chain VSTIN PDGDRTY YADS V KGRFTISRDN AKNTL YLQMNSLRAEDTAV Y Y CAKYL. RSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQ\7SLTCL. VKGFYPSDIAVFAVESNGQ PENNYKTTPPVI, DSDGSFFLYSKItVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab048-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 300 Chain VSTINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CA. KYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab049-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 301 Chain VSTINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWTYSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEY'KCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDEI. TKNQVSI. TCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVI. DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab050-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 302 Chain VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPFJ’VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYTCNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab051-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 303 Chain VSTINPDGDR TYYA DS VKGRFTISRDN AKNTLYLQMNSLRAEDTA VYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPFA7KFNWYVDGVEVHNAK TKPREEQYNSTY'RWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: A052-G1 Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 304 Chain VSTINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHI4 HYTQKSLSLSPGK SEQ ID NO: Ab053-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 305 Chain VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYI. QMNSI. RAEDTAVYY CA. KYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SI. GTQTYICNWHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL. LGGPSV FLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDLAVEWESNGQ PENNYKTI'PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab054-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 306 Chain VSTINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSW'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab055-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 307 Chain VSTINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab056-Gl Full Heavy FA'QLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 308 Chain VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab057-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 309 Chain VSTINPDGDRTYYADSVKGRFT1SRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYTPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVL. TVI. HQDWI. NGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVI. DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab058-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 310 Chain VSTINSDGRSTYYADSVKGRFTISRDNA. KNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL. QSSGLY’SLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description SequenceSEQ ID NO: Ab059-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 311 Chain VSTINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYL. RSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT1S KAKGQPREPQVYTLPPSRDELTKNQVSLTCL. VKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab060-Gl Full Heavy EVQL. VESGGGL. VQPGGSL. RLSCAASGFTFGSYFMSWVRQAPGKGI. EW 312 Chain VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab061-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 313 Chain VSTINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSW'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab062-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 314 Chain VSTINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL. QSSGLYSLSSVVTVPSS SLGTQTYICNX'NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab063-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 315 Chain VSTINSDGDSTYYADSVKGRFTISRDNAKNTI. YL. QMNSL. RAEDTAVYYCAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL.Attorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV'TVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab064-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 316 Chain VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYL. RSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVTQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCL. VKGFYPSDIAVFAVESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab065-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 317 Chain VSTINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTT'PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab066-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW 318 Chain VSTINSDGRSTYYADSVXGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWTYSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEY’KCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDEI. TKNQVSI. TCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVI. DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab067-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW 319 Chain VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEJ> VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL. LGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTKPREEQAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab068-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW 320 Chain VSFINRRQSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCWVDVSHEDPEVKFNWWDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY'KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab069-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 321 Chain VSFIGRDV SITS Y ADS VKGRFT1SRDNAKNTLY LQMNSLRAEDT AVY YC ASRDWLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab070-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW Chain VSFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDVVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT’Y ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSVFL. FPPKPK DTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYPLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab071-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 323 Chain VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLV7TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVS3WSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLM1SRTPEV TC VVVDV SHEDPEVKFNW Y V DGVEV HNAKTKPREEQ YNSTYRVVSVLTVL. HQDWL. NGKEYKCKVSNKAI. PAPIEKTISKAKGQP REPQVYTL. PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab072-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW 324 Chain VSFIGRASS1TSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVt7VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCL. VKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab073-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 325 Chain VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYPLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVxMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab074-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW 326 Chain VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLM1SRTPEV TC VVVDV SHEDPEVKFNW Y V DGVEV HNAKTKPREEQ YNSTYRVVSVLTVL. HQDWLNGKEYKCKVSNKAI. PAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE’ftT. SNGQPENNYK TTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab075-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW 327 Chain VSFINRRQSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPFJ> VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCWVDVSHEDPEVKFNWYX7DGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYILPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNWSCSVMHEALHNHYTQKS LSLSPGKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description SequenceSEQ ID NO: Ab076-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 328 Chain VSFIGRDV SITS Y ADS VKGRFTISRDNAKNTLY LQMNSLRAEDTA VYYC ASRDWLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCJA’KGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab077-Gl Full Heavy FA'QLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW 329 Chain VSFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDVVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYl'LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab078-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW 330 Chain VSFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDVVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLM1SRTPEV TC VVVDV SHEDPEVKFNW Y V DGVEV HNAKTKPREEQ YNSTYRVVSVLTVL. HQDWLNGKEYKCKVSNKAI. PAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab079-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 331 Chain VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEJ> VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCWVDVSHEDPEVKFNWYX7DGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFI. YSKLTVDKSR\VQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab080-Gl Full Heavy EY7QIA7ESGGGIA7QPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW 332 Chain VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASRDFVLWGQGTI. VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCWVDVSHEDPEVKFT4WYVTX3VTVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab081-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW 333 Chain VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVTQSSGLYSLSSVA’TVTSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVtrVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSL. TCLVKGFYPSDIAVEWESNGQPENNY~K TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab082-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 334 Chain VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYl'LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab083-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW 335 Chain VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVtVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSAWSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLM1SRTPEV TC VVVDV SHEDPEVKFNW Y V DGVEV HNAKTKPREEQ YNSTYRVVSVLTVL. HQDWLNGKEYKCKVSNKAI. PAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab084-Gl Full Heavy- EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW 336 Chain VSFINRRQSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPFJ> VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTKPREEQAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab085-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 337 Chain VSFIGRDVSITSYADSVKGRFTISRDNAKNTLYI. QK4NSLRAEDTAVYYC ASRDVVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSU'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCWVDVSHEDPEVKFNWWDGVEVHNAKTKPREEQ YNSTYRVVSVLTV7LHQDWI, NGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab086-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW 338 Chain VSFIGRDV SITS Y ADS VKGRFT1SRDNAKNTLY LQMNSLRAEDT AVY YC ASRDWLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVYVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab087-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW 339 Chain VSFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDVVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSVFL. FPPKPK DTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYl'LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab088-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW 340 Chain VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVI. WGQGTLVTVSSASTKGPSVFPL. APSSKSTSGGTAAI. GCL. VKD YFPEPVTVS3WSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLM1SRTPEV TC VVVDV SHEDPEVKFNW Y V DGVEV HNAKTKPREEQ YNSTYRVVSVLTVL. HQDWL. NGKEYKCKVSNKAI. PAPIEKTISKAKGQP REPQVYTL. PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab089-Gl Full Heavy EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW 341 Chain VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVt7VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCL. VKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab090-Gl Full Heavy FA'QLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW 342 Chain VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYl'LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVxMHEALHNHYTQKS LSLSPGK SEQ ID NO: Ab091-Gl Full Heavy- EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEW 343 Chain VSTINSDGKRTYYADSVKGRFT1SRDNAKNTVYLQMNSLKPEDTAVYA CAKYIRRWALDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY'SLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQY’NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVI. DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab092-Gl Full Heavy- EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEW 344 Chain V STINSTGDKT YYADS VKGRFTISRDNAKNT V YLQMN SLKPEDTAV Y A CAKY1RRWALDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTY7SWNSGALTSCA7HTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNY’NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSV FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description SequenceSEQ ID NO: Ab093-Gl Full Heavy EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEW 345 Chain VSTIN SDGDRTY YADS V KGRFTISRDN AKNTV Y LQMNSLKPEDTAVY A CAKYIRRWALDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVA’TVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCL. VKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: Ab094-Gl Full Heavy EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEW 346 Chain VSTINPDGRSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYA CAKYIRRWALDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEW VSTINSDGDSTYYADSVKGRFTISRDNAKNTVYL. QMNSL. KPEDTAVYA CAKYLRSWALDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSW'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: AbOOl-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1080 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDEI. TKNQVSI. TCLVKGFYPSDLAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW VSFINRDSSITSYVDSVKGRF'riSRDNAKNTLYLQMNSLNAEDTAVYYC ASRDFVLWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEJ> VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY SEQ ID NO: Ab002-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK 1081 Chain w / o terminal lysine DTLMISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNWSCSVMHEALHNHYTQKS LSLSPG QVQL. VESGGGL. VEPGGSLRVSCAASGFTFSNYNMNWVRQAPGKGGEW SEQ ID NO: Ab003-Gl Full Heavy VSVINTGGGSTAYADSVKGRFTTSRDNAKNTVYLQMNSLKPEDTALYY1082 Chain w / o terminal lysineCATSGYDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QT'YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG QVHLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEW VSSIPTSGGNTY YADSVKGRFTISRDNAKNTLYLQMNSLKSELITAVY YC AKNGFGRSYYWDYWGQGTQVTVSSASTKGPSVFPL. APSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL. QSSGLYSLSSVVTVPS SEQ ID NO: Ab004-Gl Full Heavy SSLGTQTYICNWHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1083 Chain w'o terminal lysine VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYN STY RVVS VLTVLHQDWLNGKE YKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG QVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNft'VRQAPGKGLEW VSDIWSDGTTTYYADSVKGRFQISRDNAKNTLYLQMSSLKSEDTAVYY CVKQGYDSWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT SEQ ID NO: Ab005-Gl Full Heavy QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP 1084 Chain w / o terminal lysine KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLFIQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG QVQLVESGGGLVQPGGSLRVSCAASGFTFSAYYMSWVRQTPGKGLEW VSAINADGGSTYSTDSVKGRFTISRDNAKNTLYLQMSSLKPEDTALYYC ARVPIYYLGDRDFYRYLEIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVS’ft'NSGALTSGVHTFPAVLQSSGLYSLSSVV SEQ ID NO: Ab006-Gl Full Heavy TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL 1085 Chain w / o terminal lysine GGPS VFLFPPKPKDTLMISRTPEVTCV V VDVSHEDPEV KFNWY VDGV E VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL. PA PIEKTISIGA. KGQPREPQVYTLPPSRDEI. TKNQVSI. TCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKI. TVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPG EMQLVESGGGLVQPGGSLRLSCVASGFTFASYFMGWVRQAPGKGPEW VSTINSGGEDTYYSDSVKGRFT1SRDNAKNTLYLQMNSLKPEDTAVYAC SEQ ID NO: Ab007-Gl Full Heavy- AKYLRNWALDYWGQGT'QVTVSSASTKGPSVFPLAPSSKSTSGGTAALG 1086 Chain w / o terminal lysine CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSI.GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSVFL. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description SequencePREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP1EKTISK AKGQPREPQV YTLPPSRDELTKNQV SLTCLVKGFYPSD1A VEWESN GQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPG QVHLVESGGGLV QPGGSLRLSCAASGFTFNT Y YLNW VRQAPGKGLEWI. SSINI. DGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLKSEDTAKYYC AKPQPGNSLATYDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SEQ ID NO: Ab008-Gl Full Heavy S SLGTQT YICN VNHKPSN TKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1087 Chain w / o terminal lysine VFI. FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL. PAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EMQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQTPGKGPEWV S AINADGGDTYYADS VKGRFTISRDNAKNMLY LQMNSLKPEDTAVYTC AKYJ.. SYWALDHWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CL. VKDYFPEPVTVSWNSGALTSGVHTFPAVI. QSSGLYSLSSVVTVPSSSL SEQ ID NO: Ab009-Gl Full Heavy- GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL 1088 Chain w'o terminal lysine FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVK4HEALHNH YTQKSLSLSPG QVQLVESGGGFVQPGGSLRLSCASSGFPFSSYWMFWVRQAPGKGLEW VSHIKPGGGSTYYADSVKGRFTISRDDTKNTLYLQMNNLKSEDTALYY CARQGYGTTWYVDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVH'rFPAVLQSSGLYSLSSVVT'VP SEQ ID NO: AbOJ O-Gl Full Heavy SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1089 Chain w / o terminal lysine VFLFPPKPKDTLMISRTPEVTCVWDVSHE. DPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVI. HQDWI. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTX'DKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EMQLVESGGGLVQPGGSLRLSCAASGFTFGSFFMGWVRQAPGKGPEW VSTINSGGDSTYYEDSVKGRFTISRDNAKNTLHLQMNSLKPEDTAVYAC AKYLRNWAI. DFWGQGTQVTVSSASTKGPSVFPL. APSSKSTSGGTAALG SEQ ID NO: AbOll-Gl Full Heavy- CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSI.1090 Chain w'o terminal lysine GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVWDVSHEDPEVKF'NWY'VDGVEVHNAKTK PREEQ YNSTYRVVSVI. TVLHQDWLNGKEYKCKVSNKAL. PAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVTQSSGLYSLSSVVTVPSS SEQ ID NO: Ab012-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1091 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLxNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHt-J HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRI, SCAVSGSSFSGWRMNWVRQAPGKGLEW VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY SEQ ID NO: Ab013-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK 1092 Chain w / o terminal lysine DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYl'LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW V STINSDGRSTY YADSVKGRFHSRDNAKNTL YLQMN SLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab014-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1093 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVI. DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVrKDYFPEPVTVSWNSGALTSGVrHTFPAVIJQSSGLYSLSSVVTVPSS SEQ ID NO: Ab015-Gl Full Heavy SLGTQTYICNY’NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSV 1094 Chain w / o terminal lysine FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWICMNWVRQAPGKGLEW VSFIGRDV SITS Y ADS VKGRFTISRDNAKNTLY LQMNSLRAEDTA VYYC ASRDWLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY SEQ ID NO: Ab016-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL. FPPKPK 1095 Chain w'o terminal lysine DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQY7SLTCL. VKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY SEQ ID NO: Ab017-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSVFL. FPPKPK 1096 Chain w / o terminal lysine DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYl'LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EMQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGPEW VSTINSDGSSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYAC AKYIRRWALDYWGQGTQVTVSSASTK. GPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL SEQ ID NO: Ab018-Gl Full Heavy GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL 1097 Chain w / o terminal lysine FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK. TK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDEL. TKNQV’SL. TCI. VKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQAPGKGLEW VSSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKNGFGRSYYWDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSVv7NSGAL. TSGVHTFPAY7LQSSGL. YSI. SSVVTY7PS SEQ ID NO: Ab019-Gl Full Heavy SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1098 Chain w / o terminal lysine VFI. FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVFINA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEV.'ESN GQPENNYKTTPPY7LDSDGSFFLYSKL. TY7DKSRWQQGNY7FSCSY7MHEAL. HNHYTQKSLSLSPG EA7QLVESGGGLVQPGGSIJt. SCAASGFTFGSYWMSWVRQAPGKGLEW SEQ ID NO: Ab020-Gl Full Heavy VSSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC1099 Chain w / o terminal lysineAKNGFGRSYYWDYVv'GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description SequenceLGCLVKDYFPEPVTVSWNSGALTSGVI-rrFPAVLQSSGLYSLSSVVTVPS S SLGTQT YICN VNHKPSN TKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFI. FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTI. PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYWMYWVRQAPGKGLEW VSSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKNGFGRSYYWDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL. QSSGLYSLSSVVTVPS SEQ ID NO: Ab021-Gl Full Heavy SSLGTQTYICNWHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1100 Chain w'o terminal lysine VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYN STY RVVS VLTVLHQDWLNGKE YKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLR1, SCAASGFTFGSYWMYWVRQAPGKGLEW VSSIPTSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKNGFGRSYYWDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SEQ ID NO: Ab022-Gl Full Heavy SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1101 Chain w / o terminal lysine VFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTY'DKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEW VSDIWSDGTTTYYADSVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYY CVKQGYDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVI. QSSGLYSLSSVVTVPSSSLGT SEQ ID NO: Ab023-Gl Full Heavy QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP 1102 Chain w / o terminal lysine KPKDTLMISRTPEVTCVVVDVSHEDPEVKF'NWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL. PAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNAVVRQAPGKGLEW VSYIWSDGTTTYYADSVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYY SEQ ID NO: Ab024-Gl Full Heavy- CVKQGYDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV 1103 Chain w / o terminal lysine KDYFPEPVTVSWNSGALTSGVHTFPAVI. QSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP1EKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRMNWVRQAPGKGLEW VSYIWSDGTTTYYADSVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYY CVKQGYDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT SEQ ID NO: Ab025-Gl Full Heavy QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP 1104 Chain w / o terminal lysine KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVL. HQDWL. NGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFSESRN1NWVRQAPGKGLEW VSDIWSDGTTTYYADSVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYY CVKQGYDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT SEQ ID NO: Ab026-Gl Full Heavy- QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP 1105 Chain w'o terminal lysine KPKDTLM1SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTL. PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG EVQLVESGGGLVQPGGSLRLSCVASGFTFSSYFMGWVRQAPGKGLEW VSTINSGGEDTYYSDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYC AKYLRNWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL SEQ ID NO: Ab027-Gl Full Heavy GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL. LGGPSVFL 1106 Chain w / o terminal lysine FPPKPKDTLMISRTPEVTCVVVDVSHE. DPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVI. TVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCVASGFTFASYFMGWVRQAPGKGLEW VSTINSGGEDTYYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYY CAKYLRNWAL. DYWGQGTLVTVSSASTKGPSVFPL. APSSKSTSGGTAAL SEQ ID NO: Ab028-Gl Full Heavy- GCLVKDYFPEPVTVSVi / 'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS 1107 Chain w'o terminal lysine SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCVASGFTFASYFMGWVRQAPGKGLEW VSTIN SGGEDTY YADS VKGRFHSRDN AKNTL YLQMN SLRPEDTAV Y A CAKYLRNWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVTQSSGLYSLSSVVTVPSS SEQ ID NO: Ab029-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1108 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVFAVESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHt’J HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFASYFMGWVRQAPGKGPEW VSTINSGGEDTYYSDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYA CAKYLRNWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab030-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1109 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGLEW VSSINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY' CAKPQPGNSIATYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGAL. TSGVHTFPAVLQSSGL. YSI. SSVVTVP SEQ ID NO: Ab031-Gl Full Heavy SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1110 Chain w / o terminal lysine VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQY’NSTYRVVSVL. TVI. HQDWI. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKL. TVDKSRWQQGNVFSCSVMHEAL. HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYYMNWVRQAPGKGLEW VSSINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKPQPGNSIATYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SEQ ID NO: Ab032-Gl Full Heavy SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1111 Chain w / o terminal lysine VFI. FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA. LPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEV / ESN GQPENNYKTTPPVLDSDGSFFLYSKL. TVDKSRWQQGNVFSCSVMHEAL. HNHYTQKSLSLSPGAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGLEW LSSINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKPQPGNSIATYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL. QSSGLYSLSSVVTVP SEQ ID NO: Ab033-Gl Full Heavy SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1112 Chain w / o terminal lysine VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYN STY RVVS VLTVLHQDWLNGKE YKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYYLNWVRQAPGKGLEW VSSINLDGSNTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKPQPGNSIATYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SEQ ID NO: Ab034-Gl Full Heavy SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1113 Chain w / o terminal lysine VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVS VLTVLHQDWLNGKE YKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTY'DKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQAPGKGLEWV SAINADGGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYC AKYLSYWALDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL SEQ ID NO: Ab035-Gl Full Heavy GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL 1114 Chain w / o terminal lysine FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFLNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQAPGKGLEWV SAINADGGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYC AKYLSYV.'ALDHV.'GQGTLVT'VSSAST'KGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSI. SEQ ID NO: Ab036-Gl Full Heavy GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSVFL.1115 Chain w / o terminal lysine FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP1EKTISK AKGQPREPQV YTLPPSRDELTKNQV SLTCLVKGFYPSD1A VEW ESN GQP ENNYKTTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPG EVQLVTSGGGLVQPGGSLRLSCAASGFTFGSSFMSWV'RQAPGKGLEWV SEQ ID NO: Ab037-Gl Full HeavyS AINA DGGDTYY ADS VKGR FTISRDNSKNTLYLQMNSLRPEDTA VYTC1116 Chain w / o terminal lysineAKYLSYAVALDHWGQGTL. VTVSSASTKGPSVFPI. APSSKSTSGGTAALGAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence CLVKDYFPEPV'FVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTK PREEQYNSTY'RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSSFMSWVRQAPGKGPEWV SAINADGGDTYYADSVKGRFT1SRDNSKNTLYLQMNSLRAEDTAVYTC AKYLSYWALDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGAL. TSGVHTFPAVLQSSGL. YSLSSVVTVPSSSL SEQ ID NO: Ab038-Gl Full Heavy GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL 1117 Chain w'o terminal lysine FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMFWVRQAPGKGLEW VSHIKPGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYC ARQGYGTTWYVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SEQ ID NO: Ab039-Gl Full Heavy SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1118 Chain w / o terminal lysine VFLFPPKPKDTL. MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTX'DKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFPFSSYWMHWVRQAPGKGLEW VSHIKPGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYC ARQGYGTTWYVDYWGQGTI. VTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL. YSI. SSVVTVPS SEQ ID NO: Ab040-Gl Full Heavy SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1119 Chain w / o terminal lysine VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVL. TVI. HQDVvT. NGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKL. TVDKSRWQQGNVFSCSVMHEAL. HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMFWVRQAPGKGLEW VSHIKPGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYC SEQ ID NO: Ab041-Gl Full Heavy- ARQGYGTTWYVDYWGQG'FLVTVSSASTKGPSVFPLAPSSKSTSGGTAA 1120 Chain w / o terminal lysine LGCLVKDYFPEPVTVSWNSGAL. TSGVHTFPAVLQSSGL. YSI. SSVVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFI. FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVFINAAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFPFSSYWMFWVRQAPGKGLEW VSHIKPGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYC ARQGYGTTWYVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SEQ ID NO: Ab042-Gl Full Heavy S SLGTQT YICN VNHKPSN TKVDKKVEPKSCDKTHTCPPCPAPELLGGPS 1121 Chain w / o terminal lysine VFI. FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTIN SDGSSTY YADSVKGRFTISRDN AKNTL YLQMNSLRAEDTAVYYC AKYIRRWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL SEQ ID NO: Ab043-Gl Full Heavy- GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL 1122 Chain w'o terminal lysine FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYFMSWVRQAPGKGLEWV STINSDGSSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA KYIRRWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTX'PSSSLG SEQ ID NO: Ab044-Gl Full Heavy TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP 1123 Chain w / o terminal lysine PKPKDTL. MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVI. HQDWI. NGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVTDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSRINSDGSSTYYADSVKGRFTISRDNAKNTLYL. QMNSL. RAEDTAVYY CAKYIRRWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL SEQ ID NO: Ab045-Gl Full Heavy- GCLVKDYFPEPVTVSW'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS 1124 Chain w'o terminal lysine SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab046-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1125 Chain w'o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVTWESNGQ PENNYKTTPPVLFJSDGSFFLYSKItVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLATJSGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab047-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1126 Chain w / 'o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW V STINSDGRSTY YADSVKGRFTTSRDNAKNTL YLQMN SLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSW'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab048-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1127 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPATDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL. QSSGLY’SLSSVVTVPSS SEQ ID NO: Ab049-Gl Full Heavy SLGTQTYICNWIHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSV 1128 Chain w / o terminal lysine FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab050-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1129 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCL. VKGFYPSDIAVFAVESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab051-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1130 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: A052-G1 Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1131 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGG SLRLSC AASGFTFG SYFMSWVRQAPGKGLEW VSTINPRGGSTYYADSVKGRFTISRDNA. KNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL. QSSGLY’SLSSVVTVPSS SEQ ID NO: Ab053-Gl Full Heavy SLGTQTYICNX'NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1132 Chain w / o terminal lysine FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRL. SCAASGFTFGSYFMSWVRQAPGKGLEW SEQ ID NO: Ab054-Gl Full HeavyVSTINPDGDRTYYA DS VKGRFTISRDN AKNTLYLQMNSLRAEDTA VYY1133 Chain w / o terminal lysineCAKYLRSWALDYWGQGTLXTVSSASTKGPSVFPLAPSSKSTSGGTAALAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV'TVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDY’WGQGTLV'TVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPF. PVTVSWNSGALTSGVHTFPAVTQSSGLYSLSSVVTVPSS SEQ ID NO: Ab055-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1134 Chain w'o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCL. VKGFYPSDIAVFAVESNGQ PENNYKTTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLR1, SCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab056-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1135 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVWDVSHEDPF. VKFNWYVDGVF. VHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPDGDRTYYADSVKGRFTISRDNAKNTLY'LQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWTYSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab057-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1136 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEY’KCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDEI. TKNQVSI. TCLVKGFYPSDIAVEWESNGQ PENNYKTTPPXTDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY SEQ ID NO: Ab058-Gl Full Heavy- CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL 1137 Chain w / o terminal lysine GCLV'KDYFPEPVTVSWNSGALTSGVTJTFPAVI. QSSGLYSLSSVVTVPSS SLGTQTYTCNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGDSTYYADSVKGRFTISRDNAKNTLY'LQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV'TVPSS SEQ ID NO: Ab059-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1138 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPFA'KFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab060-Gl Full Heavy- SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1139 Chain w'o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVTWESNGQ PENNYKTTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHt-J HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPDGDRTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab061-Gl Full Heavy SI. GTQTYICNWHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL. LGGPSV 1140 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVWDVSHE. DPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGRSTYYADSVXGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL SEQ ID NO: Ab062-Gl Full Heavy- GCLVKDYFPEPVTVSW'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS 1141 Chain w'o terminal lysine SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGDSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab063-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1142 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVTWESNGQ PENNYKTTPPVLFJSDGSFFLYSKItVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLAT3SGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPRGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab064-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1143 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINPDGDRTYYADSVKGRFT1SRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSW'NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SEQ ID NO: Ab065-Gl Full Heavy SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV 1144 Chain w / o terminal lysine FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVI. DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPG EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYFMSWVRQAPGKGLEW VSTINSDGRSTYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYY CAKYLRSWALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL. QSSGLY’SLSSVVTVPSS SEQ ID NO: Ab066-Gl Full Heavy SLGTQTYICNWIHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSV 1145 Chain w / o terminal lysine FI. FPPKPKDTI. MISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQ V YTLPPSRDELTKNQV SLTCLVKGFYPSD1 A VEW ESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRYINWVRQAPGKGLEW VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY SEQ ID NO: Ab067-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL. FPPKPK 1146 Chain w'o terminal lysine DTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW VSFINRRQSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY SEQ ID NO: Ab068-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSVFL. FPPKPK 1147 Chain w / o terminal lysine DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTY'RWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYPLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVxMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW VSFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDWLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY SEQ ID NO: Ab069-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK 1148 Chain w / o terminal lysine DTLM1SRTPEV TC VVVDV SHEDPEVKFNW Y V DGVEV HNAKTKPREEQ YNSTYRVVSVLTVL. HQDWLNGKEYKCKVSNKAI. PAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW VSFIGRDVSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDVVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPFA> VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY SEQ ID NO: Ab070-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK 1149 Chain w / o terminal lysine DTLMISRTPEVTCVVVDVSHEDPEVKFMVYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYILPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFI. YSKLTVDKSR\VQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLY7ESGGGLY7QPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW SEQ ID NO: Ab071-Gl Full Heavy VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC1150 Chain w / o terminal lysineASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCWVDVSHEDPEVKFT4WYVTX3VTVHNAKTKPREEQ YNSTYRVY’SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCA. VSGLSFGGWRMNWVRQAPGKGLEW VSFIGRASSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVTQSSGLYSLSSVA’TVTSSSLGTQTY SEQ ID NO: Ab072-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL. FPPKPK 1151 Chain w'o terminal lysine DTLMISRTPEVTCVtrVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQV7SLTCL. VKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY SEQ ID NO: Ab073-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL. GGPSVFL. FPPKPK 1152 Chain w / o terminal lysine DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYl'LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW VSFINRDSSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPV’TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY SEQ ID NO: Ab074-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK 1153 Chain w / o terminal lysine DTLM1SRTPEV TC VVVDV SHEDPEVKFNW Y V DGVEV HNAKTKPREEQ YNSTYRVVSVLTVL. HQDWLNGKEYKCKVSNKAI. PAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFI. YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGTSFGGWRMNWVRQAPGKGLEW VSFINRRQSITSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYC SEQ ID NO: Ab075-Gl Full Heavy- ASRDFVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD 1154 Chain w / o terminal lysine YFPFJ> VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNAVYVDGVEVHNAKTKPREEQAttorney Docket No. DEMB-010 / 02WOSEQ ID NO: Description Sequence YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGSSFSGWRMNWVRQAPGKGLEW VSFIGRDVSITSYADSVKGRFTISRDNAKNTLYL. QMNSL. RAEDTAVYYC ASRDVVLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY SEQ ID NO: Ab076-Gl Full Heavy ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK 1155 Chain w / o terminal lysine DTLMISRTPEVTCWVDVSHEDPEVKFT’JWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWI, NGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPG EVQLVESGGGLVQPGGSLRLSCAVSGLSFGGWRMNWVRQAPGKGLEW VSFIGRDV SITS Y ADS VKGRFT1SRDNAKNTLY LQMNSLRAEDT A...

Claims

Attorney Docket No. DEMB-010 / 02WOWHAT IS CLAIMED:

1. An antibody that specifically binds Small Cell Adhesion Glycoprotein (SMAGP), wherein the antibody comprises:(a) a heavy chain variable region (VH) comprising the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in any one of SEQ ID NOs: 2-123; and(b) a light chain variable region (VL) comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in any one of SEQ ID NOs: 124-252.

2. The antibody of claim 1, wherein the VH amino acid sequence and VL amino acid sequence are as set forth in: SEQ ID NOs: 44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, 70 and 197, 2 and 124, 3 and 125, 4 and 126, 5 and 127, 6 and 128, 7 and 129, 8 and 130, 9 and 131, 10 and 132, 11 and 133, 12 and 134, 13 and 135, 14 and 136, 15 and 137, 16 and 138, 17 and 139, 18 and 140, 19 and 141, 20 and 142, 21 and 143, 22 and 144, 24 and 146, 25 and 147, 26 and 148, 27 and 149, 28 and 150, 29 and 151, 30 and 152, 31 and 153, 32 and 154, 33 and 155, 34 and 156, 35 and 157, 36 and 158, 37 and 159, 38 and 160, 39 and 161, 40 and 162, 41 and 163, 42 and 164, 43 and 165, 45 and 168, 46 and 169, 47 and 170, 48 and 171, 49 and 172, 50 and 173, 51 and 174, 52 and 175, 53 and 176, 54 and 177, 55 and 178, 56 and 179, 57 and 180, 58 and 181, 59 and 182, 60 and 183, 61 and 184, 62 and 185, 63 and 186, 64 and 187, 65 and 188, 71 and 189, 72 and 190, 73 and 191, 74 and 192, 75 and 204, 76 and 205, 77 and 206, 78 and 207, 79 and 208, 80 and 209, 81 and 210, 82 and 211, 83 and 212, 84 and 213, 85 and 214, 86 and 215, 87 and 216, 88 and 217, 89 and 218, 90 and 219, 91 and 220, 92 and 221, 93 and 222, 94 and 223, 95 and 224, 96 and 225, 97 and 226, 98 and 227, 99 and 228, 100 and 229, 101 and 230, 102 and 231, 103 and 232, 104 and 233, 105 and 234, 106 and 235, 107 and 236, 108 and 237, 109 and 238, 110 and 239, 111 and 240, 112 and 241, 113 and 242, 114 and 243, 115 and 244, 116 and 245, 117 and 246, 118 and 247, 119 and 248, 120 and 249, 121 and 250, 122 and 251, or 123 and 252, respectively.Attorney Docket No. DEMB-010 / 02WO3. The antibody of any one of the preceding claims, wherein the VH amino acid sequence and VL amino acid sequence are as set forth in: SEQ ID NOs: 44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, or 70 and 197, respectively.

4. Tlie antibody of any one of the preceding claims, wherein the CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, and 697; 489, 605, and 703; 487, 603, and 677; 487, 603, and 701; 487, 603, and 705; 487, 603, and 706; 487, 603, and 707; 487, 603, and 708; 487, 603, and 709; 487, 603, and 710; 462, 561, and 677; 441, 540, and 656; 442, 541, and 657; 443, 542, and 658; 444, 543, and 659; 445, 544, and 660; 446, 545, and 661; 447, 546, and 662; 448, 547, and 663; 449, 548, and 664; 450, 549, and 665; 451, 550, and 666; 452, 551, and 667; 453, 552, and 668; 454, 553, and 669; 455, 554, and 670; 456, 555, and 671; 457, 556, and 672; 458, 557, and 673; 459, 558, and 674; 460, 559, and 675; 461, 560, and 676; 463, 562, and 678; 464, 563, and 679; 465, 564, and 680; 466, 565, and 681; 467, 566, and 682; 468, 567, and 683; 469, 568, and 684; 470, 569, and 685; 471, 570, and 686; 472, 571, and 687; 473, 572, and 688; 474, 573, and 689; 475, 574, and 690; 476, 575, and 691; 477, 576, and 692; 478, 577, and 693; 479, 578, and 694; 480, 579, and 695; 481, 580, and 696; 483, 582, and 698; 484, 583, and 699; 485, 584, and 700; 452, 585, and 667; 452, 586, and 667; 452, 587, and 667; 452, 588, and 667; 452, 589, and 667; 452, 590, and 667; 452, 591, and 667; 452, 592, and 667; 452, 593, and 667; 452, 594, and 667; 452, 595, and 667; 452, 596, and 667; 452, 1198, and 667; 452, 1199, and 667; 452, 1200, and 667; 452, 1201, and 667; 452, 1202, and 667; 452, 1203, and 667; 452, 1204, and 667; 452, 1205, and 667; 452, 1206, and 667; 486, 597, and 668; 486, 598, and 668; 486, 599, and 668; 486, 600, and 668; 486, 601, and 668; 486, 602, and 668; 488, 604, and 702; 488, 604, and 678; 490, 606, and 704; 491, 607, and 711; 492, 608, and 712; 493, 609, and 713; 494, 610, and 714; 495, 611, and 715; 496, 612, and 716; 497, 613, and 717; 498, 614, and 718; 499, 615, and 719; 500, 616, and 720; 501, 617, and 721; 502, 618, and 722; 503, 619, and 723; 504, 620, and 724; 505, 621, and 725; 506, 622, and 726; 507, 623, and 727; 508, 624, and 728; 509, 625, and 729; 510, 626, and 730; 511, 627, and 731; 512, 628, and 732;Attorney Docket No. DEMB-010 / 02WO513, 629, and 733; 514, 630, and 734; 515, 631, and 735; 516, 632, and 736; 517, 633, and 737; 518, 634, and 738; 519, 635, and 739; 520, 636, and 740; 521, 637, and 741; 522, 638, and 742; 523, 639, and 743; 524, 640, and 744; 525, 641, and 745; 526, 642, and 746; 527, 643, and 747; 528, 644, and 748; 529, 645, and 749; 530, 646, and 750; 531, 647, and 751; 532, 648, and 752; 533, 649, and 753; 534, 650, and 754; 535, 651, and 755; 536, 652, and 756; 537, 653, and 757; 538, 654, and 758; or 539, 655, and 759, respectively.

5. The antibody of any one of the preceding claims, wherein the CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, and 697, respectively.

6. Tlie antibody of any one of the preceding claims, wherein the CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 462, 561, and 677, respectively.

7. Die antibody of any one of claims 1-6, wherein the CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 801, 919, and 1013; 823, 919, and 1013; 824, 919, and 1013; 825, 919, and 1013; 826, 919, and 1013; 827, 919, and 1013; 828, 919, and 1013; 781, 899, and 993; 814, 899, and 993; 818, 899, and 993; 819, 899, and 993; 820, 899, and 993; 821, 899, and 993; 822, 899, and 993; 760, 878, and 972; 761, 879, and 973; 762, 880, and 974; 763, 881, and 975; 764, 882, and 976; 765, 883, and 977; 766, 884, and 978; 767, 885, and 979; 768, 886, and 980; 769, 887, and 981; 770, 888, and 982; 771, 889, and 983; 772, 890, and 984; 773, 891, and 985; 774, 892, and 986; 775, 893, and 987; 776, 894, and 988; 777, 895, and 989; 778, 896, and 990; 779, 897, and 991; 780, 898, and 992; 782, 900, and 994; 783, 901, and 995; 784, 902, and 996; 785, 903, and 997; 786, 904, and 998; 787, 905, and 999; 788, 906, and 1000; 789, 907, and 1001; 790, 908, and 1002; 791, 909, and 1003; 792, 910, and 1004; 793, 911, and 1005; 794, 912, and 1006; 795, 913, and 1007; 796, 914, and 1008; 797, 915, and 1009; 798, 916, and 1010; 799, 917, and 1011; 800, 918, and 1012; 802, 920, and 1014; 803, 921, and 1015; 804, 922, and 1016; 805, 889, and 983; 806, 889, and 983; 807, 889, and 983; 808, 890, and 984; 809, 890, and 984; 810, 890, and 984; 811, 890, and 984; 812, 890, and 984; 813, 890, and 984; 815, 900, and 994; 816, 919, and 1013; 817, 920, and 1014; 829, 923, and 1017; 830, 924, and 1018; 831, 925, and 1019; 832, 926, and 1020; 833, 927, and 1021; 834, 928, and 1022; 835, 929, and 1023; 836, 930, and 1024; 837, 931, and 1025; 838, 932, and 1026; 839, 933, and 1027; 840, 934, and 1028; 841, 935, and 1029; 842, 936, and 1030; 843, 937, and 1031; 844, 938, and 1032; 845, 939, and 1033; 846, 940, and 1034; 847, 941, and 1035; 848, 942, and 1036; 849, 943, and 1037;Attorney Docket No. DEMB-010 / 02WO850, 944, and 1038; 851, 945, and 1039; 852, 946, and 1040; 853, 947, and 1041; 854, 948, and 1042; 855, 949, and 1043; 856, 950, and 1044; 857, 951, and 1045; 858, 952, and 1046; 859, 953, and 1047; 860, 954, and 1048; 861, 955, and 1049; 862, 956, and 1050; 863, 957, and 1051; 864, 958, and 1052; 865, 959, and 1053; 866, 960, and 1054; 867, 961, and 1055; 868, 962, and 1056; 869, 963, and 1057; 870, 964, and 1058; 871, 965, and 1059; 872, 966, and 1060; 873, 967, and 1061; 874, 968, and 1062; 875, 969, and 1063; 876, 970, and 1064; or 877, 971, and 1065, respectively.

8. The antibody of any one of the preceding claims, wherein the CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 801, 919, and 1013, respectively.

9. The antibody of any one of the preceding claims, wherein the CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 781, 899, and 993, respectively.

10. The antibody of any one of the preceding claims, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, 697, 801, 919, and 1013; 489, 605, 703, 823, 919, and 1013; 489, 605, 703, 824, 919, and 1013; 489, 605, 703, 825, 919, and 1013; 489, 605, 703, 826, 919, and 1013; 489, 605, 703, 827, 919, and 1013; or 489, 605, 703, 828, 919, and 1013; 462, 561, 677, 781, 899, and 993; 462, 561, 677, 818, 899, and 993; 462, 561, 677, 819, 899, and 993; 462, 561, 677, 820, 899, and 993; 462, 561, 677, 821, 899, and 993; 462, 561, 677, 822, 899, and 993; 487, 603, 705, 781, 899, and 993; 487, 603, 705, 818, 899, and 993; 487, 603, 705, 819, 899, and 993; 487, 603, 705, 820, 899, and 993; 487, 603, 705, 821, 899, and 993; 487, 603, 705, 822, 899, and 993; 487, 603, 706, 781, 899, and 993; 487, 603, 706, 818, 899, and 993; 487, 603, 706, 819, 899, and 993; 487, 603, 706, 820, 899, and 993; 487, 603, 706, 821, 899, and 993; 487, 603, 706, 822, 899, and 993; 487, 603, 707, 781, 899, and 993; 487, 603, 707, 818, 899, and 993; 487, 603, 707, 819, 899, and 993; 487, 603, 707, 820, 899, and 993; 487, 603, 707, 821, 899, and 993; 487, 603, 707, 822, 899, and 993; 487, 603, 708, 781, 899, and 993; 487, 603, 708, 818, 899, and 993; 487, 603, 708, 819, 899, and 993; 487, 603, 708, 820, 899, and 993; 487, 603, 708, 821, 899, and 993; 487, 603, 708, 822, 899, and 993; 487, 603, 709, 781, 899, and 993; 487, 603, 709, 818, 899, and 993; 487, 603, 709, 819, 899, and 993; 487, 603, 709, 820, 899, and 993; 487, 603, 709, 821, 899, and 993; 487, 603, 709, 822, 899, and 993; 487, 603, 710, 781, 899, and 993; 487, 603, 710, 818, 899, and 993; 487, 603, 710, 819, 899, and 993; 487, 603, 710, 820, 899, and 993; 487, 603, 710, 821, 899, and 993; 487, 603, 710, 822,Attorney Docket No. DEMB-010 / 02WO899, and 993; 441, 540, 656, 760, 878, and 972; 442, 541, 657, 761, 879, and 973; 443, 542, 658, 762, 880, and 974; 444, 543, 659, 763, 881, and 975; 445, 544, 660, 764, 882, and 976; 446, 545, 661, 765, 883, and 977; 447, 546, 662, 766, 884, and 978; 448, 547, 663, 767, 885, and 979; 449, 548, 664, 768, 886, and 980; 450, 549, 665, 769, 887, and 981; 451, 550, 666, 770, 888, and 982; 452, 551, 667, 771, 889, and 983; 453, 552, 668, 772, 890, and 984; 454, 553, 669, 773, 891, and 985; 455, 554, 670, 774, 892, and 986; 456, 555, 671, 775, 893, and 987; 457, 556, 672, 776, 894, and 988; 458, 557, 673, 777, 895, and 989; 459, 558, 674, 778, 896, and 990; 460, 559, 675, 779, 897, and 991; 461, 560, 676, 780, 898, and 992; 463, 562, 678, 782, 900, and 994; 464, 563, 679, 783, 901, and 995; 465, 564, 680, 784, 902, and 996; 466, 565, 681, 785, 903, and 997; 467, 566, 682, 786, 904, and 998; 468, 567, 683, 787, 905, and 999; 469, 568, 684, 788, 906, and 1000; 470, 569, 685, 789, 907, and 1001; 471, 570, 686, 790, 908, and 1002; 472, 571, 687, 791, 909, and 1003; 473, 572, 688, 792, 910, and 1004; 474, 573, 689, 793, 911, and 1005; 475, 574, 690, 794, 912, and 1006; 476, 575, 691, 795, 913, and 1007; 477, 576, 692, 796, 914, and 1008; 478, 577, 693, 797, 915, and 1009; 479, 578, 694, 798, 916, and 1010; 480, 579, 695, 799, 917, and 1011; 481, 580, 696, 800, 918, and 1012; 483, 582, 698, 802, 920, and 1014; 484, 583, 699, 803, 921, and 1015; 485, 584, 700, 804, 922, and 1016; 452, 585, 667, 805, 889, and 983; 452, 586, 667, 805, 889, and 983; 452, 587, 667, 805, 889, and 983; 452, 588, 667, 805, 889, and 983; 452, 589, 667, 805, 889, and 983; 452, 590, 667, 805, 889, and 983; 452, 591, 667, 805, 889, and 983; 452, 592, 667, 805, 889, and 983; 452, 593, 667, 805, 889, and 983; 452, 594, 667, 805, 889, and 983; 452, 595, 667, 806, 889, and 983; 452, 596, 667, 807, 889, and 983; 452, 1198, 667, 805, 889, and 983; 452, 1199, 667, 805, 889, and 983; 452, 1200, 667, 805, 889, and 983; 452, 1201, 667, 805, 889, and 983; 452, 1202, 667, 805, 889, and 983; 452, 1203, 667, 805, 889, and 983; 452, 1204, 667, 805, 889, and 983; 452, 1205, 667, 805, 889, and 983; 452, 1206, 667, 805, 889, and 983; 452, 551, 667, 806, 889, and 983; 452, 551, 667, 807, 889, and 983; 486, 597, 668, 808, 890, and 984; 486, 598, 668, 809, 890, and 984; 486, 599, 668, 810, 890, and 984; 486, 600, 668, 811, 890, and 984; 486, 601, 668, 812, 890, and 984; 486, 602, 668, 813, 890, and 984; 488, 604, 702, 782, 900, and 994; 483, 582, 698, 817, 920, and 1014; 490, 606, 704, 817, 920, and 1014; 491, 607, 711, 829, 923, and 1017; 492, 608, 712, 830, 924, and 1018; 493, 609, 713, 831, 925, and 1019; 494, 610, 714, 832, 926, and 1020; 495, 611, 715, 833, 927, and 1021; 496, 612, 716, 834, 928, and 1022; 497, 613, 717, 835, 929, and 1023; 498, 614, 718, 836, 930, and 1024; 499, 615, 719, 837, 931, and 1025; 500, 616, 720, 838, 932, and 1026; 501, 617, 721, 839, 933, and 1027; 502, 618, 722, 840, 934, and 1028; 503, 619, 723, 841, 935, and 1029; 504, 620, 724, 842, 936, and 1030; 505, 621, 725, 843, 937, and 1031; 506, 622, 726, 844, 938, and 1032;Attorney Docket No. DEMB-010 / 02WO507, 623, 727, 845, 939, and 1033; 508, 624, 728, 846, 940, and 1034; 509, 625, 729, 847, 941, and 1035; 510, 626, 730, 848, 942, and 1036; 511, 627, 731, 849, 943, and 1037; 5512, 628, 732, 850, 944, and 1038; 513, 629, 733, 851, 945, and 1039; 514, 630, 734, 852, 946, and 1040; 515, 631, 735, 853, 947, and 1041; 516, 632, 736, 854, 948, and 1042; 517, 633, 737, 855, 949, and 1043; 518, 634, 738, 856, 950, and 1044; 5519, 635, 739, 857, 951, and 1045; 520, 636, 740, 858, 952, and 1046; 521, 637, 741, 859, 953, and 1047; 522, 638, 742, 860, 954, and 1048; 523, 639, 743, 861, 955, and 1049; 524, 640, 744, 862, 956, and 1050; 525, 641, 745, 863, 957, and 1051; 526, 642, 746, 864, 958, and 1052; 527, 643, 747, 865, 959, and 1053; 528, 644, 748, 866, 960, and 1054; 529, 645, 749, 867, 961, and 1055; 530, 646, 750, 868, 962, and 1056; 531, 647, 751, 869, 963, and 1057; 532, 648, 752, 870, 964, and 1058; 533, 649, 753, 871, 965, and 1059; 534, 650, 754, 872, 966, and 1060; 535, 651, 755, 873, 967, and 1061; 536, 652, 756, 874, 968, and 1062; 537, 653, 757, 875, 969, and 1063; 538, 654, 758, 876, 970, and 1064; or 539, 655, 759, 877, 971, and 1065, respectively.

11. The antibody of any one of the preceding claims, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, 697, 801, 919, and 1013; 489, 605, 703, 823, 919, and 1013; 489, 605, 703, 824, 919, and 1013; 489, 605, 703, 825, 919, and 1013; 489, 605, 703, 826, 919, and 1013; 489, 605, 703, 827, 919, and 1013; or 489, 605, 703, 828, 919, and 1013; 462, 561, 677, 781, 899, and 993; 462, 561, 677, 818, 899, and 993; 462, 561, 677, 819, 899, and 993; 462, 561, 677, 820, 899, and 993; 462, 561, 677, 821, 899, and 993; 462, 561, 677, 822, 899, and 993; 487, 603, 705, 781, 899, and 993; 487, 603, 705, 818, 899, and 993; 487, 603, 705, 819, 899, and 993; 487, 603, 705, 820, 899, and 993; 487, 603, 705, 821, 899, and 993; 487, 603, 705, 822, 899, and 993; 487, 603, 706, 781, 899, and 993; 487, 603, 706, 818, 899, and 993; 487, 603, 706, 819, 899, and 993; 487, 603, 706, 820, 899, and 993; 487, 603, 706, 821, 899, and 993; 487, 603, 706, 822, 899, and 993; 487, 603, 707, 781, 899, and 993; 487, 603, 707, 818, 899, and 993; 487, 603, 707, 819, 899, and 993; 487, 603, 707, 820, 899, and 993; 487, 603, 707, 821, 899, and 993; 487, 603, 707, 822, 899, and 993; 487, 603, 708, 781, 899, and 993; 487, 603, 708, 818, 899, and 993; 487, 603, 708, 819, 899, and 993; 487, 603, 708, 820, 899, and 993; 487, 603, 708, 821, 899, and 993; 487, 603, 708, 822, 899, and 993; 487, 603, 709, 781, 899, and 993; 487, 603, 709, 818, 899, and 993; 487, 603, 709, 819, 899, and 993; 487, 603, 709, 820, 899, and 993; 487, 603, 709, 821, 899, and 993; 487, 603, 709, 822, 899, and 993; 487, 603, 710, 781, 899, and 993; 487, 603, 710, 818, 899, and 993; 487, 603, 710, 819, 899, andAttorney Docket No. DEMB-010 / 02WO993; 487, 603, 710, 820, 899, and 993; 487, 603, 710, 821, 899, and 993; or 487, 603, 710, 822, 899, and 993, respectively.

12. The antibody of any one of the preceding claims, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, 697, 801, 919, and 1013, respectively.

13. The antibody of any one of the preceding claims, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 462, 561, 677, 781, 899, and 993, respectively.

14. The antibody of any one of the preceding claims, wherein the VH comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 2-123.

15. Tire antibody of any one of the preceding claims, wherein the VH comprises the amino acid sequence of SEQ ID NO: 44.

16. The antibody of any one of the preceding claims, wherein the VH comprises the amino acid sequence of SEQ ID NOs: 23, 66, 67, 68, 69, or 70.

17. Tire antibody of claim 16, wherein the VH comprises the amino acid sequence of SEQ ID NO: 23.

18. The antibody of any one of the preceding claims, wherein the VL comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 124-252.

19. Tlie antibody of any one of the preceding claims, wherein the VL comprises the amino acid sequence of SEQ ID NOs: 166, 198, 199, 200, 201, 202, or 203.Attorney Docket No. DEMB-010 / 02WO20. The antibody of claim 19, wherein the VL comprises the amino acid sequence of SEQ ID NO: 166.

21. The antibody of any one of the preceding claims, wherein the VL comprises the amino acid sequence of SEQ ID NOs: 145, 193, 194, 195, 196, or 197.

22. The antibody of claim 21, wherein the VL comprises the amino acid sequence of SEQ ID NO: 145.

23. Tlie antibody of any one of the preceding claims, wherein the VH amino acid sequence and the VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs: 44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, 70 and 197, 2 and 124, 3 and 125, 4 and 126, 5 and 127, 6 and 128, 7 and 129, 8 and 130, 9 and 131, 10 and 132, 11 and 133, 12 and 134, 13 and 135, 14 and 136, 15 and 137, 16 and 138, 17 and 139, 18 and 140, 19 and 141, 20 and 142, 21 and 143, 22 and 144, 24 and 146, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 25 and 147, 26 and 148, 27 and 149, 28 and 150, 29 and 151, 30 and 152, 31 and 53, 32 and 154, 33 and 155, 34 and 156, 35 and 157, 36 and 158, 37 and 159, 38 and 160, 39 and 161, 40 and 162, 41 and 163, 42 and 164, 43 and 165, 45 and 168, 46 and 169, 47 and 170, 48 and 171, 49 and 172, 50 and 173, 51 and 174, 52 and 175, 53 and 176, 54 and 177, 55 and 178, 56 and 179, 57 and 180, 58 and 181, 59 and 182, 60 and 183, 61 and 184, 62 and 185, 63 and 186, 64 and 187, 65 and 188, 71 and 189, 72 and 190, 73 and 191, 74 and 192, 75 and 204, 76 and 205, 77 and 206, 78 and 207, 79 and 208, 80 and 209, 81 and 210, 82 and 211, 83 and 212, 84 and 213, 85 and 214, 86 and 215, 87 and 216, 88 and 217, 89 and 218, 90 and 219, 91 and 220, 92 and 221, 93 and 222, 94 and 223, 95 and 224, 96 and 225, 97 and 226, 98 and 227, 99 and 228, 100 and 229, 101 and 230, 102 and 231, 103 and 232, 104 and 233, 105 and 234, 106 and 235, 107 and 236, 108 and 237, 109 and 238, 110 and 239, 111 and 240, 112 and 241, 113 and 242, 114 and 243, 115 and 244, 116 and 245, 117 and 246, 118 and 247, 119 and 248, 120 and 249, 121 and 250, 122 and 251, or 123 and 252, respectively.Attorney Docket No. DEMB-010 / 02WO24. The antibody of any one of the preceding claims, wherein the VH amino acid sequence and the VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs: 44 and 166, 44 and 167, 44 and 198, 44 and 199, 44 and 200, 44 and 201, 44 and 202, 44 and 203, 23 and 145, 23 and 193, 23 and 194, 23 and 195, 23 and 196, 23 and 197, 66 and 145, 66 and 193, 66 and 194, 66 and 195, 66 and 196, 66 and 197, 67 and 145, 67 and 193, 67 and 194, 67 and 195, 67 and 196, 67 and 197, 68 and 145, 68 and 193, 68 and 194, 68 and 195, 68 and 196, 68 and 197, 69 and 145, 69 and 193, 69 and 194, 69 and 195, 69 and 196, 69 and 197, 70 and 145, 70 and 193, 70 and 194, 70 and 195, 70 and 196, or 70 and 197, respectively.

25. Tlie antibody of any one of the preceding claims, wherein the VH amino acid sequence and the VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs: 44 and 166, respectively.

26. The antibody of any one of the preceding claims, wherein the VH amino acid sequence and die VL amino acid sequence comprise the amino acid sequences of SEQ ID NOs: 23 and 145, respectively.

27. The antibody of any one of the preceding claims, wherein the antibody comprises a heavy chain constant region.

28. The antibody of claim 27, wherein the heavy chain constant region is selected from the group consisting of human IgGi, IgGi, IgGa, IgGi, IgAi, and IgAa.

29. The antibody of any of the preceding claims, wherein the heavy chain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%. at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, or 1074.

30. The antibody of any one of the preceding claims, wherein the antibody comprises an IgGi heavy chain constant region.Atorney- Docket No. DEMB-010 / 02WO31. The antibody of claim 30, wherein the IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1066 or 1070.

32. Hie antibody of any one of claims 1-29, wherein the antibody comprises an IgGi heavy¬ chain constant region comprising amino acids Asp239 and Glu332, wherein the amino acid position is indicated according to the EU numbering system.

33. The antibody of claim 32, wherein the IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1067 or 1071.

34. Hie antibody of any one of claims 1-29, wherein the antibody comprises an IgGi heavychain constant region comprising amino acids Ala236, Asp239, and Glu332, wherein the amino acid position is indicated according to the EU numbering system.

35. The antibody of claim 34, wherein the IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1068 or 1072.

36. Hie antibody of any one of claims 1-29, wherein the antibody comprises an IgGi heavychain constant region comprising amino acids Ala234, Ala235, and Gly329, wherein the amino acid position is indicated according to the EU numbering system.

37. The antibody of claim 36, wherein the IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1069 or 1073.

38. Hie antibody of any one of claims 1-37, wherein the antibody comprises an afucosylated IgGi heavy chain constant region.

39. The antibody of claim 38, wherein the afucosylated IgGi heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 1074 or 1174.

40. Hie antibody of any of the preceding claims, wherein the light chain constant region comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%,Attorney Docket No. DEMB-010 / 02WOat least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 1075, 1076, or 1077.

41. The antibody of any one of the preceding claims, wherein the antibody comprises a light chain constant region comprising the amino acid sequences of SEQ ID NOs: 1075, 1076, or 1077.

42. The antibody of any of the preceding claims, wherein the antibody comprises a heavy chain comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 253-346, 1080-1173, or 1175-1184.

43. The antibody of claim 42, wherein the heavy chain lacks its C-terminal lysine.

44. The antibody of any one of the preceding claims, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 294.

45. The antibody of any one of claims 1-43, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 1121,46. The antibody of any one of claims 1-43, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 274.

47. The antibody of any one of claims 1-43, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 1101.

48. The antibody of any of the preceding claims, wherein the antibody comprises a light chain comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 347-440 or 1185-1195.Attorney Docket No. DEMB-010 / 02WO49. The antibody of any one of the preceding claims, wherein the antibody comprises a light chain comprising tire amino acid sequence of SEQ ID NO: 388.

50. The antibody of any one of the preceding claims, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 368.

51. The antibody of any of the preceding claims, wherein antibody comprises(a) a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 253-346, 1080-1173, or 1175-1184; and(b) a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 347-440 or 1185-1195.

52. The antibody of claim 1, wherein the heavy chain and light chain comprise the amino acid sequences of SEQ ID NOs: 294 and 388, 294 and 1190, 294 and 1191, 294 and 1192, 294 and 1193, 294 and 1194, 294 and 1195, 1121 and 388, 1121 and 1190, 1121 and 1191, 1121 and 1192, 1121 and 1193, 1121 and 1194, 1121 and 1195, 274 and 368, 1101 and 368, 274 and 1185, 274 and 1186, 274 and 1187, 274 and 1188, 274 and 1189, 1175 and 368, 1175 and 1185, 1175 and 1186, 1175 and 1187, 1175 and 1188, 1175 and 1189, 1176 and 368, 1176 and 1185, 1176 and 1186, 1176 and 1187, 1176 and 1188, 1176 and 1189, 1177 and 368, 1177 and 1185, 1177 and 1186, 1177 and 1187, 1177 and 1188, 1177 and 1189, 1178 and 368, 1178 and 1185, 1178 and 1186, 1178 and 1187, 1178 and 1188, 1178 and 1189, 1179 and 368, 1179 and 1185, 1179 and 1186, 1179 and 1187, 1179 and 1188, 1179 and 1189, 1101 and 1185, 1101 and 1186, 1101 and 1187, 1101 and 1188, 1101 and 1189, 1180 and 368, 1180 and 1185, 1180 and 1186, 1180 and 1187, 1180 and 1188, 1180 and 1189, 1181 and 368, 1181 and 1185, 1181 and 1186, 1181 and 1187, 1181 and 1188, 1181 and 1189, 1182 and 368, 1182 and 1185, 1182 and 1186, 1182 and 1187, 1182 and 1188, 1182 and 1189, 1183 and 368, 1183 and 1185, 1183 and 1186, 1183 and 1187, 1183 and 1188, 1183 and 1189, 1184 and 368, 1184 and 1185, 1184 and 1186, 1184 and 1187, 1184 and 1188, 1184 and 1189, 253 and 347, 254 and 348, 255 and 349, 256 and 350, 257 and 351, 258 and 352, 259 and 353, 260 and 354, 261 and 355, 262 and 356, 263 and 357, 264 and 358, 265 and 359, 266 and 360, 267 and 361, 268 and 362, 269 and 363, 270 and 364, 271 and 365, 272 and 366, 273 and 367, 275 and 369, 276 and 370, 277 and 371, 278 and 372, 279 and 373, 280 and 374, 281 and 375, 282 and 376, 283 and 377, 284 and 378, 285 and 379, 286 and 380, 287 and 381, 288 and 382, 289 and 383, 290 and 384, 291 and 385, 292 and 386, 293 and 387, 295 and 389, 296 and 390, 297 and 391, 298 and 392, 299 and 393, 300Attorney Docket No. DEMB-010 / 02WOand 394, 301 and 395, 302 and 396, 303 and 397, 304 and 398, 305 and 399, 306 and 400, 307 and 401, 308 and 402, 309 and 403, 310 and 404, 311 and 405, 312 and 406, 313 and 407, 314 and 408, 315 and 409, 316 and 410, 317 and 411, 318 and 412, 319 and 413, 320 and 414, 321 and 415, 322 and 416, 323 and 417, 324 and 418, 325 and 419, 326 and 420, 327 and 421, 328 and 422, 329 and 423, 330 and 424, 331 and 425, 332 and 426, 333 and 427, 334 and 428, 335 and 429, 336 and 430, 337 and 431, 338 and 432, 339 and 433, 340 and 434, 341 and 435, 342 and 436, 343 and 437, 344 and 438, 345 and 439, or 346 and 440, 1080 and 347,1081 and 348, 1082 and 349,1083 and 350,1084 and 351, 1085 and 352, 1086 and 353, 1087 and 354, 1088 and 355,1089 and 356, 1090 and 357, 1091 and 358, 1092 and 359, 1093 and 360, 1094 and 361, 1095 and 362, 1096 and 363, 1097 and 364, 1098 and 365, 1099 and 366, 1100 and 367,1102 and 369, 1103 and 370, 1104 and 371, 1105 and 372, 1106 and 373, 1107 and 374, 1108 and 375, 1109 and 376, 1110 and 377, 1111 and 378, 1112 and 379, 1113 and 380, 1114 and 381, 1115 and 382, 1116 and 383, 1117 and 384, 1118 and 385, 1119 and 386, 1120 and 387, 1122 and 389, 1123 and 390, 1124 and 391, 1125 and 392, 1126 and 393, 1127 and 394, 1128 and 395, 1129 and 396, 1130 and 397, 1131 and 398, 1132 and 399, 1133 and 400, 1134 and 401, 1135 and 402, 1136 and 403, 1137 and 404, 1138 and 405, 1139 and 406, 1140 and 407, 1141 and 408, 1142 and 409, 1143 and 410, 1144 and 411, 1145 and 412, 1146 and 413, 1147 and 414, 1148 and 415, 1149 and 416, 1150 and 417, 1151 and 418, 1152 and 419, 1153 and 420, 1154 and 421, 1155 and 422, 1156 and 423, 1157 and 424, 1158 and 425, 1159 and 426, 1160 and 427, 1161 and 428, 1162 and 429,1163 and 430, 1164 and 431, 1165 and 432, 1166 and 433, 1167 and 434, 1168 and 435, 1169 and 436, 1170 and 437, 1171 and 438, 1172 and 439, or 1173 and 440, respectively.

53. The antibody of claim 52, wherein the heavy chain and the light chain comprise the amino acid sequences of SEQ ID NOs: 294 and 388, respectively.

54. The antibody of claim 52, wherein the heavy chain and the light chain comprise the amino acid sequences of SEQ ID NOs: 1121 and 388, respectively.

55. The antibody of claim 52, wherein the heavy chain and the light chain comprise the amino acid sequences of SEQ ID NOs: 274 and 368, respectively.

56. The antibody of claim 52, wherein the heavy chain and the light chain comprise the amino acid sequences of SEQ ID NOs: 1101 and 368, respectively.Attorney Docket No. DEMB-010 / 02WO57. An antibody that cross-competes for binding with the antibody of any one of the preceding claims.

58. An antibody that specifically binds to the same epitope of human Small Cell Adhesion Glycoprotein (SMAGP) extracellular domain (ECD) as the antibody of any one of the preceding claims.

59. An antibody that specifically binds to an epitope of human SMAGP ECD.

60. The antibody of claim 58 or 59, wherein the human SMAGP ECD comprises amino acids 1-36 of SEQ ID NO: 1.

61. The antibody of any one of claims 57-60, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consisting of: Leu5; Thr7; Argil; Glul2; Glul3; Leul4; Metl5; Thrl6; Prol8; Ilel9; Leu20; Gln21; Pro22; Thr23; Glu24; Leu26; Leul4 and MetE5; lie 19 and Glu24; and Gln21 and Pro22.

62. The antibody of claim 61, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consisting of: Gln21, Pro22, and GIu24; Gln21, Pro22, and Thr23; GIul3, Leul4, and Metl5; and Glul2, Leul4, and Metl5.

63. The antibody of claim 62, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consisting of: Glul2, Glul3, Leul4, and Metl5; and Prol8, lie 19, Leu20, and Gln21.

64. The antibody of any one of claims 57-63, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consisting of: Thr7; Glul2; Glul3; Leul4; MetE5; Prol8; Ilel9; Leu20; Gln21; Pro22: Thr23; Glu24; Leu20, Gln21, Pro22, Thr23, and Glu24; He 19, Gln21, and Ghi24; and Thr7 and Leul4.

65. The antibody of any one of claims 57-64, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consistingAttorney Docket No. DEMB-010 / 02WOof: Glul2; Glul3; Leul4; Metl5; Prol8; Ilel9; Leu20; Gln21; Pro22; Thr23; Glu24; Ilel9, Gln21, Pro22, Glu24, and Leu26; He 19, Gln21, Glu24, and Leu26; Glul2, Leul4, and Metl5; and He 19, Gln21, and Pro22.

66. The antibody of claim 65, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids selected from the group consisting of: Leu5, Glul2, Glul3, Leul4, and Metl5; Glul2, Glul3, Leul4, Metl5, and Thrl6; and Thrl6, He 19, Leu20, Gln21, Pro22, Thr23, and Glu24.

67. The antibody of claim 66, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Argl1, Glu12, Glul3, Leu14, Met15, and Thrl6.

68. The antibody of claim 65, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Prol8, Ilel9, Leu20, Gln21, Pro22, Thr23, Glu24, and Leu26.

69. The antibody of claim 59, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Gln21, Pro22, or Thr23.

70. The antibody of claim 69, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Gln21 and Pro22.

71. The antibody of claim 69 or 70, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Ile19, Leu20, Gln21, Pro22, and Thr23.

72. Tlie antibody of claim 69 or 70, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Gln21, Pro22, and Thr23,73. The antibody of claim 72, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Leu20, Gln21, Pro22, and Thr23.

74. The antibody of claim 73, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids Leu20, Gln21, Pro22, Thr23, and Glu24.Attorney Docket No. DEMB-010 / 02WO75. The antibody of claim 74, wherein the antibody specifically binds to an epitope of human SMAGP ECD comprising amino acids lie 19, Leu20, Gln21, Pro22, Thr23, and Glu24.

76. The antibody of any one of the preceding claims, wherein the antibody reduces binding of Paired Immunoglobulin-like Type 2 Receptor-a (PILRa) to SMAGP.

77. The antibody of any one of the preceding claims, wherein the antibody reduces binding of CD 177 to SMAGP.

78. A polypeptide comprising a VH which comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in any one of SEQ ID NOs: 2-123.

79. The polypeptide of claim 78, wherein the CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 482, 581, and 697; 489, 605, and 703; 487, 603, and 677; 487, 603, and 701; 487, 603, and 705; 487, 603, and 706; 487, 603, and 707; 487, 603, and 708; 487, 603, and 709; 487, 603, and 710; 462, 561, and 677; 441, 540, and 656; 442, 541, and 657; 443, 542, and 658; 444, 543, and 659; 445, 544, and 660; 446, 545, and 661; 447, 546, and 662; 448, 547, and 663; 449, 548, and 664; 450, 549, and 665; 451, 550, and 666; 452, 551, and 667; 453, 552, and 668; 454, 553, and 669; 455, 554, and 670; 456, 555, and 671; 457, 556, and 672; 458, 557, and 673; 459, 558, and 674; 460, 559, and 675; 461, 560, and 676; 463, 562, and 678; 464, 563, and 679; 465, 564, and 680; 466, 565, and 681; 467, 566, and 682; 468, 567, and 683; 469, 568, and 684; 470, 569, and 685; 471, 570, and 686; 472, 571, and 687; 473, 572, and 688; 474, 573, and 689; 475, 574, and 690; 476, 575, and 691; 477, 576, and 692; 478, 577, and 693; 479, 578, and 694; 480, 579, and 695; 481, 580, and 696; 483, 582, and 698; 484, 583, and 699; 485, 584, and 700; 452, 585, and 667; 452, 586, and 667; 452, 587, and 667; 452, 588, and 667; 452, 589, and 667; 452, 590, and 667; 452, 591, and 667; 452, 592, and 667; 452, 593, and 667; 452, 594, and 667; 452, 595, and 667; 452, 596, and 667; 486, 597, and 668; 486, 598, and 668; 486, 599, and 668; 486, 600, and 668; 486, 601, and 668; 486, 602, and 668; 488, 604, and 702; 488, 604, and 678; 490, 606, and 704; 491, 607, and 711; 492, 608, and 712; 493, 609, and 713; 494, 610, and 714; 495, 611, and 715; 496, 612, and 716; 497, 613, and 717; 498, 614, and 718; 499, 615, and 719; 500, 616, and 720; 501, 617, and 721; 502, 618, and 722; 503, 619, and 723; 504, 620, and 724; 505, 621, and 725; 506, 622, and 726; 507, 623, and 727; 508, 624, and 728;Attorney Docket No. DEMB-010 / 02WO509, 625, and 729; 510, 626, and 730; 511, 627, and 731; 512, 628, and 732; 513, 629, and 733; 514, 630, and 734; 515, 631, and 735; 516, 632, and 736; 517, 633, and 737; 518, 634, and 738; 519, 635, and 739; 520, 636, and 740; 521, 637, and 741; 522, 638, and 742; 523, 639, and 743; 524, 640, and 744; 525, 641, and 745; 526, 642, and 746; 527, 643, and 747; 528, 644, and 748; 529, 645, and 749; 530, 646, and 750; 531, 647, and 751; 532, 648, and 752; 533, 649, and 753; 534, 650, and 754; 535, 651, and 755; 536, 652, and 756; 537, 653, and 757; 538, 654, and 758; or 539, 655, and 759, respectively.

80. A polypeptide comprising a VL which comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in any one of SEQ ID NOs: 124-252.

81. The polypeptide of claim 80, wherein the CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 801, 919, and 1013; 823, 919, and 1013; 824, 919, and 1013; 825, 919, and 1013; 826, 919, and 1013; 827, 919, and 1013; 828, 919, and 1013; 781, 899, and 993; 814, 899, and 993; 818, 899, and 993; 819, 899, and 993; 820, 899, and 993; 821, 899, and 993; 822, 899, and 993; 760, 878, and 972: 761, 879, and 973; 762, 880, and 974; 763, 881, and 975; 764, 882, and 976; 765, 883, and 977; 766, 884, and 978; 767, 885, and 979; 768, 886, and 980; 769, 887, and 981; 770, 888, and 982; 771, 889, and 983; 772, 890, and 984; 773, 891, and 985; 774, 892, and 986; 775, 893, and 987; 776, 894, and 988; 777, 895, and 989; 778, 896, and 990; 779, 897, and 991; 780, 898, and 992; 782, 900, and 994; 783, 901, and 995; 784, 902, and 996; 785, 903, and 997; 786, 904, and 998; 787, 905, and 999; 788, 906, and 1000; 789, 907, and 1001; 790, 908, and 1002; 791, 909, and 1003; 792, 910, and 1004; 793, 911, and 1005; 794, 912, and 1006; 795, 913, and 1007; 796, 914, and 1008; 797, 915, and 1009; 798, 916, and 1010; 799, 917, and 1011; 800, 918, and 1012; 802, 920, and 1014; 803, 921, and 1015; 804, 922, and 1016; 805, 889, and 983; 806, 889, and 983; 807, 889, and 983; 808, 890, and 984; 809, 890, and 984; 810, 890, and 984; 811, 890, and 984; 812, 890, and 984; 813, 890, and 984; 815, 900, and 994; 816, 919, and 1013; 817, 920, and 1014; 829, 923, and 1017; 830, 924, and 1018; 831, 925, and 1019; 832, 926, and 1020; 833, 927, and 1021; 834, 928, and 1022; 835, 929, and 1023; 836, 930, and 1024; 837, 931, and 1025; 838, 932, and 1026; 839, 933, and 1027; 840, 934, and 1028; 841, 935, and 1029; 842, 936, and 1030; 843, 937, and 1031; 844, 938, and 1032; 845, 939, and 1033; 846, 940, and 1034; 847, 941, and 1035; 848, 942, and 1036; 849, 943, and 1037; 850, 944, and 1038; 851, 945, and 1039; 852, 946, and 1040; 853, 947, and 1041; 854, 948, and 1042; 855,Attorney Docket No. DEMB-010 / 02WO949, and 1043; 856, 950, and 1044; 857, 951, and 1045; 858, 952, and 1046; 859, 953, and 1047; 860, 954, and 1048; 861, 955, and 1049; 862, 956, and 1050; 863, 957, and 1051; 864, 958, and 1052; 865, 959, and 1053; 866, 960, and 1054; 867, 961, and 1055; 868, 962, and 1056; 869, 963, and 1057; 870, 964, and 1058; 871, 965, and 1059; 872, 966, and 1060; 873, 967, and 1061; 874, 968, and 1062; 875, 969, and 1063; 876, 970, and 1064; or 877, 971, and 1065, respectively.

82. A polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs: 2-252.

83. The polypeptide of claim 78 or 79, wherein the VH comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 2-123.

84. The polypeptide of claim 83, wherein the antibody comprises a heavy chain comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 253-346, 1080-1173, or 1175-1184.

85. The polypeptide of claim 80 or 81, wherein the VL comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 124-252.

86. The polypeptide of claim 85, wherein the antibody comprises a light chain comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any of SEQ ID NOs: 347-440 or 1185-1195.

87. A polynucleotide encoding: the VH, the VL, the heavy chain, and / or the light chain of the antibody of any one of claims 1-77 or the polypeptide of any one of claims 78-86.Attorney Docket No. DEMB-010 / 02WO88. A vector comprising the polynucleotide of claim 87.

89. A recombinant host cell comprising:(a) the polynucleotide of claim 87;(b) the vector of claim 88;(c) a first polynucleotide encoding the VH or the heavy chain of the antibody of any one of claims 1-77 and a second polynucleotide encoding the VL or the light chain of the antibody of any one of claims 1-77; and / or(d) a first vector comprising a first polynucleotide encoding the VH or the heavy chain of the antibody of any one of claims 1-77 and a second vector comprising a second polynucleotide encoding the VL or the light chain of the antibody of any one of claims 1-77.

90. A composition comprising the antibody of any one of claims 1-77, the polypeptide of any one of claims 78-86, the polynucleotide of claim 87, the vector of claim 88, or the host cell of claim 89, and a pharmaceutically acceptable carrier or excipient.

91. A method of producing an antibody, the method comprising culturing the host cell of claim 89, under suitable conditions such that the polynucleotide is expressed, and the antibody is produced.

92. A method of treating a disease or disorder in a subject, the method comprising administering to the subject an effective amount of the antibody of any one of claims 1-77; the polypeptide of any one of claims 78-86; the polynucleotide of claim 87; the vector of claim 88; the host cell of claim 89; or the composition of claim 90.

93. The method of claim 92, further comprising administering an additional therapeutic agent to the subject.

94. The method of claim 92, wherein the disease or disorder is a cancer,95. The method of claim 94, wherein the cancer is selected from the group consisting of colon cancer, rectal cancer, colorectal cancer, gastric cancer, esophageal cancer, gastric-Attorney Docket No. DEMB-010 / 02WOesophageal junction cancer, bladder cancer, pancreatic adenocarcinoma, cervical squamous and adenocarcinoma, lung squamous and adenocarcinoma, liver cancer (hepatocellular carcinoma), breast cancer, triple negative breast cancer, thyroid cancer, endometrial carcinoma, kidney renal papillary cell carcinoma, glioblastoma, thymoma, and testicular germ cell tumor.

96. The method of claim 93, wherein the additional therapeutic agent is a chemotherapeutic, a radiotherapeutic, or a targeting agent.

97. The method of claim 93, wherein the additional therapeutic agent is selected from the group consisting of an antagonist anti-PD-1 antibody, an antagonist anti-PD-Ll antibody, an antagonist anti-PD-L2 antibody, an antagonist anti-PD-l / VEGF antibody, an antagonist anti-CTLA-4 antibody, an anti-HERl antibody, an anti -HER1 -LGR5 antibody, an anti -HER1 -MET antibody, an anti -HERZ antibody, an anti-EGFR antibody, an anti-CMET antibody, an anti-VEGF antibody, an anti-VEGFR antibody, an anti-VEGFR-2 antibody, a TROP-2 directed antibody, an anti-Nectin-4 antibody, an antagonist anti-TIM-3 antibody, an antagonist anti-LAG-3 antibody, an antagonist anti-VISTA antibody, an antagonist tyrosine kinase inhibitor antibody, an antagonist anti-TIGIT antibody, an antagonist anti-STRPa antibody, a BRAF inhibitor, an anti-Claudin 18.2 antibody, an MEK inhibitor, an antagonist anti-CD96 antibody, an antagonist anti-CEACAMl antibody, an agonist anti-CD137 antibody, an mTOR inhibitor, a tropomyosin kinase receptor inhibitor, a CDK4 / 6 inhibitor, a PIK3CA inhibitor, an AKT inhibitor, a KRAS inhibitor, a pan-RAS inhibitor, an agonist anti-GITR antibody, and an agonist anti-OX40 antibody.

98. Use ofthe antibody of any one of claims 1-77; the polypeptide of any one of claims 78-86; the polynucleotide of claim 87; the vector of claim 88; the host cell of claim 89; or the composition of claim 90, for the manufacture of a medicament for treating cancer.

99. The antibody of any one of claims 1 -77; the polypeptide of any one of claims 78-86; the polynucleotide of claim 87; the vector of claim 88; the host cell of claim 89; or the composition of claim 90, for use in medicine.

100. The antibody of any one of claims 1-77; the polypeptide of any one of claims 78-86; the polynucleotide of claim 87; the vector of claim 88; the host cell of claim 89; or the composition of claim 90, for use in treating cancer in a subject.Attorney Docket No. DEMB-010 / 02WO101. A kit comprising the antibody of any one of claims 1-77; the polypeptide of any one of claims 78-86; the polynucleotide of claim 87; the vector of claim 88; the host cell of claim 89; or the composition of claim 90.

Images